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Osteoarthritis (OA) is a disease estimated to affect 10-12% of the adult US population and 
there are currently no clinically proven disease modifying therapies. Micronized 
dehydrated human amnion/chorion membrane (μ-dHACM) is an extracellular matrix 
(ECM)-based therapy that has been shown to attenuate OA progression in rats but many of 
the underlying mechanisms and design variables involved with μ-dHACM are not well 
understood. The primary objective of this proposed research is to investigate factors that 
influence the therapeutic benefit of potential disease modifying OA therapies. Specifically 
this work (i) developed a technological platform using contrast enhanced µCT to quantify 
cartilage surface roughness and utilized this platform to characterize early articular joint 
tissue changes in a rat OA model (Chapter 3), (ii) used contrast enhanced µCT and near-
infrared fluorescent tracking to evaluate the effect of μ-dHACM particle size on the intra-
articular residence time and therapeutic efficacy in a rat OA model (Chapter 4), and (iii) 
characterized and utilized synoviocyte and cartilage co-culture models to investigate the 
effect of interactions between synovium and μ-dHACM on OA disease progression 
(Chapter 5). This work increased the scientific community’s understanding of the factors 
influencing the efficacy of μ-dHACM treatment for OA. It also increased the 





CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Osteoarthritis (OA) is a disease characterized by articular cartilage degeneration, 
subchondral bone sclerosis, and synovitis [1]. An estimated 10-12% of the adult US 
population are diagnosed with OA, including 37% of those over 60 years of age with knee 
OA alone, and the total number of cases is expected to increase as the population ages [2]. 
Currently, there are no FDA approved OA therapies that modify or prevent disease 
development. One of the challenges in the development of disease modifying OA therapies 
is the need for better tools and models to understand the factors that influence the 
therapeutic benefit of potential therapies [3], [4]. Current methods of measuring cartilage 
surface roughness, an important first indicator of cartilage degradation, do not allow for 
non-destructive measurements over large surfaces, such as the tibial plateaus of rats. 
Micronized dehydrated human amnion/chorion membrane (μ-dHACM) is an extracellular 
matrix (ECM)-based therapy that has been shown to attenuate OA development in the rat 
medial meniscus transection (MMT) model. However, many questions remain about μ-
dHACM treatment, including: 1) how μ-dHACM particle size effects the treatments intra-
articular residence time and overall therapeutic benefit, and 2) how μ-dHACM treatment 
interacts with the synovium, in which it becomes embedded, to influence the health of the 
cartilage. This proposed research will seek to answer the questions on μ-dHACM treatment 
and develop additional tools and models to aid in this investigation. 
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The objective of this research was to investigate factors that influence the 
therapeutic benefit of potential disease modifying OA therapies.  
1.2 Specific Aims 
Specific Aim 1: Develop technological platform for quantifying cartilage surface 
roughness and use to characterize early articular joint tissue changes in rat OA 
model. The working hypothesis of this aim was that there were quantifiable morphological 
and compositional changes detectable by EPIC-μCT in the tibial bone and cartilage one 
week after MMT surgery. An algorithm for quantifying cartilage surface roughness from 
EPIC-μCT scans was developed and a MATLAB® program was written to run the 
algorithm. Changes in cartilage and bone were quantified one and three weeks post-MMT 
surgery. The outcome of this aim was a software program capable of measuring cartilage 
surface roughness and an increased characterization of the early morphological and 
compositional changes in the rat MMT model. These results are presented in Chapter 3. 
Specific Aim II: Evaluate the effect of particle size on μ-dHACM treatment. The 
working hypothesis of this aim was that reducing the particle size of μ-dHACM will alter 
the attenuation of OA progression and result in faster clearance of the μ-dHACM particles 
from the joint. μ-dHACM treatments of two different particle size profiles were used in 
this aim. The efficacy of the two treatments in preventing OA progression was compared 
in the rat MMT model using EPIC-μCT. The clearance of fluorescently tagged particles of 
both treatments were also compared in the rat MMT models. Through this aim, we 
achieved a better understanding of the effect of particle size on μ-dHACM treatment in the 
rat MMT model. The results of this aim are presented in Chapter 4. 
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Specific Aim III: Investigate the interactions between synoviocytes and μ-dHACM. 
The working hypothesis of this aim was that µ-dHACM will influence the cytokine, 
chemokine, and MMP production from IL-1 and TNF-α stimulated synoviocytes. It was 
also hypothesized that interaction of synoviocytes and μ-dHACM will provide protection 
against IL-1 and TNF-α induced PG loss from chondrocyte pellets. The results of this aim 
are presented in Chapter 5. 
1.3 Significance 
This research will result in 1) a surface roughness measurement algorithm that allows for 
a large-scale, high-throughput, non-destructive measurement of cartilage surface 
roughness; 2) increased characterization of early (one-week post-surgery) disease 
progression in the MMT rat model; 3) a better understanding of how particle size affects 
intra-articular residence time and therapeutic effectiveness; 4) increased characterization 
of synovium/cartilage co-cultures; and 5) increased understanding of how μ-dHACM 
affects the synovium secretome and, in turn, potentially affects cartilage health.  
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CHAPTER 2. BACKGROUND AND LITERATURE REVIEW  
2.1 Osteoarthritis 
2.1.1 Normal Joint Tissues 
2.1.1.1 Cartilage 
Articular cartilage consists of three main components: the chondrocytes, or cells within the 
cartilage; the interstitial fluid; and the macromolecular matrix consisting of proteoglycans 
and collagen, with trace amounts of other macromolecules and proteins. Each plays a vital 
role in the function of the overall tissue [5]. 
Cartilage is sparsely populated with cells and the only cells within the cartilage are 
chondrocytes. These cells are responsible for any matrix remodeling and maintain the 
integrity of the cartilage [6]. Because there is no vascularization within the cartilage, 
nutrition and waste transport is achieved through diffusion in the interstitial fluid, aided by 
joint movement [7]. 
Water is abundant in both the synovial fluid inside the joint and the cartilage lining the 
bones, making up 70-80% of the tissue. It permeates through the entire tissue, carrying 
salts and proteins, and is extremely important for both the function of the cartilage under 
loads (which will be discussed later) and for nutrient supply. Cartilage has no vascularity 
and diffusion through the interstitial fluid is the only mechanism by which nutrients and 
waste can be taken to and from the chondrocytes. Interstitial fluid flow, caused by joint 
movement, facilitates this transport.[8], [9] 
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Collagens and proteoglycans make up most the dry weight of cartilage. 50-75% of the 
weight is collagen and 15-30% is proteoglycans. The remaining dry weight consists of 
minor proteins and the chondrocytes. [10] 
Collagen is a prominent structural molecule throughout the body and provides a semi-rigid 
frame for the rest of the macromolecules and the chondrocytes. Collagen type II accounts 
for most the collagen in the cartilage[11] and provides the structural support for the 
cartilage. There are smaller amounts of types V, VI, IX, and XII[12] and it is thought that 
these other types help stabilize type II and participate in intermolecular interactions[10]. 
The structure, amount, and orientation of collagen fibers vary with both depth in the tissue 
and proximity to chondrocytes [13]. 
Proteoglycans are protein cores surrounded by long polysaccharides. They form into large 
globular groups that are kept in place by the collagen frame. These proteoglycans have a 
net negative charge and attract water into the cartilage, especially following compression 
of the cartilage. Most the proteoglycan is aggrecan but amounts of biglycan, decorin, and 
fibromodulin are also present. The minor proteoglycans are thought to assist in the 
development and repair of the cartilage. [14] 
The overall structure of articular cartilage can be divided into different zones delineated 
according to their depth in the cartilage. These zones vary by both macromolecular and 
cellular composition and material properties. The zones, in order from the articulating 
surface bordering the synovial fluid to the subchondral bone, are called the 
superficial/tangential zone, middle/transitional zone, and deep/radial zone[15].  
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On the surface of cartilage, there is also the lamina splendens, a very thin, acellular, fibrous 
layer[16]. Though the exact purpose and origin of this layer is uncertain, it is thought that 
it could assist in reducing the friction within the joint. 
The superficial or tangential zone is the upper 10-20% of the articular cartilage. The 
collagen fibers have small diameters and are densely packed, aligned parallel to the surface 
of the cartilage. There is low proteoglycan content and low permeability to fluids. The cells 
are flat and discoidal in shape, aligned with the collagen fibers, and are densely packed. 
They secrete specialized proteins thought to help with the overall wear and frictional 
properties of the cartilage. 
The middle 40-60% section is called the middle or transitional zone. Here the collagen 
fibers have a more random alignment as they transition from the tangential alignment to a 
more radial alignment in the deep zone. This zone has the highest proteoglycan content. 
The cells are spherical and there are fewer in number than in the superficial zone. 
The deepest of the zones, the deep or radial zone, usually consists of 20-50% of the 
cartilage depth. Here the collagen fibers are bundled together and aligned radially, 
anchored to the underlying bone. The proteoglycan amount is much less than the middle 
zone and the cell amount is the lowest of the three zones. The cell shape is generally 
elliptical and the cells are aligned in columns in the same direction as the collagen. [5] 
The tidemark marks the transition from the deep zone to the calcified zone of articular 
cartilage. This calcified zone is the transition from cartilage to subchondral bone, the 
anchor of the cartilage to the bone.[17] 
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The structure of the cartilage also changes with proximity to the individual chondrocytes. 
The pericellular matrix immediately surrounds the cell and has fine collagen fibers, high 
proteoglycan amounts, fibronectin, and collagen type VI. The territorial matrix surrounds 
the pericellular matrix and is a transition from that matrix to the surrounding extracellular 
matrix. The extracellular, also called the interterritorial, matrix is furthest from the cell and 
the makeup depends on the depth of the cartilage at that point. It is thought that these three 
matrices around the cell help to alter the strains felt by the chondrocytes as a result of forces 
within the cartilage.[5] 
Function 
The function of articular cartilage is to provide a low friction shock absorber to facilitate 
joint movement and load transfer. The overall biochemical and mechanical structure of 
tissue are both important for this to occur. If one or both is damaged or changed, the force 
profile within the tissue changes and a general overall loss of function can occur, leading 
to disability and pain in that joint. [5] 
In normal use, cartilage experiences compression, tension, and shear; compression being 
the primary loading mode while there is also substantial shear stress that are relevant to 
cartilage degeneration. These different modes are the result of the complex intermolecular 
interactions between the macromolecules, cells, fluid, and surrounding bone.[10], [18] 
The interstitial fluid is extremely important to the cartilage function, especially under 
compression. When suddenly loaded, the fluid is forced out of the cartilage, but because of 
the low permeability of the surrounding matrix, there is a great deal of friction going against 
the flow. This causes a pressurization of the fluid and the fluid carries the initial loading, 
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sparing the solid matrix. The high friction between the fluid and the matrix also acts as a 
damping system to dissipate the energy from the loading. As the fluid leaves the matrix, 
the solid phase carries more of the load, but the impact has been reduced. The cartilage 
also deforms with the loading which increases the contact area and decreases the pressure 
on the solid matrix. [19] Because of this interplay between the fluid and matrix, healthy 
cartilage can hold up for decades of use without deteriorating.  
Tension and shear also occur throughout the tissue as a result of the interactions between 
the collagen fibers and the proteoglycan network. Tension is a result of the tissue sliding 
across one another and when the tissue is compressed, pulling the fibers in to the point of 
contact. Shear is a result of the normal rotation and translational movements of the joint. 
Another important function of articular cartilage is to provide a low friction environment 
for rotation of the joint. This low friction is thought to be facilitated through proteins in the 
lamina splendens and the superficial zone. There are also some other theories, including 
squeeze film lubrication, elastic-hydrodynamic lubrication, boundary lubrication, and fluid 
pressurization. The latter is assumed to be the major player in reducing friction within the 
joint.[5] 
Chondrocyte Function 
Crucial to the overall tissue function of articular cartilage is the function of the individual 
chondrocytes. Chondrocytes, from their position within the cartilage, are the main 
metabolic unit of cartilage. They are responsible for the turnover and production of 
collagen and proteoglycans, thus maintaining the cartilage around them.[6] 
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The general low density of chondrocytes within the cartilage is one of the main reasons 
cartilage is unable to heal itself after injury.  Without chondrocytes to shore up and repair 
the surrounding matrix, the cartilage quickly degenerates and ceases to function properly. 
This leads to fissures within the cartilage and bone and results in the pain and disability 
associated with osteoarthritis.[20] 
When healthy, chondrocytes remodel the cartilage makeup in their immediate vicinity. This 
leads to the territorial zones that were mentioned earlier with finer collagen fibers and 
higher proteoglycan content surrounding the chondrocytes. Further out, the fibers thicken 
and the proteoglycan content drops.[5] 
When cartilage is first developing, there is a high number of chondrocytes within the 
cartilage as well as higher vascularization to provide nutrition for the chondrocytes. As the 
person ages and the cartilage matures, cell division is rarely seen in the cartilage. Fewer 
new chondrocytes are present, metabolic output and growth factor response decreases, and 
apoptosis increases. Though this is normal chondrocyte behavior, this leads to the inability 
of cartilage to heal itself properly.[5] 
2.1.1.2 The Synovium 
The synovial membrane or synovium is a specialized connective tissue that surrounds the 
joint cavities of synovial joints. Synovium consists of two main layers, a thin intimal layer 
roughly 20-40um thick and the subintimal layer which can be up to 5mm thick. The 
characteristics of the subintimal layer are used to classify synovium into three types: 
areolar, adipose, and fibrous. The areolar is the most specialized type, being crimped into 
folds to allowing stretching during joint movement and containing layers of intimal cells, 
  
 10 
capillaries, and then blood and lymphatic vessels in deep subintimal layer. Adipose 
synovium consists of the layer of intimal cells followed by deeper fat tissue and is present 
as fat pads and within villi. Fibrous synovium, consisting of fibrous tissue, is less well 
defined and often difficult to distinguish from fibrocartilage.[21]  
The intimal layer of the synovium consists of two main types of cells: fibroblast-like 
synoviocytes (FBLS) and macrophage-like synoviocytes (MPLS), with the FBLS being the 
dominant cell type in healthy synovium. MPLS are often identified through CD68 positive 
staining and are responsible for removing debris and regulating the inflammatory 
environment. In disease, the proportion of MPLS can rise to 80% as more macrophages are 
recruited to the synovium. FBLS produce hyaluronan and other proteoglycans which form 
the synovial fluid within the joint space[22] and can be identified through CD55 positive 
staining [21]. 
The synovium provides several important functions within the joint space[22]. It maintains 
a malleable but intact surface around the joint that is nonadherent to allow free movement 
of the joint. This surface provides lubrication for the cartilage by providing various 
glycoproteins such as lubricin and superficial zone protein. Through the secretion of 
hyaluronan, the synovium also maintains the fluid volume within the joint cavity. Finally, 
the synovium is the major path by which articular chondrocytes receive nutrients and waste 
clearance.[21] 
2.1.2 OA Pathology 
Originally thought to involve just the cartilage, OA has been recently recognized as a 
disease involving the entire joint, with cartilage, bone, and synovium all playing a role in 
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disease progression [23]. While the precise etiology of this disease is not known, risk 
factors include age, previous joint injury, obesity, and abnormal joint development [24]. 
Some researchers have postulated that these factors could result in pathological changes in 
the joint biology, structure, and mechanics which lead abnormal joint remodeling and the 
progressive degenerative changes seen in osteoarthritis [25]. Whatever the etiology may 
be, OA is characterized “by localized loss of cartilage, remodeling of adjacent bone, and 
associated inflammation [1].” All of these degenerative changes result in failure of the joint 
as a whole organ, leading to the pain and disability seen in those who suffer from OA [23], 
[25], [26] 
2.1.3 OA Prevalence 
An estimated 10-12% of the adult population in the US (~27 million people) has clinical 
OA with an estimated 37% of the U.S. adult population over 60 years of age being affected 
by knee OA alone [2], [27]. It has been estimated that OA results in directs costs to US 
insurers and individuals of more than $185 billion annually [28]. As the population ages, 
the total number of patients with doctor diagnosed OA is expected to increase to 25% of 
the adult US population (~67 million people) by 2030 [29]. The lifetime risk of developing 
systematic OA has been estimated to be 44.7% with those with a history of knee injury 
having a risk of 56.8%[30].  
2.1.4 OA Treatments 
Current recommended OA treatment includes four main categories: holistic patient 
assessment (to assess how the clinical symptoms of the disease affect the patient), non-
pharmacological treatment (appropriate information, activity and exercise, weight loss, 
  
 12 
biomechanical interventions), pharmacological pain treatment (acetaminophen, non-
steroidal anti-inflammatory drugs, capsaicin, duloxetine, cox-2 inhibitors, opioids, intra-
articular corticosteroid injections) and joint replacement surgery, all of which require 
repeated follow-up and review [1], [31]–[34]. While hip and knee joint replacement 
surgeries have a very successful track record at improving quality of life [35]–[37], they 
are still major surgical procedures with associated risks and there is concern about long-
term outcomes, especially in younger patient populations [38], [39]. 
Most current pharmacological treatments for OA are only designed for pain management, 
not to modify or cure the disease; there are currently no widely recommended disease 
modifying OA therapies. The search for such a therapy has included many strategies, 
including cell, growth factor, and extracellular matrix treatments. Micronized dehydrated 
human amnion/chorion membrane (μ-dHACM) is one such potential OA treatment derived 
from the amnion/chorion membrane of donated human placenta [40]. This ECM-based 
treatment has been shown to be anti-inflammatory and non-immunogenic [41], [42]; to 
secrete a number of beneficial growth factors, including platelet derived growth factor 
(PDGF), fibroblast growth factor (FGF), and tumor growth factor beta (TGF-β) [43], [44]; 
and to maintain chondrocyte phenotype [45], [46]. All of these properties are potentially 
beneficial in a treatment for the inflammatory, degenerated environment of an 
osteoarthritic joint and previous work in our lab demonstrated that intra-articular injection 
of μ-dHACM has been shown to attenuate osteoarthritis development in the MMT rat 
model of OA [40]. There are, however, several factors in the treatment of OA with μ-
dHACM that have yet to be explored, including the effect of particle size on the retention 
and efficacy of the treatment and the therapeutic mode of action. 
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2.2 In Vivo Evaluation of OA Treatments 
2.2.1 Models 
Multiple species, including mice, rats, guinea pigs, rabbits, and larger animals, and disease 
induction strategies have been used as in vivo models of OA [4]. One commonly used 
model is the medial meniscal transection (or tear) model in rats [47], [48]. In this surgically 
induced OA model, the medial collateral ligament is cut to expose the joint space and the 
medial meniscus transected at the narrowest point. This destabilizes the joint and results in 
rapid focal cartilage degeneration and osteophyte development. 
2.2.2 Imaging Techniques1 
The most common assessment measure of osteoarthritis disease progression in in vivo 
models is through histopathological measurements [49]. These, however, are time 
consuming, semi-quantitative, display moderate inter- and intra-observer variability, and 
destructive. As such, histomorphometric measures of cartilage thickness, proteoglycan 
content, and subchondral bone size have been developed [50]. Though these allow for more 
quantitative analysis of joint parameters, they are still time consuming and result in the 
destruction of the sample. 
MRI is the most appropriate imaging modality for assessing joint disease state in humans 
because it can detect pathologies in many different tissues involved in OA [51], [52]. In 
animals, MRI has been used to investigate OA models in mice, rats, guinea pigs, rabbits, 
                                                 
1 Part of this chapter has been adapted from Reece, Lin, Guldberg. (2014) “Contrast Enhanced MicroCT 
Imaging” in The Handbook of Imaging in Biological Mechanics, Boca Raton, FL: CRC Press. 
  
 14 
and dogs, among other animals [53]. This imaging of small animal models requires 
specialized, dedicated equipment that can produce the resolution necessary, and providing 
this high-resolution imaging in an acceptable amount of time remains a limitation of MRI 
use in small animal models [54]. 
Ultrasound has been heavily investigated for the use of measuring the surface roughness 
of cartilage plugs [55]–[60] and shows some utility in detecting cartilage lesions in intact 
joints [61] but has not been combined with bone analyses nor used to quantify an entire 
cartilage surface. In addition, ultrasound imaging has shown that disruptions on the 
cartilage surface detectible by ultrasound are correlated with histomorphometric measures 
of disease progression [62]. 
To overcome some of the shortcomings of other imaging techniques of cartilage joints, our 
lab has developed EPIC-μCT, a non-destructive, quantitative, faster method of cartilage 
and bone analysis for OA research. Palmer, et al. introduced equilibrium partitioning of an 
anionic contrast agent for µCT imaging (EPIC-µCT) to evaluate the morphology and 
proteoglycan (PG) content of cartilaginous tissues[63]. PGs are a key component of 
articular cartilage, playing an important functional role in cartilage matrix by regulating 
the osmotic pressure within the tissue, and PG loss is an early indicator of cartilage 
damage[64]. As PGs have a negative charge, areas of high PG content have a high overall 
negative charge density and areas of low PG content have low negative charge density. An 
anionic contrast agent diffused into cartilage until equilibrium would therefore be expected 
to distribute inversely proportional to PG content. Indeed, when cartilage is equilibrated 
with the contrast agent Hexabrix™ (ioxalgate meglumine and ioxaglate sodium, Guerbet) 
and is then scanned with µCT, areas of lower X-ray attenuation indicate lower contrast 
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agent concentration, which correlate to regions of greater PG content and healthy cartilage. 
Conversely, areas of higher X-ray attenuation indicate higher contrast agent concentration 
and correspond to regions of lower PG content, indicative of cartilage degradation[63]. 
Xie, et al. utilized EPIC-µCT to extract 3D cartilage morphological[65] data for distal 
femoral cartilage in the rat. Cartilage thickness measurements were repeatable and agreed 
well with experimental needle probe thickness measurements and 2D histomorphometry 
estimates. Significant differences were shown in cartilage volume, thickness, and surface 
area for rats of different ages. A later study demonstrated EPIC-µCT was also capable of 
quantifying significant changes in PG content (as measured by average volumetric EPIC-
µCT attenuation and correlated to histological safranin-O optical density of a central 8µm 
section) resulting from chondroitinase ABC digestion[66]. These studies demonstrate that 
EPIC-µCT can be used to quantify morphological and compositional properties in healthy 
and degraded articular cartilage in intact joints, suggesting that the technique may be useful 
for evaluating therapeutics in small animal models of cartilage degeneration.  
Thote, et al. showed that this analysis can provide quantitative analysis of the damage, 
including focal lesion volumes, resulting from both the MMT and the MIA small-animal 
OA models [3] and Willet, et al. demonstrated it can be used to evaluate the therapeutic 
benefit of μ-dHACM [40]. Different variations of this technique have also been used to 
evaluate cartilage damage and regeneration [67]–[70]. 
Cationic contrast agents have also been utilized for cartilage imaging[71]–[75]. These 
solutions contain positively charged molecules; therefore, contrast agent molecules can 
permeate readily into tissues of high negative charge or PG content such as healthy 
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cartilage. Use of cationic contrast agent has been shown to provide higher contrast 
enhancement and increased correlation with PG content within non-degraded cartilage 
when compared to the same concentration of anionic contrast agents[72], [73]. Hayward, 
et al. used this technique to calculate cartilage volume in calluses of a mouse femoral 
fracture model[76]. They showed that cartilage volumes matched in contrast-enhanced 
µCT and histomorphometric measurements. This suggests that cationic contrast-enhanced 
µCT can measure cartilage volume in callus formation and can provide better 
understanding of the fracture healing process. 
The major assumption with EPIC-µCT is that the contrast agent distribution is most 
significantly dependent on the fixed charge density of the cartilage. However, a recent 
paper by Kokonnen, et al. showed that increased collagen crosslinking significantly 
decreased contrast agent diffusion into the cartilage while leaving the PG content 
unaltered[77]. These results may influence the interpretation of studies utilizing 
equilibrium based ionic contrast agent techniques. Other studies have also shown that 
cartilage degeneration can affect contrast agent diffusion, and this change in diffusion 
coefficient can therefore be used to identify cartilage defects[78], [79]. 
To measure cartilage changes in joint degeneration models in vivo, Siebelt, et al. employed 
µCT arthrography whereby HexabrixTM was injected into the knee joints of rats 
immediately prior to imaging[80]. In three different joint degeneration models, cartilage 
volume decreased and attenuation increased compared to baseline, signifying an increase 
in cartilage damage, and this correlated well with histological scoring. The authors 
acknowledged that joints were scanned before contrast equilibrium was reached. Thus, 
attenuation changes could not be directly correlated with PG content and instead were 
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likely due to combined changes in PG content and matrix properties. These factors, along 
with differences in diffusion properties, may have limited the sensitivity in detecting 
degradative changes. However, this study importantly showed that cartilage degradation 
changes were detectable in vivo, thus enabling longitudinal analyses. 
Surface fibrillation and erosion and the presence of lesions in the articular cartilage are 
some of the hallmarks of OA progression and disease severity in human OA. Accordingly, 
they are used as indicators of OA progression in the histological grading of joints [81]. 
Local measurements of cartilage surface roughness have been performed in multiple 
studies, using optical coherence tomography [82], scanning electron microscopy [83], and 
atomic force microscopy [83]. These local measures are useful only in small areas in 
relation to the entire surface of a rat tibia and are usually destructive techniques. Ultrasound 
has been heavily investigated for the use of measuring the surface roughness of cartilage 
plugs [55]–[60] and shows some utility in detecting cartilage lesions in intact joints [61] 
but has not been combined with bone analyses nor used to quantify an entire cartilage 
surface. Calculating the surface roughness over the entire tibial plateau may be feasible 
using EPIC-μCT techniques, which also allows morphological and compositional analyses 
of cartilage and bone. 
2.3 In Vitro Evaluation of OA Treatments 
Ex vivo models of osteoarthritis involve removing sections of tissue from healthy or 
disease joints and exposing them to the potential OA therapies. Most commonly, cartilage 
or osteochondral explants have been used, but some researchers have investigated the 
effects of potential therapeutics on synovium or joint capsule tissues [84]. Some of the 
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studies using explant models include investigating the effect of autologous conditioned 
serum on cartilage explants [85], the effect of stem cells on osteoarthritic synovium and 
cartilage [86], and exploring the joint capsule effects on cartilage explant proteoglycan 
production [87]. Limitations to these explant culture models include tissue availability and 
variability as well as maintaining tissue viability for extended time periods. 
2.3.1 Primary Cell Cultures 
To address some of the limitations of explant cultures, many researchers have utilized 
isolated primary cells and investigated the effects of potential OA therapies. Most studies 
have used chondrocytes [68], [88] but some have started to explore the effect of therapies 
on other cell types that are present in the synovium, such as fibroblast-like synoviocytes 
and macrophages [89], [90]. One of the major limitations of chondrocyte cultures is their 
propensity to rapidly dedifferentiate in culture, requiring the formation of the cells into 3D 
pellets or hydrogel constructs to help maintain the chondrocyte phenotype. Other 
limitations include limitations in donor cell availability. 
2.3.2 Stem Cell Cultures 
Because of their high availability and proliferative ability, stem cells differentiated down a 
chondrogenic lineage have started to be used as therapeutic screening tools. Some 
examples include using mesenchymal stem cell pellets to test the effects of synovial cell 
lines and macrophage co-culture [90] and induced pluripotent stem cells to develop high-
throughput OA drug screening models [91]. The limitations of these models include the 
lack of characterized models, the obvious distance from the in vivo or clinical setting and, 
accordingly, their translatability as effective screening tools for potential OA therapies.  
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CHAPTER 3. EARLY CHARACTERIZATION OF A RAT OA 
MODEL 
3.1 Introduction 
In osteoarthritis (OA) therapeutic testing, small animal models are commonly used to 
investigate the progression of the disease and the influence of potential disease modifying 
OA drugs [92]–[94]. The rat medial meniscus transection (MMT) model has been used 
extensively for both these purposes[40], [47], [48] and is characterized by rapid 
degradation of the cartilage surface with lesion and osteophyte formation evident as early 
as three weeks [47]. 
Histological grading is most commonly used to measure articular tissue changes in small 
animal models[49], but this technique is time consuming, destructive, sample intensive, 
and semi-quantitative[50]. Contrast-enhanced μCT provides  a quantitative, non-
destructive three-dimensional (3D) imaging modality that has been used to analyze the 
structure and composition of various tissues and organs[95]. Recent work with equilibrium 
partitioning of an ionic contrast agent micro-computed tomography (EPIC-μCT) has 
shown an  ability to quantify both cartilage and bone changes in various small animal OA  
models[3], [96] and to investigate the efficacy of potential disease modifying OA 
drugs[40], [97], [98].  
While the ability to quantify these cartilage and bone changes using EPIC-μCT has been 
previously demonstrated, early measures of joint degeneration such as cartilage surface 
fibrillation and the sequence of pathological changes in the MMT model have not yet been 
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fully investigated. Previous work with EPIC-μCT measurement of cartilage proteoglycan 
content and lesion volume did not reveal any statistical differences between sham and 
MMT samples at one-week post-surgery[99]. Janusz et al., however, showed that cartilage 
fibrillations, one of the earliest indicators of disease in human joints[81], are qualitatively 
apparent in two-dimensional (2D) histological sections at one-week post-surgery[48]. 
Therefore, a technique that provides quantitative 3D measurement of changes in cartilage 
surface roughness caused by fibrillation may enable statistical detection of changes in the 
MMT samples as early as one-week post-surgery and may provide additional insight on 
the progression of disease development in this commonly used OA model. 
While many of the histological hallmarks of OA progression have been measured using 
EPIC-μCT analysis, cartilage surface roughness changes associated with fibrillation[81] 
has not yet been quantified using this technique. Quantitative local measurements of 
cartilage surface roughness have been performed with other imaging modalities, including 
optical coherence tomography[82], scanning electron microscopy[83], and atomic force 
microscopy[83], but these local measures are useful only in small areas in relation to the 
entire surface of a rat tibia and are usually destructive techniques. Ultrasound has shown 
some utility in detecting changes in cartilage surface roughness in cartilage plugs[55], [57], 
[58], [60], [61], intact rabbit joints[59], and ex vivo rat joints[100]. However, ultrasound 
measurements do not provide measurements of other hallmarks of OA progression such as 
proteoglycan loss, subchondral bone sclerosis, or osteophyte development. 
Subchondral bone sclerosis and the development of osteophytes are also known to occur 
in OA[23], and other studies have shown osteophyte development in the MMT model[47], 
[48]. However, how these additional joint pathologies relate spatially and temporally to the 
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disease development in cartilage is unknown. Knowledge of the degree and timing of early 
cartilage and subchondral bone changes in this model will aid in understanding the effects 
of potential OA therapies[48]. 
This study provides quantification of early disease development and progression in 
cartilage and bone tissues in the rat MMT model using EPIC-μCT. To add an additional 
measure of cartilage surface roughness changes associated with fibrillation to this 
characterization, this work also describes the design and validation of an algorithm for 
measuring the cartilage surface roughness of the rat tibial plateau using non-destructive 
EPIC-μCT imaging. 
3.2 Materials and Methods 
3.2.1 Animal Study and EPIC-μCT Imaging 
The Georgia Institute of Technology IACUC approved all animal studies (Protocol# 
A12018). Weight matched male Lewis rats (300-350g) underwent sham or MMT surgery 
in the left leg as described previously[48]. Briefly, for MMT surgery, the left medial 
collateral ligament (MCL) was exposed through blunt dissection and transected to reveal 
the joint space. The medial meniscus was reflected proximally towards the femur and 
transected at its narrowest point. The muscle was sutured closed, and the skin incision was 
stapled. For sham samples, the same procedure was performed up to and including 
reflecting the meniscus towards the femur, but the meniscus was not transected. 
Animals were euthanized with CO2 one or three weeks after surgery (n=7 for sham groups 
and n=8 for MMT groups at both time points). The left legs were harvested and prepared 
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for EPIC-μCT scans as described previously[3], [40], [65], [99]. Briefly, after fixation, soft 
tissue was removed from the tibias, and the tibias were incubated in 2mL of 30% 
Hexabrix™ 320 (Mallinckrodt Inc., St. Louis, MO, USA) contrast agent in phosphate 
buffered saline (PBS) without minerals at 37°C for 30 minutes. The tibias were then placed 
within covered sample chambers to retain a humid environment and scanned in air using a 
Scanco μCT 40 (Scanco Medical, Brüttisellen, Switzerland) at 45kVp, 177μA, 200ms 
integration time, 16μm voxel size, and with a scan time of 26min. After scanning, the tibias 
were incubated in PBS at 37°C for 30 minutes to remove contrast agent. The axial greyscale 
EPIC-μCT images were orthogonally transposed to both sagittal and coronal sections, and 
cartilage, subchondral bone, and lesion volume analyses of the medial tibial plateau were 
performed on both sets of images as described below. Osteophyte growth on the medial 
edge of the tibial plateau was measured using coronal slices as described below. 
Segmentation of cartilage, subchondral bone, lesions, and osteophytes was performed with 
global thresholds (based on visual inspection and histogram analysis) and Gaussian 
filtering (sigma = 1.00, support = 1) as described previously[3], [65], [101]. Direct distance 
transformation algorithms were used for the thickness measurements. 
3.2.2 Cartilage Contouring and Analysis 
The cartilage on the medial tibial plateau was separated spatially from regions of bone and 
surrounding air with a semi-automatic contouring process (that produces outer borders of 
the region of interest) and thresholds[3]. Cartilage x-ray attenuation (which is inversely 
proportional to proteoglycan content after contrast agent equilibration with 
Hexabrix™[63], [66]), volume, and thickness were calculated over the entire medial tibial 
plateau and in the lateral, central, and medial thirds of the medial plateau[3], [40], [65], 
  
 23 
[99]. These cartilage measurements have been shown to have high reproducibility and 
correlation with histology, needle probe testing, and protein assays[63], [65], [66]. Figure 
3.1.A, B, show representative images of the analyzed cartilage. Details and examples of 
cartilage evaluation procedures are included in Appendix A. 
 
Figure 3.1: Representative images of EPIC-µCT VOIs and surface fibrillations. (A 
and D) 3D representations of the analyzed medial tibial plateau cartilage volumes 
(darker grey) overlaid on bone volumes of entire proximal tibia. (B and E) 
Representative sagittal EPIC-μCT images used in surface roughness analysis with 
white line representing cartilage surface. (C and F) Representative sagittal 
histological images of the same regions as the EPIC-μCT images. A, B, and C are 
from a single sham joint and D, E, and F are from a joint three weeks after medial 
meniscus transection. Cartilage fibrillations and lesions on the medial tibial plateau 
are indicated with arrows. Scale bars equal 1 mm. 
3.2.3 Subchondral Bone Contouring and Analysis 
Spatial separation by contouring and global thresholding was used to segment the 
subchondral bone from any pores, cartilage, or marrow space. Subchondral bone mineral 
density, volume, porosity, and thickness were calculated over the entire medial tibial 
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plateau and in the lateral, central, and medial thirds of the medial plateau. Details and 
examples of subchondral bone evaluation procedures are included in Appendix A. 
3.2.4 Lesion Contouring and Analysis 
Lesions were defined as cartilage defects extending through approximately 50% or more 
of the cartilage thickness. Volumes of interest (VOIs) of the lesions were defined by 
contouring of the lesion area, closely following the cartilage surface and extending into the 
subchondral bone while avoiding pores and trabecular spaces. Within this VOI, cartilage 
volume was segmented via thresholding and subtracted from total volume to give lesion 
volume[3]. Details and examples of lesion volume evaluation procedures are included in 
Appendix A. 
3.2.5 Osteophyte Volume Contouring and Analysis 
As measures of osteophyte growth along the medial edge of the tibial plateau, the thickness 
and volume of osteophyte cartilage and the volume of mineralized osteophyte tissue were 
measured, as previously described[99]. The edge of the medial tibial plateau was contoured 
to include any bony outgrowth and cartilage thickening. Two sets of VOIs were used, one 
for mineralized tissue outgrowth that included extraneous soft tissue on the tibial edge, and 
another for cartilage thickness and volume that excluded the soft tissue. After contouring, 
one range of thresholds was used to analyze mineralized tissue in the first set of VOIs and 
another to analyze cartilage in the second set. Details and examples of osteophyte 
evaluation procedures are included in Appendix A. 
3.2.6 Surface Roughness Algorithm Design 
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A custom MATLAB® (MathWorks®, Natick, MA, USA) algorithm was created for 
measuring the roughness of surfaces from EPIC-μCT images. The program imports 
sequential 2D 8-bit images. Using a user-defined threshold, the program creates a 3D 
surface representation of the scanned object. The natural curvature of the surface can be 
removed by subtracting fitted surfaces using polynomial, LOWESS spline, or discrete 
cosine transform functions, similar to using low-pass frequency filters in other roughness 
measurements[102]. The surface roughness is calculated as the root mean square value of 
the deviation of every index point over the entire analysis surface (see Figure 3.2). The 
MATLAB® files for this algorithm along with instructions and sample files are available 
for download at http://guldberglab.gatech.edu/downloads. Descriptions of the files along 
with instructions and the text of the files is also contained in Appendix B. 
 
Figure 3.2: Schematic of surface rendering algorithm. (A) Greyscale 2D image 
exported from µCT. (B) Local threshold used to locate cartilage surface position 
(indicated by white circles). (C) Magnified inset of (B) with white circles marking 
the cartilage surface as determined by the cartilage threshold used in the analysis. 
(D) 3D cartilage surface rendered from 2D image stack. (E) Differential surface 
after fitted surface is subtracted from surface in (D). (F) Equation for calculating 
surface roughness where M and N represent the number of greyscale images 
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analyzed and the number of rows analyzed in each greyscale image, respectively; 
zsurf,m,n is the value of the differential surface (E) at the index (m,n); and VS is the 
voxel size of the greyscale images determined by the voxel size of the μCT scan. In 
(D) and (E), red indicates the point is farther to the right in the greyscale images 
with blue indicating further to the left. 
3.2.7 Surface Roughness Algorithm Validation 
To validate the accuracy of the surface roughness algorithm and to understand the 
relationship between voxel size and surface roughness measurements, digital phantom 
surfaces (40x180 voxels) with varying roughness were created. The roughness of the 
surfaces was set using cosine waves along both surface axes such that the root mean square 
values of the surface roughness were 0.25, 0.5, 0.75, 1, 1.25, 1.5, or 2 voxels (n=5 for each 
roughness value). Using quadratic and quartic polynomials, curvatures were added to each 
surface to make three sets: with curvature in no planes (linear-linear), one plane (linear-
quartic), or two planes (quadratic-quartic). The surfaces were then converted to TIFF 
images and imported into the custom algorithm described above. This algorithm measured 
the roughness of the phantom surfaces using subtracted linear-linear, linear-quartic, or 
quadratic-quartic fitted surfaces. Absolute percent error of the measured surface roughness 
was calculated using the formula:  




3.2.8 Surface Roughness Analysis 
Greyscale images of the sagittal sections of the medial tibial plateau were imported into 
the custom algorithm, and a threshold equivalent to that used in the previous cartilage 
quantification was used to separate the cartilage surface from air. Cartilage surface 
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roughness was calculated using a polynomial fitted surface to account for the general 
curvature of the cartilage surface. The polynomial surface was 2nd order (quadratic) along 
the medial-lateral axis and 4th order (quartic) along the anterior-posterior axis. The lateral, 
central, and medial thirds of the medial tibial plateau were each analyzed separately. Figure 
3.1 contains representative images of EPIC-μCT (Figure 3.1.E) and histology (Figure 
3.1.F) showing the location of joint fibrillation. 
3.2.9 Surface Roughness Evaluation of Acute Delivery of a Potential OA Therapeutic 
Male Lewis rats weighing 300-325g were acclimated for 1 week after receipt and 
underwent MMT surgery in the left leg as described previously. 24 hours after surgery, 
50μL of either micronized dehydrated human amnion/chorion membrane (µ-dHACM; 
AmnioFix® Injectable, MiMedx Group Inc, Marietta, GA, USA) suspended in saline at 
80µg/mL or saline was injected intra-articularly into the knee of the left leg (n=5) using 
25-gauge needles. The animals were euthanized with CO2 three weeks after surgery and 
the left tibias were harvested and fixed in 10% NBF for 48 hours. EPIC-µCT imaging with 
surface roughness analysis was performed on the tibias as described in the previous 
sections. 
3.2.10 Surface Roughness Evaluation of Delayed Delivery of a Potential OA Therapeutic 
Male Lewis rats weighing 300-325g were acclimated for 1 week after receipt and 
underwent sham (n=7) or MMT surgery in the left leg as described previously. At either 
24-hours (n=7) or three-weeks (n=5) after surgery, 50μL of µ-dHACM (EpiFix® 
Injectable, MiMedx Group Inc, Marietta, GA, USA) suspended in saline at 80µg/mL was 
injected intra-articularly into the knee of the left leg using 25-gauge needles. Other MMT 
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animals received saline injections at three-weeks post-surgery as control (n=6). The 
animals were euthanized with CO2 six weeks after surgery and the left tibias were harvested 
and fixed in 10% NBF for 48 hours. EPIC-µCT imaging with surface roughness analysis 
was performed on the tibias as described in the previous sections. 
3.2.11 Histology 
After scanning, tibias were decalcified in Cal-Ex™ II (Thermo Fisher Scientific, Waltham, 
MA), embedded in paraffin, sectioned into 5μm sections, and stained with Safranin-O with 
fast green counterstain. 
3.2.12 Statistics 
All statistical analyses were performed using GraphPad Prism® Version 7 (GraphPad 
Software, Inc., La Jolla, CA), and all quantitative data are shown as mean ± 95% 
confidence interval of the mean. Two-way ANOVAs were used to determine significant 
effects of time (one-week vs three-week) and surgery (sham vs MMT) for all parameters 
except lesion volume and occurrence, and a Bonferroni post-hoc test was used to compare 
means across time points or surgery groups in each parameter that showed significant 
overall group effects or interactions. The Wilcoxon signed rank test was used to determine 
if lesion volume medians in the MMT samples were significantly different than a 
theoretical mean of 0.000 mm3. In the surface roughness validation, the relationship 
between the actual and the measured roughness values of the digital phantom surfaces was 
analyzed using linear regression analysis. For the surface roughness analysis of the delivery 
of µ-dHACM, data is shown one-way ANOVAs with Bonferroni post-hoc tests were used 




After completing the analyses in both the sagittal and coronal planes, a greater number of 
significant differences (though similar overall results) between MMT and sham samples 
were observed in the sagittal datasets; therefore, only sagittal data will be presented here. 
The coronal analysis data are included in Appendix C for reference. 
3.3.1 Cartilage Analysis 
A complete summary of the cartilage EPIC-µCT parameter results is in Figure 3.3. One-
week post-surgery, MMT resulted in significant positive effect sizes in attenuation, 
volume, and thickness (2.0, 1.9, 1.8, respectively) in the medial third of the medial tibial 
plateau compared to sham. At three-weeks post-surgery, MMT resulted in a significant 
positive effect size in attenuation (4.3) in the medial third while significant positive effect 
sizes in volume (5.4, 3.1, 3.3, and 3.6) and thickness (6.2, 2.6, 5.6, and 4.2, respectively) 
were seen in the entire medial tibial plateau and the lateral, central, and medial thirds, 




Figure 3.3: EPIC-μCT cartilage parameters – attenuation (A), volume (B), and 
thickness (C) in the sagittal slice method of analysis. Data are grouped by location 
(entire medial tibial plateau and lateral, central, and medial thirds thereof), time 
point (one- or three-weeks post-surgery), and surgery group (sham or medial 
meniscus transection {MMT}). Data shown as mean ± 95% confidence interval and 
significance was determined using two-way ANOVAs with Bonferroni post-hoc 
tests. n = 7-8. 
3.3.2 Subchondral Bone Analysis 
A complete summary of the subchondral bone parameter results is shown in Figure 3.4. In 
all parameters at one-week post-surgery and in most parameters at three-weeks post-
surgery, there were no significant differences between sham and MMT samples. At three-
weeks post-surgery, subchondral plate mineral densities of the entire plateau and in the 
medial third were significantly greater (effects sizes were 1.5 and 1.7, respectively) in 
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MMT samples when compared to sham controls. Subchondral plate volume and thickness 
of the medial third of the medial tibial plateau were significantly greater (effect sizes were 
2.3 and 2.7, respectively) in the MMT samples compared to sham controls. 
 
Figure 3.4: EPIC-μCT subchondral plate parameters – mineral density (A), volume 
(B), porosity (C), and thickness (D) in the sagittal slice method of analysis. Data are 
grouped by location (entire medial tibial plateau and lateral, central, and medial 
thirds thereof), time point (one- or three-weeks post-surgery), and surgery group 
(sham or medial meniscus transection {MMT}). Data shown as mean ± 95% 
confidence interval and significance was determined using two-way ANOVAs with 
Bonferroni post-hoc tests. n = 7-8. 
3.3.3 Lesion Analysis 
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No lesions were detected in the sham samples but lesions were detected in 3 out of 8 one-
week MMT samples and 7 out of 8 three-week MMT samples. At three-weeks post-
surgery, the median lesion volume was significantly different than 0.0 mm3 in MMT 
samples as determined by the Wilcoxon signed rank test (Figure 3.5.A). 
 
Figure 3.5: EPIC-μCT lesion and osteophyte (OP) parameters – lesion volume (A) in 
the sagittal slice method of analysis and OP cartilage volume (B), OP cartilage 
thickness (C), and OP mineralized volume (D) in the coronal slice method of 
analysis. Data shown as mean ± 95% confidence interval. n = 7-8. Significance for 
lesion volume was determined using from Wilcoxon signed rank test comparing if 
lesion volumes are significantly different from 0.000mm3. Significance for OP 
parameters was determined using two-way ANOVAs with Bonferroni post-hoc tests. 
3.3.4 Osteophyte Analysis 
At one-week post-surgery, MMT samples showed a significant increase in osteophyte 
cartilage thickness and volume compared to sham samples (effect sizes were 5.7 and 3.7, 
respectively; Figure 3.5.B, C). At three-weeks post-surgery, osteophyte cartilage thickness 
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and volume, and osteophyte mineralized tissue volume were significantly higher compared 
to sham controls (effect sizes were 12.8, 13.1, and 2.9, respectively; Figure 3.5.B, C, D). 
3.3.5 Surface Roughness Algorithm Validation 
There was strong agreement between the actual and measured surface roughness values of 
all three sets of phantom surfaces (r2 = 0.986, 0.997, and 0.999 for linear-linear, linear-
quartic, and quadratic-quartic, respectively, with p-values <0.001 for each) (Figure 3.6.B). 
The average percentage error of the surface roughness measurements decreased as 
roughness value increased (Figure 3.6.C), and, when the relationship between roughness 
and average percentage error was fit using semi-logarithmic curves, surface roughness 
values greater than 0.6 voxels were related to average percentage errors below 10% for all 
three surface fits. 
 
Figure 3.6: Surface roughness validation with digital phantom surfaces. Phantom 
surfaces of varying defined roughness (0.25 to 2 voxels, n=5 for each roughness 
value) were exported as serial TIFFs and imported into the custom surface 
roughness program for roughness measurement. (A) Representative phantom 
surface with curvature in two planes (quadratic-quartic in the M-N directions, 
respectively). (B) Relationship between actual roughness values and measured 
roughness values (mean ± 95% confidence interval) for linear-linear, linear-
quadratic and quartic-quadratic surfaces at varying roughness values. (C) 
Percentage error (mean ± 95% confidence interval) of measured roughness values 
compared to actual roughness values of the phantom surfaces at varying roughness 
values. Scale bar equals 25 voxels. 
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3.3.6 Surface Roughness Analysis 
One-week post-surgery, MMT cartilage surface roughness was significantly greater in the 
central and medial thirds of the medial tibial plateaus when compared to sham controls 
(effect sizes were 15.0 and 3.4, respectively). At three weeks, surface roughness was 
significantly greater in both the central and medial thirds compared to sham controls (effect 
sizes were 15.0 and 19.7, respectively; Figure 3.7). 
 
Figure 3.7: Cartilage surface roughness measurements. Representative differential 
surfaces of VOIs of lateral (A, D), central (B, E), and medial (C, F) thirds of the 
medial tibial plateau in rats that underwent sham (A, B, C) or medial meniscus 
transection (MMT; D, E, F) surgery. The differential surfaces were created by 
subtracting individual quadratic-quartic fits from the corresponding cartilage 
surface renderings. Surface roughness values for sham and MMT samples at one 
and three weeks in VOIs of the lateral (G), central (H), and medial (I) thirds of the 
medial tibial plateaus. Data shown as mean ± 95% confidence interval and 
significance was determined using two-way ANOVAs with Bonferroni post-hoc 
tests. n = 7-8.  In A-F, red indicates the point is more proximal and blue indicates a 
point is further distal. Scale bars equal 500 μm. 
3.3.7 Surface Roughness Analysis of Acute Delivery of µ-dHACM 
  
 35 
Surface roughness was calculated using the surface roughness program. Analysis of medial 
third of the medial tibial plateau showed an increase in surface roughness in saline and µ-
dHACM treatment compared to non-operated control limbs. (Figure 3.8). 
 
Figure 3.8: Cartilage surface roughness analysis of acute delivery of µ-dHACM. 
Surface roughness was significantly higher than non-operated control in both the 
saline and acute (24-hours post-surgery) micronized dehydrated human 
amnion/chorion membrane (μ-dHACM) treatment groups, Data shown as mean ± 
SEM. n = 5. 
3.3.8 Surface Roughness Analysis of Delayed Delivery of µ-dHACM 
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Surface roughness was calculated using the surface roughness program. Analysis of medial 
third of the medial tibial plateau showed an increase in surface roughness in saline and 
acute treatment groups compared to sham and delayed treatment (Figure 3.9). 
 
Figure 3.9: Cartilage surface roughness analysis of delayed delivery of µ-dHACM. 
Surface roughness was significantly higher than sham in the saline and acute (24-
hours post-surgery) micronized dehydrated human amnion/chorion membrane (μ-
dHACM) treatment groups, while surface roughness in the delayed μ-dHACM 
treatment (three-weeks post-surgery) group was significantly lower than saline and 
acute treatment groups. Data shown as mean ± 95% confidence interval. n = 5-7. 
3.3.9 Histology 
Safranin-O staining showed a qualitative decrease in cartilage proteoglycan content and 
the presence of fibrillation, lesions, and cartilage thickening in the MMT samples at both 
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one and three weeks compared to sham, supporting the results seen with EPIC-μCT (Figure 
3.10). 
 
Figure 3.10: Representative histology sections. Sections (paraffin processing, 
Safranin O with fast green counterstain) from central (A, B, C) and medial (D, E, F) 
thirds of the medial tibial plateau for sham (A, D), one week medial meniscus 
transection (MMT; B, E), and three week MMT (C, F) groups illustrate differences 
in the fibrillations and lesions (black arrows) and cartilage thickening (red arrows). 
Red staining indicates presence of proteoglycans in the tissue. Sections are sagittal 
slices and scale bars equal 1 mm. 
3.4 Discussion 
Small animal pre-clinical models of OA are used for screening potential OA therapies 
because of their low cost, reproducibility, and ability to recapitulate disease manifestations 
similar to human OA[4]. Using these models requires accurate characterization of the 
models to verify their relevance to human disease and to inform the effects and mechanisms 
of the tested therapies. EPIC-μCT has been used to provide accurate characterization of 
multiple pre-clinical models and the effects of various potential OA therapies[3], [40], [65], 
[103]. The purpose of this study was to use EPIC-μCT to provide quantification of early 
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disease development and progression in cartilage and bone tissues, including a measure of 
cartilage surface roughness, in the rat MMT model. 
Previous studies of cartilage changes in the MMT model have shown that degenerative 
changes progressively develop. Janusz, et al., demonstrated that degenerative changes, as 
measured with histological scoring, increased at three- and six-weeks post-surgery 
compared to one-week post-surgery[48]. EPIC-μCT quantification of degeneration in this 
model showed that decreases in cartilage proteoglycan content and increases in lesion and 
osteophyte volumes were present at two- and three-weeks post-surgery but not at one-week 
post-surgery[99]. Within these studies, there were no apparent changes at the earliest 
timepoint (one-week post-surgery) and no investigation of how the EPIC-μCT parameters 
develop spatially in the first three-weeks post-surgery. Understanding the location and 
timing of tissue changes in this model will assist researchers in relating data from the MMT 
model to clinical situations. Thus, this work has sought to 1) expand the capabilities of 
EPIC-μCT to include measuring surface roughness associated with cartilage fibrillation, 
one of the earliest indicators of human OA development[81], and 2) quantify early 
degenerative tissue changes within the MMT model.  
The current study demonstrated that increases in cartilage surface roughness appeared at 
one-week post-surgery in the central and medial thirds of the medial tibial plateau while 
increases in cartilage attenuation (inversely proportional to proteoglycan content), 
thickness, and volume were apparent only in the medial third at one-week post-surgery. By 
three weeks, changes in multiple cartilage parameters were evident throughout the tibial 
plateau. These changes, similar to those presented in other studies[3], [40], [99], suggest 
that in EPIC-μCT analysis of the MMT model, quantifiable cartilage surface changes 
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appear earlier than changes in proteoglycan content, volume, and thickness. This is similar 
to the development of OA in humans where surface fibrillations have been shown to be 
one of the earliest disease indicators[81]. 
Subchondral bone thickening and changes in mineral density are known to occur early in 
human OA and to be evident before radiographic indications of joint space narrowing[104], 
[105]. In a previous study by Yu, et al., MMT resulted in increases in subchondral plate 
thickness and decreases in plate mineral density within the medial tibial plateau at eight- 
and twelve-weeks post-surgery[106]. In the current study, however, there were significant 
increases in mineral density, volume, and thickness in the subchondral bone at three-weeks 
post-surgery. This suggests that subchondral bone changes do occur in the MMT model at 
earlier timepoints than previously reported and initially develop later than and over a more 
focal region than changes in the cartilage.  
While MMT resulted in changes in multiple parameters and locals in the medial tibial 
plateau, the largest effect sizes were in the surface roughness measures at three-weeks post-
surgery with effect sizes of 15.0 and 19.7 in the central and medial thirds, respectively. 
Osteophyte cartilage thickness and volume measurements also resulted in large effect sizes 
of 5.7 and 3.7 at one-week post-surgery and 12.8 and 13.1 at three-weeks post-surgery. 
Within the cartilage volume and thickness measurements at three-weeks post-surgery, the 
largest effect sizes due to MMT were in analyses of the entire medial plateau and in the 
central third, not in the medial third of the medial tibial plateau where the changes first 
appear. Altogether, these results suggest surface roughness and osteophyte measurements 
may be the most sensitive in the MMT model. In addition, EPIC-μCT analysis of this model 
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need not be restricted to the medial third of the medial tibial. Rather, there could be benefit 
in quantifying changes throughout the medial plateau. 
There are few previous studies of surface roughness changes in the rat tibial plateau 
cartilage. A recent study by Maerz et al. used a mesh parameterization technique to 
calculate cartilage thickness and surface roughness in contrast enhanced μCT images of 
rats that underwent ACLT surgery[107]; however, the authors defined surface roughness 
as deviation of cartilage thickness from an average thickness rather than deviation of the 
cartilage surface features from a smooth surface. Thus, their surface roughness 
measurement is a better measure of variations in the cartilage thickness rather than surface 
changes resulting from fibrillations as measured in the current study. The utility of one 
measure over the other would depend on the specific patterns of cartilage fibrillation and 
thickening determined by the model and the endpoint of the study. 
For the work presented here, a polynomial surface (quadratic and quartic in the 
medial/lateral and anterior/posterior planes, respectively) was chosen to eliminate 
curvature of the tibial plateau, comparable to using a low-pass filter in other surface 
roughness measurement techniques[102]. When qualitatively comparing the fitted quartic-
quadratic surface to the actual cartilage surface as imaged by EPIC-μCT, it appears that the 
use of this fitted surface captures not only cartilage surface roughness changes associated 
with fibrillations but also deviations in the more general cartilage surface shape of MMT 
joints when compared to sham-operated joints. These surface shape changes may indicate 
local changes in cartilage thickness caused by altered joint kinematics in the MMT animals. 
In humans, it has been found that knee kinematics are correlated with ratios of medial to 
lateral cartilage thickness, and these correlations change with age and presence of knee 
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OA[25], [108]. Future work combining gait mechanics and EPIC-μCT imaging in the 
MMT model could lead to greater understanding of the relationship between knee 
kinematics and specific areas of tissue changes. 
This study included a validation of the surface roughness measurements using digital 
phantom surfaces but did not include a validation using physical surfaces. μCT is a well-
established and validated technique that has been shown to accurately represent the 3D 
structure of numerous materials and tissues, including cartilage[65], [99], [107]. As 
demonstrated by the excellent linear fits in the digital phantom validation data (r2>98%), 
the algorithm used in this study can accurately measure roughness values greater than 
~50% of a given surface’s voxel size. In addition, even though the feature resolution of 
16μm scans is not high enough to resolve individual cartilage fibrils, the large increase in 
surface roughness (124%) with high effect size (19.7) in the in vivo surface roughness data 
demonstrate that the utilized voxel size is sufficient to detect the increase in macroscale 
surface roughness associated with cartilage fibrillation in the MMT model. Thus, the digital 
phantom and in vivo data demonstrate that 16μm scans have sufficient accuracy and 
sensitivity to detect changes in cartilage surface roughness associated with fibrillations 
resulting from MMT surgery. 
Surface roughness analysis of joints that received treatment with µ-dHACM demonstrate 
that surface roughness analysis does provide additional information when analyzing 
potential OA therapeutics. The three-week study in Willett, et al, saw no difference in 
attenuation or lesion volume between the acutely delivered µ-dHACM group and the 
unoperated control[40] but surface roughness analysis performed in this aim demonstrated 
that there were still substantial changes on the cartilage surface. This suggests that µ-
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dHACM delivery did not prevent OA development, simply delayed it. This conclusion is 
supported by the six-week study (see Appendix 4) which showed that an acute delivery of 
µ-dHACM resulted in no difference in overall joint damage compared to saline-treated 
controls. The delayed delivery of µ-dHACM, however, did result in decreased surface 
roughness compared to saline-treated controls, implying that delayed µ-dHACM may be 
more effective as a delayed treatment than an acute treatment. 
The scope of the data presented here is limited in that it is from one model of post-traumatic 
osteoarthritis in one strain of rat. As has been shown in other studies, the parameters 
quantified in this study will be different in different rat strains and in different models of 
OA[3], [107]. In addition, the sensitivity of the different analysis parameters in this study 
could influence the detected sequence of tissue changes. Further expansion of EPIC-μCT 
analyses, such as adapting voxel-based techniques from magnetic resonance imaging[109] 
to increase sensitivity of attenuation changes, could alter this detected sequence of changes. 
This study also did not include robust comparison to traditional histological measures of 
OA development[49], [50], and the ability of histological staining to assess microscale 
fibrillation, cellular health, more specific protein concentration, synovium health, calcified 
cartilage, and other relevant parameters in OA research are not replicated with EPIC-μCT. 
One of the advantages of contrast enhanced μCT analysis of OA models is that it is non-
destructive and does not preclude further histological analyses. The scope of this study was 
not to provide a comparison to histology, which previous studies have done[3], [99]; rather, 
the purpose of this study was to demonstrate how the measured EPIC-μCT parameters 
varied as a function of disease and time and to validate that changes in surface roughness 
could be quantified using EPIC-μCT. Despite the limitations, this study and previous 
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EPIC-μCT studies demonstrate the utility and adaptability of contrast enhanced μCT 
imaging in OA pre-clinical research. 
In conclusion, this work has established that an algorithm using EPIC-μCT images can 
accurately quantify increases in cartilage surface roughness resulting from MMT surgery. 
It has characterized early degenerative changes in joint tissues in a preclinical OA model, 
displaying the extent of cartilage fibrillation, proteoglycan loss, subchondral bone 
sclerosis, and lesion and osteophyte development quantified using nondestructive EPIC-
μCT techniques. With the continued unmet need for effective OA therapeutics, this work 
demonstrates the utility of EPIC-μCT imaging in understanding early stage pathological 
development in small animal OA models and its potential to evaluate disease modifying 




CHAPTER 4. IN VIVO EVALUATION OF THE EFFECT OF 
PARTICLE SIZE ON AN ECM BASED OA THERAPEUTIC 
4.1 Introduction 
Osteoarthritis (OA), the most common form of arthritis, affects an estimated 13% of the 
adult population in the US (~27 million people) with an estimated 37% of the U.S. adult 
population over 60 years of age being affected by knee OA alone[2], [27]. OA is 
characterized by overall joint degeneration that includes cartilage loss, bone sclerosis, 
osteophyte formation, and synovial changes[110]. While researchers continue to explore 
many promising disease modifying therapies, including platelet rich plasma and stem cells, 
there is still a lack of FDA-approved treatments that prevent the progression of OA[110]. 
Recently, multiple researchers have tested the safety and efficacy of amniotic membrane 
suspensions to treat OA progression. This extracellular matrix-based therapy has been 
shown to possess immunomodulatory properties and multiple soluble factors that 
encourage tissue healing[44], [111]–[114], and amniotic membrane has been used 
extensively to treat ocular tears and skin ulcers[111], [115]. Due to these factors and the 
abundant clinical availability, amniotic membrane suspensions are an attractive potential 
OA therapy and various formulations have been studied for their effect on OA. Willett et 
al. showed that intra-articular injection of micronized dehydrated amnion/chorion 
membrane (µ-dHACM) reduced OA progression three weeks after surgery in the rat medial 
meniscus transection (MMT) model[40]. Raines et al. showed that treating MMT joints 
two weeks post-surgery with suspensions of combined amniotic membrane and umbilical 
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cord particles reduced damage progression[116]. Vines et al. tested the safety of 
suspensions consisting of combined amniotic membrane particles and amniotic fluid 
derived cells in human knee joints and showed no adverse reactions to the suspension 
injections[117]. While these results are consistently promising, many of the factors 
influencing the potential therapeutic efficacy of these amniotic membrane suspensions 
remain unexplored. 
The size of the amniotic membrane particles could play a large role in the therapeutic 
efficacy of the suspension. Size of particles would likely affect the release of factors, 
clearance of particles, and degradation of particles. A recent study by Chen et al. explored 
the factor release kinetics and degradation patterns of drug-loaded poly(lactide-co-
glycolide) (PLGA) microparticles fractionated along well defined sizes (<20, 20-50, 50-
100, and >100 μm)[118]. Smaller particles resulted in more of a burst release of the drug, 
independent of particle degradation, while the drug release from the large particles was 
dependent on both short-term diffusion and long-term particle degradation. While PLGA 
is a different material, these results are consistent for particles in general and support the 
hypothesis that changing the particle size could alter the factor release from and 
degradation of micronized amniotic membrane particles. 
This work investigated two commercially available formulations of micronized amniotic 
membrane that were expected to have two different distributions of particle sizes 
(AmnioFix® Injectable and AmnioFix® Sports Medicine, MiMedx Group, Inc., Marietta, 
GA). Specifically, the particle size profiles of both formulations were quantified and the 
influence of the different size profiles on the in vivo therapeutic efficacy of µ-dHACM in 
the MMT model was evaluated using equilibrium partitioning of an ionic contrast agent 
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microcomputed tomography (EPIC-µCT) and histology. In addition, the effect of the size 
profiles on in vivo particle retention within the joint and on in vitro protein elution was 
quantified. We hypothesized that varying the size profile of the µ-dHACM particles would 
alter the therapeutic efficacy, particle retention, and protein elution of the particles. 
4.2 Materials and Methods 
4.2.1 Manufacture and preparation of μ-dHACM 
Particulate amniotic membrane was produced using the proprietary PURION® process 
(MiMedx Group, Inc.) that generates a dehydrated, devitalized amnion and chorion tissue 
graft which is then sterilized and micronized into particulate form. Two different 
formulations were used in this study: µ-dHACM (AmnioFix® Injectable, MiMedx Group 
Inc.) and reduced particle size µ-dHACM (RPS µ-dHACM; AmnioFix® Sports Medicine, 
MiMedx Group, Inc.). For each formulation, independently processed samples from five 
donors were pooled while in dehydrated form, and the required amount by mass was 
measured from the pooled material and rehydrated for each experiment in this study. 
4.2.2 Size Characterization 
µ-dHACM and RPS µ-dHACM particles were stained for 30 minutes in Eosin, centrifuged 
at 6000 RCF for 3 minutes, and washed with 0.1% Triton X-100 after injecting through a 
25-gauge needle. The particles were suspended in Triton X and mixed well throughout the 
process to prevent clumping. Particles were suspended in 0.1% Triton X-100 at 6mg/mL, 
and 10uL of each particle suspension was imaged via Zeiss LSN 700 confocal microscope 
(Carl Zeiss, Inc Thornwood, NY). The maximum intensity images were then imported into 
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Volocity Quantitation (Perkin Elmer, Inc, Waltham, MA, USA) and the area of each 
particle was calculated. All particles from both formulations were combined and then 
binned according to particle area (<10µm2, 10-<20µm2, 20-<50µm2, 50-<100µm2, 50-
<100µm2, 100-<250µm2, 250-<500µm2, and >500 µm2). 
4.2.3 Animal Study and EPIC-μCT Imaging 
The Georgia Institute of Technology IACUC approved all animal studies (Protocol # 
A14019). Weight matched male Lewis rats (300-350g) underwent sham or MMT in the 
left leg. One day after surgery, µ-dHACM and RPS µ-dHACM were resuspended in saline 
at a concentration of 80mg/mL, and 50µL of either saline, μ-dHACM, or RPS μ-dHACM 
were injected intra-articularly using a 25-gauge needle (BD, Franklin Lakes, NJ, USA) 
through the infrapatellar ligament. Three weeks post-surgery all animals were euthanized 
with CO2 inhalation, and the left legs were harvested and prepared for equilibrium 
partitioning of an ionic contrast agent microcomputed tomography (EPIC-μCT) scans as 
described previously[65]. EPIC-µCT imaging is a contrast-enhanced µCT imaging 
technique that allows simultaneous 3D quantification of cartilage, subchondral bone, and 
osteophyte parameters. Briefly, after formalin fixation for 3-4 days, the knee joints were 
disarticulated and the femurs retained for later histological analysis. The soft tissue 
surrounding the tibias was removed and the tibias were incubated in 30% Hexabrix™ 320 
(Mallinckrodt Inc., St. Louis, MO, USA) contrast agent in PBS without calcium and 
magnesium at 37°C for 30 minutes. The tibias were then scanned using a Scanco μCT 40 
(Scanco Medical, Brüttisellen, Switzerland) at 45 kVp, 177 μA, 200 ms integration time, 
and a voxel size of 16 μm. After scanning, the tibias were incubated in PBS at 37°C for 30 
minutes to remove contrast agent. 
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The 2D axial greyscale EPIC-μCT images were rotated to sagittal  sections, and cartilage, 
subchondral bone, and lesion volume analyses were performed as described previously[3], 
[99], [119]. Briefly, three sets of contours were used to indicate cartilage, subchondral 
bone, or lesions in the medial tibial plateau. Global thresholds and Gaussian filters (sigma 
= 1.0, support = 1) were then applied to separate cartilage, subchondral bone, and air. 
Analyzed parameters included cartilage X-ray attenuation (as an indicator of proteoglycan 
content[63], [66]), cartilage thickness, cartilage lesion volume, subchondral bone mineral 
density, and subchondral bone thickness. A validated, custom-built surface roughness 
algorithm was also used to quantify cartilage surface roughness[119]. Cartilage and 
subchondral bone analyses were performed for the central and medial thirds of the medial 
tibial plateau while lesion volumes were quantified for any lesions found throughout the 
medial tibial plateau. 
Osteophytes are a thickening and partial mineralization of the medial edge of the medial 
tibial plateau. As a measure of osteophyte growth, the 2D axial images were rotated to 
coronal sections and the edge of the medial tibial plateau was contoured to include any 
bony outgrowth and cartilage thickening. Two sets of contours were used, one for 
mineralized tissue outgrowth that included extraneous soft tissue on the tibial edge, and 
another for cartilage volume that excluded the soft tissue. After contouring, two ranges of 
thresholds where used: one range to include only mineralized tissue and the other to include 
only cartilage the thickness and volume of marginal cartilage thickening as well as the 
volume of mineralized tissue within the osteophyte were measured. 
4.2.4 Protein Elution Comparison 
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Pooled μ-dHACM and RPS μ-dHACM were suspended at 20mg/mL in Krebs-Ringer 
bicarbonate buffer with 0.4mM added calcium and 1% bovine serum albumin (BSA). 
Three samples from each formulation were incubated at 37°C under constant agitation for 
21 days. The samples were centrifuged and the supernatant was collected for analysis at 
0.5, 1, 2, 3, 7, 14, and 21 days. Fresh buffer with calcium and BSA was added at each time 
point. For two other samples of each formulation, collagenase I was added at 1mg/mL to 
the buffer immediately after resuspension, and the samples were incubated at 37°C for 4.5 
hours with frequent mixing. Afterwards, the samples were centrifuged and the supernatant 
was collected for analysis. 41 different cytokines and chemokines were analyzed in both 
the extract and digested samples using the MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel – Immunology Multiplex Assay (Millipore 
Corporation, Billerica MA, USA). The concentration of all 41 analytes were calculated and 
the extract levels between µ-dHACM and RPS µ-dHACM were compared for the analytes 
with sufficiently detectible levels in both the digested and extracted samples.  
4.2.5 Fluorescent Tagging and Tracking of μ-dHACM 
Pooled μ-dHACM and RPS μ-dHACM were each suspended at 1mg/mL in 50mM sodium 
bicarbonate buffer per VivoTag® manufacturer’s instructions. VivoTag® 680XL (Perkin 
Elmer, Inc, Waltham, MA, USA) was suspended at 10mg/ml in dimethyl sulfoxide and 
was added to the μ-dHACM suspensions at a ratio of 1 mg dye to 20 mg μ-dHACM. The 
suspensions were mixed for an hour at room temperature then centrifuged and washed two 
times in saline to remove excess dye. The tagged particles were then suspended in saline 
at 80 mg/mL in preparation for the intra-articular injections. 
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Weight matched Lewis rats (300-350g) underwent MMT surgery in their left legs. One day 
after surgery animals received a 50µL intra-articular injection of fluorescently tagged 
particles, either μ-dHACM or RPS μ-dHACM (n=7). Fluorescent imaging was performed 
at the specified timepoints: immediately following the injections, every two days for the 
first week, and then twice a week until six-weeks post-surgery. The fluorescent signal of 
the tagged particles in the intra-articular space was imaged using an IVIS® Spectrum 
(Perkin-Elmer, Inc) at 675-720nm excitation-emission, 0.5 sec exposure, f-stop 8, and 
6.5cm field of view. The fluorescent intensity was measured as total efficiency (calculated 
by normalizing the fluorescent signal of the sample to the transmission image measured 
with the same emission filter and open excitation filter) within an area of interest that 
included any contiguous pixels with an efficiency within 27-100% of the peak signal at the 
knee joint and was presented as both absolute efficiency and normalized to the day 7 
efficiency. 
4.2.6 Histology 
After EPIC-µCT scanning of the tibias, tibias and femurs were decalcified in Cal-Ex II 
(Thermo Fisher Scientific, Waltham, MA), embedded in paraffin, sectioned into 5 μm 
sections, and stained with hematoxylin and eosin (H&E). 
4.2.7 Statistics 
All other statistical analyses were performed using GraphPad Prism® (GraphPad Software, 
Inc. 5.01, La Jolla, CA). EPIC-µCT data were analyzed using one-way ANOVA with 
Tukey post-hoc tests to compare means across treatment groups. Comparisons between µ-
dHACM and RPS µ-dHACM in both fluorescent particle tracking and growth factor 
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elution were performed using repeated measure ANOVA with Bonferroni post-hoc tests 
when warranted. Significance in all statistical tests was set at p<0.05. 
4.3 Results 
4.3.1 Particle Size Characterization 
The area of particles of µ-dHACM and RPS µ-dHACM were calculated and then binned 
according to particle size. A representative image of eosin stained µ-dHACM particles is 
shown in Figure 4.1.A. The percentage of particles from each formulation within each bin 
are displayed in Error! Reference source not found..B. 
 
Figure 4.1: Particle size distribution of µ-dHACM and RPS µ-dHACM. A. 
Representative section of eosin stained µ-dHACM particles imaged under a 
fluorescent confocal microscope. B. Proportion of µ-dHACM (lighter bars) and RPS 
µ-dHACM (dark bars) samples split into bins based on particle area. Significant 
differences (* = p<0.05) between the two groups in each bin were determined using 
Jackknife analysis involving 1000 analyses of 500 particle samples in each bin 
4.3.2 Cartilage EPIC-μCT Analysis 
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EPIC-µCT analysis indicated significant differences in cartilage, subchondral bone, and 
osteophyte parameters three weeks after surgery. Representative sagittal cuts from 3D 
EPIC-µCT x-ray attenuation maps qualitatively showed increased X-ray attenuation 
(decreased proteoglycan content[63], [66]) in MMT+saline (saline), MMT+µ-dHACM (µ-
dHACM), and MMT+RPS µ-dHACM (RPS µ-dHACM) samples compared to sham 
samples and reduced lesion formation after µ-dHACM treatment compared to both saline 
and RPS µ-dHACM treatment (Figure 4.2.A-D). 
 
Figure 4.2: Representative EPIC-µCT imaging. A-D Representative medial tibial 
cartilage attenuation maps show lower attenuation in sham treatment samples. 
Pseudocolor attenuation bar at bottom indicates red as high attenuation and green 
as low attenuation. A. Sham sample displays smooth cartilage surface with green 
color indicating healthy sulfated glycosaminoglycan (sGAG) content. B. Saline 
treatment sample displays high attenuation indicating lower sGAG content and 
lesion formation (black arrow). C. Sample receiving micronized dehydrated human 
amnion/chorion membrane (μ-dHACM) displays increased attenuation but reduced 
lesion development D. Sample receiving reduced particle size μ-dHACM (RPS µ-
dHACM) displays high attenuation and lesion formation (black arrow). Scale bars = 
1mm; higher magnification scale bars = 0.5 mm 
Saline treatment resulted in significantly increased cartilage X-ray attenuation (signifying 
proteoglycan loss) in the medial third of the medial tibial plateau as well as increased 
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cartilage volume, thickness, and surface roughness in the central and medial thirds 
compared to the sham group (Figure 4.3.A-F). Lesion volume in the entire medial tibial 
plateau was significantly increased in the saline group compared to sham (Figure 4.3.G). 
 
Figure 4.3: EPIC-μCT cartilage parameters – attenuation (A,B), thickness (C,D), 
and surface roughness (E,F) in the central (A,C,E) and medial (B,D,F) thirds of the 
medial tibial plateau; and lesion volume (G) in the entire medial tibial plateau. H. 
Evaluation areas of the central and medial thirds of medial tibial plateau indicated 
by red rectangles. Pseudocolor cartilage thickness bar in H indicates cartilage 
thickness throughout entire medial tibial plateau. Significance was determined 
using one-way ANOVAs with Tukey post-hoc tests. n = 9. * = p<0.05 vs Sham, & = 
p<0.05 vs Saline, # = p<0.05 vs µ-dHACM. 
μ-dHACM treatment in MMT animals resulted in significantly increased cartilage X-ray 
attenuation in the medial third of the medial tibial plateau as well as significantly increased 
cartilage volume, thickness, and surface roughness in the central and medial thirds 
  
 54 
compared to the sham group (Figure 4.3.A-F). μ-dHACM treatment, however, resulted in 
a significantly decreased lesion volume compared to the saline group (Figure 4.3.G). 
RPS μ-dHACM treatment in MMT animals resulted in significantly increased cartilage X-
ray attenuation (signifying proteoglycan loss), volume, thickness, and surface roughness in 
the central and medial thirds compared to the sham group (Figure 4.3.A-F). There was 
significantly increased cartilage surface roughness in the central third compared to saline 
and μ-dHACM treated groups (Figure 4.3.E). Lesion volume in the RPS μ-dHACM group 
was significantly increased compared to both sham and μ-dHACM (Figure 4.3.G). 
4.3.3 Subchondral Bone μCT Analysis 
There were no significant differences in the subchondral bone mineral density or thickness 
between any of the groups in the central third of the medial tibial plateau (Figure 4.4.A, 
C). Changes due to surgery or treatment were isolated to the medial third of the medial 
tibial plateau (Figure 4.4.B, D). Subchondral bone thickness in the medial third was 
significantly increased in the saline group compared to sham. There were significant 
increases in subchondral bone mineral density, and thickness in the medial third of the μ-
dHACM group compared to sham. There were significant increases in the subchondral 
bone mineral density and thickness in the medial third of the RPS μ-dHACM group 




Figure 4.4: EPIC-μCT subchondral bone parameters – mineral density (A,B), 
thickness (C,D) in the central (A,C) and medial (B,D) thirds of the medial tibial 
plateau. Significance was determined using one-way ANOVAs with Tukey post-hoc 
tests. n = 9. * = p<0.05 vs Sham. 
4.3.4 Osteophyte Volume EPIC-μCT Analysis 
Osteophyte cartilage thickness, cartilage thickness, and mineralized volume in the saline 
injection group were significantly increased compared to sham (Figure 4.5.A-C). 
Osteophyte cartilage thickness, cartilage volume, and mineralized volume were all 
significantly increased in the µ-dHACM group compared to sham, and osteophyte cartilage 
volume was also increased in the µ-dHACM group compared to the saline group. 
Osteophyte cartilage thickness and cartilage volume in the RPS µ-dHACM group were 




Figure 4.5: EPIC-μCT osteophyte (OP) parameters – A. Representative image of an 
OP observed on the tibia in the rat medial meniscal transection model with volumes 
of interest for cartilage (red) and mineralized tissue (green). OP cartilage thickness 
(B), OP cartilage volume (C), and OP mineralized volume (D) along the medial edge 
of the medial tibial plateau. Significance was determined using one-way ANOVAs 
with Tukey post-hoc tests. n = 9. * = p<0.05 vs Sham, & = p<0.05 vs Saline. 
4.3.5 Protein Elution 
Of 41 analytes quantified using the MILLIPLEX assay, 12 analytes had detectable levels 
in both the digested and extracted samples (the other analytes were below the limit of 
detection). Of these 12, four (epithelial growth factor (EGF), fibroblast growth factor 2 
(FGF2), platelet derived growth factor BB (PDGF-BB), and chemokine (C-C motif) ligand 
5 (CCL5)) had significantly different levels between the µ-dHACM and RPS µ-dHACM 
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samples, with all having increased factor eluted from the RPS µ-dHACM samples 
compared to the µ-dHACM. See Figure 4.6. 
 
Figure 4.6: Protein elution from µ-dHACM and RPS µ-dHACM samples. The 
amounts of 41 factors contained in collagenase-digested samples or eluted into 
buffer over 21 days were quantified using a multiplex ELISA. The four factors with 
significant differences between µ-dHACM and RPS µ-dHACM samples are shown 
here. normalized to the amount of that factor in collagenase digested samples of the 
same µ-dHACM formulation. Epidermal growth factor (EGF; A), fibroblast growth 
factor 2 (FGF2; B), platelet derived growth factor-BB (PDGF-BB; C), and 
chemokine (C-C motif) ligand 5 (CCL5; D) all showed increased factor elution 
within the 3 weeks in vitro. Significance determined using repeated measures 
ANOVA with Bonferroni post-hoc tests. n=3. 
4.3.6 In Vivo Particle Tracking 
Error! Reference source not found..A-D show representative images of fluorescent 
signal seen in µ-dHACM (Error! Reference source not found..A, C) and RPS µ-dHACM 
(Error! Reference source not found..B, D) injected joints at 7-and 28-days post-surgery. 
There were no differences seen in fluorescent efficiency between tagged µ-dHACM and 
RPS µ-dHACM over four weeks in either the raw fluorescent efficiency data (Error! 
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Reference source not found..E) or normalized data (Error! Reference source not 
found..F) indicating that there was no difference in particle clearance over the 28-day 
period. 
 
Figure 4.7: In vivo µ-dHACM particle tracking. A-D. Representative images of 
fluorescent signal in µ-dHACM (A,C) and RPS µ-dHACM (B,D) at Day 7 (A,B) and 
Day 28 (C,D) with arrows indicating the location of the knee. E-F. Fluorescent 
efficiency (E) and after normalizing to Day 7 efficiency (F) of fluorescently tagged µ-
dHACM and RPS µ-dHACM particles. There was no significant difference as a result 
of treatment found using a repeated measures ANOVA in either dataset though there 
were significant effects of time in both. Fluorescent efficiency is calculated by 
normalizing the sample fluorescent signal to the transmission image measured with 
the same emission filter and open excitation filter. Data shown as mean ± standard 
error of the mean and n=3. 
4.3.7 Histology 
Figure 4.8 shows representative histological images of H&E stained medial tibial plateaus 
sectioned in the coronal plan. Sham samples showed no cartilage damage (Figure 4.8.A-
B). Saline samples exhibited cartilage surface damage on the medial plateau indicated by 
fibrillations and lesions and osteophyte development indicated by cartilage thickening on 
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the medial edge of the plateau (Figure 4.8.C-D). μ-dHACM treatment reduced lesion 
development but not osteophyte development (Figure 4.8.E-F). RPS μ-dHACM treatment 
did not reduce lesion nor osteophyte development (Figure 4.8.G-H). 
 
Figure 4.8: Representative H&E histology images for the tibiae. A–B. Sham sample 
showed no cartilage damage. C-D. Saline sample exhibited cartilage surface damage 
on the medial plateau indicated by fibrillations and lesions and osteophyte 
development indicated by cartilage thickening on the medial edge of the plateau. E-
F. Micronized dehydrated human amnion/chorion membrane (μ-dHACM) 
treatment reduced lesion development but not osteophyte development. G-H. 
Reduced particle size μ-dHACM treatment did not reduce lesion nor osteophyte 
development. Scale bars in A, C, E, G are equal to 0.5 mm and bars in B, D, F, H are 
equal to 0.2 mm. 
4.4 Discussion 
Numerous extracellular matrix based therapeutics are being investigated for their potential 
efficacy in treating OA[120]. Amniotic membrane based therapeutics have shown efficacy 
at preventing OA development both when delivered acutely after injury (surgically 
induced) to the joint[40] or after OA disease has already developed[116]. However, many 
of the mechanisms and bioengineering factors that potentially influence the efficacy of this 
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treatment, including particle size, have yet to be explored. The purpose of this study was 
to investigate how altering the size of the amniotic membrane particles influences 
therapeutic efficacy, and we hypothesized that decreasing the size profile of the particles 
would increase factor elution and particle clearance rate from the joint. 
In this study, two commercially available formulations of µ-dHACM, AmnioFix® 
Injectable (µ-dHACM) and AmnioFix® Sports Medicine (RPS µ-dHACM), were shown 
to have significantly different particle size profiles with the RPS µ-dHACM having a 
higher proportion of particles between 5 and 20µm2. The study demonstrated that altering 
the particle size of the µ-dHACM does affect the therapeutic efficacy of the micronized 
amniotic membrane particles, as demonstrated by the increased lesion volume and surface 
roughness in the RPS µ-dHACM samples compared to the µ-dHACM samples. This study 
also confirmed that acute delivery of µ-dHACM, as shown previously[40], resulted in a 
significant decrease in lesion volume three-weeks post-surgery. While some of the 
protective effects of µ-dHACM treatment were observed in this study, the overall 
efficiency in preventing all measured parameters was not the same as previous studies. This 
could be due to the procedure used to pool and then weigh the µ-dHACM, slight differences 
between surgeons and severity of the induced OA, or slight variability in the product. 
Unlike in previous studies investigating the use of amniotic membrane particles in which 
each experimental animal was treated with amnion from a single donor, pooled samples 
from five donors was used for both µ-dHACM and RPS µ-dHACM. Because of the 
manufacturing processes used to produce µ-dHACM and RPS µ-dHACM, it was not 
feasible to receive both µ-dHACM and RPS µ-dHACM from the same donors. To reduce 
  
 61 
potential donor-to-donor variability between single samples in each formulation, pooled 
samples were used to achieve average sample properties for the formulations tested. 
This study was the first to look at osteophyte growth in the MMT model three weeks after 
an acute delivery of µ-dHACM. After treatment with either formulation of µ-dHACM, we 
observed a significant increase in osteophyte cartilage volume and, with the RPS µ-
dHACM, in osteophyte cartilage thickness. Amniotic membrane is known to contain 
FGF2, a known regulator of cartilage formation[121], [122], and this is corroborated by 
our own data (see Figure 4.6). The release of FGF2 could be stimulating cartilage growth, 
increasing the osteophyte volume. As there is no accompanying increase in mineralized 
tissue, this could indicate that that the increased cartilage volume is related to a 
chondrogenic pathway that could later undergo endochondral ossification. 
µ-dHACM is known to contain a number of growth and immunomodulatory factors[44], 
[111], [123] and it has been hypothesized that this factor release could play a role in the 
mechanisms of µ-dHACM reducing OA progression[40]. Particle size, both in theory and 
in practice, affects factor elution from PLGA particles[118] and thus could play a role in 
the release of factors from µ-dHACM. In this study, as expected with smaller particles, the 
RPS-µ-dHACM was shown to secrete a greater percentage of several contained factors in 
vitro. However, in vivo, this 0-70% increase in factor secretion from RPS µ-dHACM did 
not translate into greater prevention of disease progression. This suggests that µ-dHACM 
acts as more than simply a factor pool and that timing of factor release may also be 
important. In vivo, the smaller particles could result in a greater burst release of factors, 
while the larger particles could act as a reservoir of factors that are released in a more 
delayed fashion. Further analyses, including flow cytometry and immunohistochemistry to 
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identify fibroblast- and macrophage-like synoviocytes[21], [22] as well as macrophage 
polarization[124], could provide greater insight into the mechanisms of µ-dHACM and if 
the differences in µ-dHACM particle size and release of immunomodulatory factors result 
in differences in cell recruitment, proliferation, or differentiation. 
Previous work with µ-dHACM in the MMT model have shown that the µ-dHACM 
particles are sequestered into the synovium within three days of injections and are still 
present 21 days after injections[40]. While in this study the µ-dHACM particles were not 
apparent after three weeks in the synovium, fluorescent signal from tagged µ-dHACM was 
detectable in the joint out to four-weeks post-injection. This discrepancy could be 
explained by the difficulty in locating and recognizing ECM based particles using 
traditional 2D histological measures. Clearance of these fluorescently tagged µ-dHACM 
particles from the joint does not appear to be affected by the size profiles differences in 
these two formulations, suggesting that the majority of particles in both formulations are 
of a sufficient size to not be readily cleared from the joint[125]. 
While a significantly greater proportion of the RPS µ-dHACM particles were in the <10 to 
<20µm2 range, there was also a greater proportion of RPS µ-dHACM particles in the 
>500µm2 bin. While this difference did not reach significance, it could be that these larger 
particles, which make up a much larger proportion of the total volume of the particles are 
have a greater influence on the therapeutic efficacy than the smaller particles. As such, 
future work comparing particle size distributions with less overlap would clarify which 
size distribution has the greatest therapeutic effect. 
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This study has shown that altering µ-dHACM particle size distribution does affect 
therapeutic efficacy in a rat MMT model of OA. While the depth of the conclusions of this 
work is constrained by the large overlap in particle size between the two formulations, the 
results of this study further supports the potential of micronized amniotic membrane 
particles as a future OA therapeutic and demonstrates the possibility for engineers to 




CHAPTER 5. IN VITRO EVALUATION OF AN ECM BASED OA 
THERAPEUTIC 
5.1 Introduction 
Osteoarthritis, the most common form of arthritis, affects an estimated 13% of the adult 
population in the US (~27 million people) with an estimated 37% of the U.S. adult 
population over 60 years of age being affected by knee OA alone [2], [27]. It is 
characterized by overall joint degeneration that includes cartilage loss, bone sclerosis, 
osteophyte formation, and synovial changes[110]. While research is ongoing concerning 
many promising disease modifying therapies, including platelet rich plasma and stems 
cells, there is still a lack of treatments that prevent the progression of OA[110]. 
Amniotic membrane with its anti-inflammatory properties, multiple soluble factors that 
encourage tissue healing, and easy clinical availability has been used extensively in the 
clinic to treat ocular tears and skin ulcers. Amniotic membrane has also shown potential as 
a disease modifying OA therapy by preserving chondrocyte viability[45] and phenotype 
and repair osteochondral defects in rabbits[126]. Recently, multiple groups have tested the 
efficacy of micronized dehydrated amnion membrane at treat OA progression in rat models 
and have shown that particulates of amniotic membrane with and without umbilical cord 
tissue reduced OA progression in the rat medial meniscus transection model[40], [116]. 
Vines et al. tested the safety of suspended amnion particles in humans[117]. However, 




The intimal layer of the synovial membrane is a specialized connective tissue consisting of 
two main cell types: fibroblast-like synoviocytes and macrophage-like synoviocytes. These 
cells are responsible for maintaining the homeostasis of the joint cavity by removing debris 
and waste, regulating the inflammatory environment, and producing the hyaluronan and 
other proteoglycans necessary for the synovial fluid to perform its load-bearing and 
motion-enabling function[22]. Previous work in our lab exploring the therapeutic efficacy 
of amniotic membrane in the rat MMT model showed that the amnion membrane is 
sequestered into the synovial membrane of the joint[40]. This suggests that interactions 
between the synovium and the amnion play a crucial role in the mechanisms behind the 
therapeutic efficacy of amnion in vivo. A better understanding of the interactions between 
synoviocytes and amnion could elucidate the specific mechanisms of therapeutic efficacy 
in vivo. 
In vitro cultures of synoviocytes have proven useful in providing information on the role 
of the synovium may play in OA development[127] and of the effects of potential OA 
therapies[128], [129]. PDGF-AA[130], interferon-γ[131], and hyaluronic acid[132] have 
all been shown to reduce inflammation or protease signaling from synoviocytes in vitro 
while platelet rich plasma has increased synoviocyte death and inflammatory 
signaling[133]. In addition to the culture of synoviocytes alone, a number of researchers 
have also used synovium/cartilage co-cultures to better recapitulate the actual in vivo 
environment[84], [87], [90], [134]–[138], with one study showing that culture of 
synoviocytes with chondrogenic stem cell pellets appears to result in increased levels of 
IL-8 and MMP-1[90]. 
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Because of the previous work showing an important role of the synovium in OA 
development and, potentially, the therapeutic benefit of µ-dHACM, this work was designed 
to investigate the effect of interactions between synoviocytes and µ-dHACM in in vitro 
culture. Specifically, it will investigate what effect µ-dHACM has on the cytokine, 
chemokine, and MMP production of IL-1β- and TNF-α-activated synoviocytes and how 
the particle size of the µ-dHACM may influence thus interaction. We also explore how the 
co-culture of synoviocytes and µ-dHACM affects the loss of proteoglycans in cytokine-
stimulated chondrocyte pellets. This outcome of this study will help explain the therapeutic 
efficacy of µ-dHACM treatment in OA models. 
5.2 Materials and Methods 
5.2.1 Preparation of μ-dHACM 
µ-dHACM was prepared using the proprietary PURION® process (MiMedx Group, Inc. 
Marietta, GA). Specifically, AmnioFix Injectable was used for all the studies while 
AmnioFix Sports Medicine, which has been shown to have a larger proportion of small 
particles (see Chapter 4) was also used to investigate the effect of particle size. To account 
for donor to donor variations in the µ-dHACM, five different batches of each formulation, 
each from a different donor, were pooled prior to adding them to in vitro cultures. 
To obtain the amnion particle extract used in this study, the amnion particles were extracted 
at 20mg/mL at 4°C for 24 hours in culture media (CM) consisting of MEM-alpha with 16% 
FBS, 1% PSA, and 1% L-Glutamine. After extraction, the particles were removed from the 
20mg/mL extract by centrifugation and filtration. 
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5.2.2 Activation of Synoviocyte Cultures 
Human fibroblast-like synoviocytes from three separate donors were purchased and 
cultured to passage 3 in proprietary Synoviocyte Growth Media (Cell Applications, Inc, 
San Diego, CA). For all following experiments, synoviocytes from all three donors were 
pooled in equal amounts. After recovery from frozen and seeding in 96-well plates in 
Synoviocyte Growth Media, synoviocytes were activated for 24 hours with human 
interleukin-1β and tumor necrosis factor α (5ng/mL each) in 0.2 mL CM. CM without 
cytokines was added to control wells. 
5.2.3 Synoviocyte and Amnion Dosing Study 
24-hours after synoviocyte activation with the cytokines, 200 µL of CM; CM with 10, 1, 
0.1, or 0.01 mg/mL µ-dHACM particles separated with a 5.0µm-pore-size transwell insert 
(Corning®, Corning, NY, USA); or 10, 1, or 0.1 mg/mL µ-dHACM extract in CM were 
added to the wells. 3 days after µ-dHACM addition, the media was removed for cytokine, 
chemokine, and matrix metalloprotease (MMP) content quantification and MMP activity 




Figure 5.1: Experimental design for in vitro studies. A) Experimental setup for 
synoviocyte/µ-dHACM co-culture. B) Experiment setup for chondrocyte 
pellet/synoviocyte/µ-dHACM co-culture. 
5.2.4 Synoviocyte and Amnion Particle Size Study 
24-hours after synoviocyte activation, 300 µL of CM; CM with 10 mg/mL of either µ-
dHACM or RPS µ-dHACM with in a 5.0-pore-size transwell insert; or CM with 10mg/mL 
µ-dHACM or RPS µ-dHACM extract was added to the synoviocytes. Acellular plates with 
the same treatments were also prepared. 3 days after µ-dHACM addition, the media was 
removed for cytokine, chemokine, and matrix metalloprotease (MMP) content 
quantification and MMP activity assay. Synoviocytes are washed in PBS, fixed in 4%PFA 
overnight, washed twice in PBS, stained with 1% DAPI in PBS, washed twice in PBS, and 
imaged using BioTek Cytation 3 Imaging Plate Reader (BioTek, Winooski, VT, USA). 
BioTek Gen 5 Software was used to count cell nuclei for synoviocyte cell count. Cytokine 
and chemokine content was analyzed using the MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel – Immunology Multiplex Assay (EMD 
Millipore). MMP content was quantified using MILLIPLEX MAP Human MMP Magnetic 
Bead Panel 1 – Immunology Multiplex Assay (EMD Millipore). MMP activity was 
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quantified using the MMP Activity Assay Kit from Abcam after a 24hour incubation with 
2mM 4-Aminophenylmercuric Acetate to quantify MMP activity. 
5.2.5 Direct µ-dHACM 
 
5.2.6 Chondrocyte Pellet Co-culture 
Primary bovine articular chondrocytes were purchased frozen from Astarte Biologics, 
thawed, and pelleted to form pellets of 200,000 cells each. They were cultured in serum-
free media (DMEM with sodium pyruvate, high glucose, l-glutamine, ITS+, non-essential 
amino acids, ascorbic acid-2-phospate, gentamicin, and dexamethasone) with media 
changes 3 times a week for two weeks prior to starting co-culture with synoviocytes and 
µ-dHACM. 
24-hours after synoviocyte activation, pellets (one per well), µ-dHACM (10ng/mL), and 
cytokines (5ng/mL IL-1β and 5ng/mL TNF-α) were added to the 96 well plates in 5 
different culture combinations: pellets alone (P), pellets + cytokines (P+C), pellets + 
synoviocytes + cytokines (P+S+C), pellets + µ-dHACM + cytokines (P+A+C), and pellets 
+ synoviocytes + µ-dHACM + cytokines (P+S+A+C). The pellets were placed in transwell 
inserts to keep them separate from the synoviocytes and µ-dHACM was added directly to 
the bottom of the 96-well plates. The wells with cytokines had cytokines added both during 
synoviocyte activation and during co-culture with pellets and µ-dHACM. Three days after 




Five pellets from each group were digested using proteinase K for 3 hours with periodic 
mixing. The digest was analyzed using DMMB and Picogreen DNA assays. 
5.2.7 Statistics 
For the purposes of analysis, the groups in synoviocyte and amnion particle size experiment 
were split into two 2x2 experimental layouts: 1) with vs without cytokine activation, and 
with vs without amnion treatment; and 2) µ-dHACM vs RPS µ-dHACM, and transwell vs 
extract culture. Partial least square discriminate analyses on both sets were performed using 
in-house software and 2-way ANOVAs with Sidak post-hoc tests were performed using 
GraphPad Prism® (GraphPad Software, Inc. 7.03, La Jolla, CA). Comparisons for the 
direct µ-dHACM and chondrocyte pellet co-culture experiments were made using one-way 
ANOVAs with Tukey Post-hoc tests. 
5.3 Results 
5.3.1.1 Synoviocyte Culture 
Throughout the experiments, synoviocytes showed a fibroblast-like morphology, 
indicating that the synoviocytes were of a fibroblast-like lineage and not a macrophage 
lineage. 
5.3.1.2 Activation vs Treatment Groups 
A 2-way ANOVA for cell number did result in significant interactions between the 
activation and treatment groups, thus all cell means were compared to each other. Both 
activation of synoviocytes with cytokines and treatment with µ-dHACM individually 
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resulted in decreased cell number compared to unactivated, untreated synoviocytes while 
the activated and µ-dHACM treated group had significantly lower cell number than the 
three other groups (See Figure 5.3.A). 
 
Figure 5.2: Synoviocyte Activation (Unactivted or Activated with 5ng/mL IL-1β and 
TNF-α) vs Treatment (Untreated or Treated with 10mg/mL µ-dHACM) Experiment. 
A) Synoviocyte cell number of groups showed that activation and µ-dHACM 
treatment, both independently and combined, reduced cell numbers compared to 
unactivated, untreated controls. B) Plot showing each sample’s score on latent 
variable 1 (LV1) and latent variable 2 (LV2) from the partial least squares discrimate 
analysis (PLSDA) of the factor content of the samples. C and D) Weighted signals of 
each factor from the PLSDA. 
The amount of each factor in pg per 1000 cells for each group is given Table 5.1. The 
partial least square discriminate analysis resulted in good separation between the groups 
(see Figure 5.2.B) and Figures 5.2.C,D show the weighted signals for both latent variables 
(LV1 and LV2) in the analysis. The clear majority of the factors heavily influenced LV1, 
which separated the differently treated groups while less of the factors heavily influenced 
LV2, which separated the unactivated, untreated group from the activated, untreated group. 
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Table 5.1: Factor Contents for Synoviocyte Activation (Unactivted or Activated with 
5ng/mL IL-1β and TNF-α) vs Treatment (Untreated or Treated with 10mg/mL µ-
dHACM) Experiment. Factor values are normalized to pg/1k cells and ‘*’ in Int, Act, 
and Trt columns indicate significant effects of interactions, activation, or treatment, 
respectively, in the 2-way ANOVA. ‘#’ indicate that that factor was significantly 
different in that group compared to the matching untreated group while ‘$’ indicate 
that that factor was sigificantly different compared to matching unactivated group as 
indicated by Sidak’s post-hoc test. N=4-5. 
 
5.3.1.3 Size vs Exposure Groups 
A 2-way ANOVA for cell number did result in significant interactions between the size 
and exposure groups, thus all cell means were compared to each other. There was no 
difference in cell number in the µ-dHACM and RPS µ-dHACM transwell groups. Both µ-
dHACM and RPS µ-dHACM extract resulted in increased cell number compared to the 
transwell groups, and RPS µ-dHACM extract resulted in decreased cell number compared 




Figure 5.3: Size (µ-dHACM or Reduced Particle Size (RPS) µ-dHACM) vs Exposure 
(Transwell or Extract) µ-dHACM Synoviocyte Experiment. A) Synoviocyte cell 
number of groups show that all four groups had lower cell numbers than stimulated 
untreated group (red line) while both extract groups had significantly higher cell 
numbers than the transwell groups and RPS µ-dHACM extract group had 
signficantly reduced cell numbers compared to µ-dHACM. B) Plot showing each 
sample’s score on latent variable 1 (LV1) and latent variable 2 (LV2) from the partial 
least squares discrimate analysis (PLSDA) of the factor content of the samples. C and 
D) Weighted signals of each factor from the PLSDA. 
The amount of each factor in pg per 1000 cells for each group is given Table 5.1. The 
partial least square discriminate analysis resulted in separation between the groups (see 
Figure 5.3.B) and Figures 5.3.C,D show the weighted signals for both latent variables (LV1 
and LV2) in the analysis. The clear majority of the factors heavily influenced LV1, which 
resulted in separating of the transwell and extract groups, indicating that there were many 
differences between the transwell and extract groups. Several factors influenced LV2, 
which resulted in separation of µ-dHACM and RPS µ-dHACM, indicating that there were 
some differences as a result of µ-dHACM particle size. 
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Table 5.2: Factor Contents for Size (µ-dHACM or Reduced Particle Size (RPS) µ-
dHACM) vs Exposure (Transwell or Extract) µ-dHACM Synoviocyte Experiment. 
Factor values are normalized to pg/1k cells and ‘*’ in Int, Act, and Trt columns 
indicate significant effects of interactions, activation, or treatment, respectively, in the 
2-way ANOVA. N=4-5. 
 
5.3.1.4 Synoviocyte and µ-dHACM Direct Study 
As shown in figure 5.4, treatment of activated synoviocytes with µ-dHACM added directly 
on top of the synoviocytes resulted in a reduced MCP-1 content compared to activated, 




Figure 5.4: IL-6 and MCP-1 content in synoviocytes treated directly with µ-dHACM. 
Fluorescent intensity values for Interleukin-6 and Monocyte Chemoattractant 
Protein-1 from multiplex ELISA for unactivated, activated, and activated+10mg/mL 
direct µ-dHACM. 
5.3.1.5 Synoviocyte and Pellet Co-Culture 
Dimethyl-methylene blue assay showed that pellets cultured with 5ng/mL each of IL-1β 
and TNF-α (cytokines) or with cytokines and synoviocytes had significantly less GAG 
content than pellets cultured in culture media alone. Adding 10mg/mL µ-dHACM to 
pellets+cytokines significantly increased GAG content compared to both pellets+cytokines 
and pellets+cytokines+synoviocytes groups. Adding 10mg/mL µ-dHACM to the 
pellets+cytokines+synoviocytes group significantly increased GAG content compared to 




Figure 5.5: Proteoglycan (PG) content of bovine articular chondrocyte pellets. 
Pellets were co-cultured with interleukin 1-β and tumor necrosis factor-α 
(cytokines), synoviocytes, and µ-dHACM. Pellets were split into five groups: pellets 
alone (P), pellets with 5 ng/mL cytokines (P+C), pellets with cytokines and 
synoviocytes (P+C+S), pellets with cytokines and 10mg/mL µ-dHACM (P+C+A), 
and pellets with cytokines, synoviocytes, and µ-dHACM (P+C+S+A). Pellets 
cultured with cytokines had less sGAG. n=4-5 and data shown as mean±95% 
confidence interval of the mean. Lines indicate pairs that are significantly different 
(p<0.05) from each other. 
5.4 Discussion 
Numerous extracellular matrix based therapeutics are being investigated for their potential 
efficacy in treating OA[120]. Amniotic membrane based therapeutics have shown efficacy 
at preventing OA development both when delivered acutely[40] or after the disease has 
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developed[116]. However, many of the mechanisms and bioengineering factors that 
potentially influence the efficacy of these treatments, such as synoviocyte interactions, 
have yet to be explored. The purpose of this study was to explore how amnion particle 
interact with synoviocytes in vitro. 
The current study demonstrated that amnion, both in a transwell co-culture and as extract, 
reduces synoviocyte proliferation. Synoviocyte hyperplasia is a known feature of 
osteoarthritis development[139], thus part of the therapeutic benefit of amnion in vivo 
could be due to a reduction of synoviocyte proliferation. While there have been few studies 
looking at the effect of reducing cellular hyperplasia, one study looking at the effects of 
cadmium on OA showed that cadmium both reduced synoviocyte proliferation and OA 
clinical scores in a rat OA model[140] thus support the theory that reducing synoviocyte 
proliferation can help reduce OA progression. 
While no previous work has been done showing the effect of devitalized amniotic 
membrane on synoviocytes, one recent paper by Parolini, et al did investigate the effect of 
amniotic membrane cells on rheumatoid arthritis synovial membrane cells[141]. The 
authors of that study showed that amniotic membrane cells did reduce TNFα production 
and proteinase activity in the synovial membrane cells. The differences between the 
proteinase activity of the Parolini, et al study and the current one could be explained by the 
fact that devitalized ECM is added to the culture in the current study while the Parolini, et 
al study included only cells. More work is needed to see if ECM from any source, such as 




Synoviocyte secretion of G-CSF and IL-8 (also known as neutrophil attractant protein) 
were both greatly increased as a result of amnion co-culture and both of these cytokines 
are known recruiters/stimulators of granulocytes, specifically neutrophils. In addition, 
synoviocyte secretion of monocyte chemoattractant protein-1 (MCP-1) was shown to be 
decreased in amnion co-culture, indicating that monocyte, and thus macrophage, 
recruitment may be decreased as a result of µ-dHACM treatment. These results suggest 
that amnion treatment could increase the neutrophil to macrophage ratio within the 
synovium, and increased neutrophil to amnion ratio has been shown to correlate with 
decreased osteoarthritis disease grade. Macrophages are also known to be the characteristic 
cell type in chronic inflammation[143] and reducing macrophage recruitment could 
decrease chronic inflammation. In addition, the increased levels of IL-6 and fractalkine 
suggest µ-dHACM treatment could result in an increase in acute inflammation proteins and 
cells[144]. This acute inflammation could thus assist in resolving the disease state and 
reducing later chronic inflammation. Altogether, the changes in cytokine production shown 
in this study indicate that µ-dHACM treatment could result in reduced chronic 
inflammation in the joint space, and show that further studies are warranted that investigate 
µ-dHACM treatment of chronic inflammation in joints. 
This work demonstrated that experimental setup is important when evaluating tissue based 
therapies. While there were few differences between µ-dHACM and RPS µ-dHACM when 
added directly to the synoviocyte culture, this was not the case with the extracts. RPS µ-
dHACM extract resulted in effects on cytokine and MMP production more similar to the 
direct µ-dHACM groups than µ-dHACM extract. This could be explained by greater factor 
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elution due to the smaller particle size[118] and demonstrates the potential importance of 
factor elution in the mechanism of action of µ-dHACM. 
The results of this study showed that µ-dHACM protects chondrocyte pellets against 
cytokine-induced GAG loss and this was the first study to show that co-culture of 
particulate amniotic membrane can protect chondrocyte pellets in this fashion. Previous 
studies have shown that amniotic membrane can act as substrates for chondrocyte 
proliferation and GAG production[45], [46], [126] but no studies have investigated the 
influence of particulate amniotic membrane or the co-culture of chondrocytes with 
amniotic membrane without direct contact between the two. The mechanism by which µ-
dHACM protects chondrocytes against proteoglycan loss still needs to be elucidated but µ-
dHACM is known to contain tissue inhibitors of metalloproteinases[44] and thus could be 
suppressing MMP activity. However, this study quantified MMP activity for synoviocytes 
co-cultured with µ-dHACM and found that MMP activity from activated synoviocytes was 
increased with the addition of µ-dHACM. This suggest that reducing MMP activity may 
not be the only mechanism by which µ-dHACM may be protecting proteoglycan loss in 
chondrocyte pellets. Synoviocytes are known to secrete hyaluronic acid in co-culture with 
µ-dHACM, which is also known to help prevent GAG loss in cartilage[145]. Thus, though 
MMP activity is increased in synoviocytes treated with amnion, the amnion may also be 
stimulating protective elements such as hyaluronic acid. In addition, the protection of the 
GAG content in the chondrocyte pellets suggest that the MMPs may be acting more to 
remove the amnion instead of digesting GAG. A disintegrin and metalloproteinase with 
thrombospondin motifs-5 (ADAMTS5) is also known to more efficiently cleave GAGs 
than MMP3[146], but the content and activity of this protease was not quantified in the 
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current study. Future work studying the effect of amnion on ADAMTS content and activity 
could show if amnion reduces ADAMTS activity and protects against GAG loss in 
osteoarthritis. 
In the activation and µ-dHACM size experiment, the µ-dHACM was kept separate from 
the synoviocytes using a transwell insert. This was to allow counting of the synoviocytes 
at the end of the experiment. However, in the chondrocyte pellet co-culture experiment, 
the µ-dHACM was added directly on top of the synoviocytes to not have the chondrocyte 
pellets in contact with the µ-dHACM. While the experimental setup was different between 
the two, the direct µ-dHACM study (which had the amnion added directly on the 
synoviocytes) showed similar effects on MCP-1 and IL-6 production as the later transwell 
study (see Figure 5.4) thus indicating that there are similar effects between the two 
experimental setups. 
While the synoviocytes used in this study did show a fibroblast like morphology throughout 
the experiment and were cultured to passage 4 before use, future work with these cells 
could use reverse transcription polymerase chain reaction to verify the presence of CD44 
and lack of CD14 expression, verifying that the synoviocytes were from a fibroblast-like 
lineage and not a macrophage-like lineage[128], [147]. In addition, as with all studies that 
measure factor production from cells, it is unknown how much cell metabolism of factor 
affected the final media content measurements as cells not only are producing these factors 
but are also metabolizing them and removing them from the media. 
While the dosing study performed did indicate that the largest effects were seen in the 
10mg/mL dose, this is a large dose that does not reflect the doses seen in vivo. This dosage 
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resulted in approximately 3mg µ-dHACM per 3800 synoviocytes which is much a much 
higher µ-dHACM:cell ratio than would be seen in vivo as previous work in our lab has 
utilized 4mg per rat joint[40]. One previous study did find that a 1mg/mL µ-dHACM dose 
resulted in a significant increase in hyaluronic acid production in synoviocytes from 
patients with rheumatoid arthritis[145]. Thus, further study into the effects of lower 
dosages of µ-dHACM are warranted as well as investigations into their effects on other 
cell types such as macrophages and stem cells. 
This study was the first to look at the effects of particulate amniotic membrane on the 
cytokine and MMP production of synoviocytes. It has shown that particulate amniotic 
membrane does alter the secretome of synoviocytes and prevents the cytokine-induced loss 
of GAG in chondrocyte pellets. This study has demonstrated the complex nature of 
synoviocyte and particulate amniotic membrane interactions, while it also illustrated the 
chondroprotective effects of µ-dHACM. These results suggest that further research into the 
mechanisms behind the therapeutic effect of amniotic membrane is needed but also add to 
the literature that suggest µ-dHACM can serve as a disease-modifying OA treatment.  
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Contributions to the Field 
This work aimed to expand current capabilities to evaluate disease modifying OA 
therapeutics and to then utilize these capabilities to evaluate the effect of µ-dHACM in 
both in vivo and in vitro models. Thus, this work represents important contributions to the 
fields of pre-clinical OA and ECM therapeutic testing. 
6.1.1 Temporal and Spatial Characterization of Joint Degeneration 
Small animal models are increasingly being used to investigate the pathophysiology of 
osteoarthritis and the efficacy of potential disease modifying therapeutics. In these studies, 
it is important to have accurate understanding of the changes within the joint tissue and 
there is a lot of work going into developing imaging techniques that aid in gaining this 
understanding[3], [99], [107]. The work in this thesis has demonstrated how EPIC-μCT 
can be utilized to quantify both the spatial and temporal changes within the joint tissues in 
small animal models. It had not previously been shown that all the following parameters 
could be gleaned from one µCT scan of a rat tibia: cartilage sGAG content, thickness, 
volume, and surface roughness; subchondral bone mineral density, volume, porosity, and 
thickness; lesion volume; and osteophyte mineralized and cartilage volume. In addition, 
EPIC-μCT was sensitive enough to quantify the changes in many of these parameters at 
both early time points and in specific locations of the tibial plateau. While most of these 
parameters had previously been quantified using µCT and EPIC-µCT, this work was the 
first to demonstrate how these changes relate to each other over time and space. This work 
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thus demonstrates that EPIC-μCT can be used to understand many different pathological 
developments in small animal models and how they relate to each other both spatially and 
temporally. These techniques were also utilized in the Chapter 4 to investigate the effect 
of particle size on the therapeutic effectiveness of µ-dHACM to treat the MMT rat model. 
6.1.2 In Vivo Analysis of Mechanisms of µ-dHACM 
Multiple studies have shown the therapeutic benefit of micronized amniotic membrane in 
the small animal MMT model[40], [116]. However, not much has been know about the 
mechanisms behind this benefit. This work has found that particle size does alter the 
therapeutic benefit of micronized amniotic membrane with a particle size distribution with 
more large particles resulting in greater prevention of lesion formation in the MMT model. 
This work was also the first to show that acute treatment of micronized amniotic membrane 
resulted in increased osteophyte cartilage volume, potentially indicating that these 
micronized amniotic membrane particles are increasing cartilage production in the medial 
tibial plateau. Reducing the particle size was also found to increase protein elution from 
the particles, supporting previous work showing that decreased particle size results in 
increased elution of small molecules[118]. This work also showed that decreasing the 
particle size did not significantly alter the particle clearance from the joint suggesting that 
even in the RPS µ-dHACM sample, most the tissue was of a sufficient size to not be readily 
cleared from the joint. Altogether, the work in Chapter 4 supports that the EPIC-µCT 
techniques described in Chapter 3 can be used to evaluate potential disease modifying OA 
therapeutics and adds to the growing body of evidence showing that micronized amniotic 
membrane prevents cartilage degradation in OA development. 
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6.1.3 In Vitro Analysis of Mechanisms of µ-dHACM 
In addition to the further in vivo studies of micronized amniotic membrane carried out in 
Chapter 4, this work added valuable understanding into the influence of micronized 
amniotic membrane on in vitro cell cultures. While synoviocytes have been used 
extensively to evaluate potential OA and rheumatoid arthritis therapeutics[84], [135], 
[148], [149], this was the first to look at the effects of a particulate ECM therapeutic on the 
cytokine and MMP production of synoviocytes. It has shown that particulate amniotic 
membrane does alter the secretome of synoviocytes and prevents the cytokine-induced loss 
of GAG in chondrocyte pellets. This study has demonstrated the complex nature of 
synoviocyte and particulate amniotic membrane interactions, while it also illustrated the 
chondroprotective effects of µ-dHACM. In addition, this work explored the importance of 
in vitro experimental setup when evaluating tissue based therapies by demonstrating 
different effects in extract cultures vs co-cultures. These results suggest that further 
research into the mechanisms behind the therapeutic effect of amniotic membrane is 
needed but also add to the literature that suggest µ-dHACM can serve as a disease-
modifying OA treatment. 
6.1.4 Summary 
The work in this thesis has demonstrated 1) that surface roughness from contrast enhanced, 
non-destructive µCT imaging can be used as an early indicator of OA progression and that 
these µCT images can provide temporal and spatial mapping to tissue level changes in pre-
clinical models, 2) the therapeutic benefit of µ-dHACM is influenced by particle size and 
therefore can be tuned to improve therapeutic efficacy, and 3) µ-dHACM has both a 
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stimulatory and inhibitory effect on synoviocyte production of cytokines and chemokines 
that may increase acute inflammation while decreasing chronic inflammation, thus 
improving tissue healing/inflammation resolution in damaged knees. 
6.2 Future Directions 
6.2.1 Evaluation of small animal OA models 
This work has demonstrated that contrast enhanced µCT can detect a wide range of changes 
in joint tissue ranging from cartilage composition to osteophyte growth to subchondral 
bone sclerosis and that it is sensitive enough to elicit the temporal and spatial nature of 
these changes. Future work could use the parameters described in this work to investigate 
how all the various small animal models of osteoarthritis are similar and divergent from 
one another. This can aid our understanding of how different small animal models of OA, 
such as the rat monoiodoacetate model, the rat collagen induced arthritis, the rat anterior 
cruciate ligament transection and meniscectomy, and the rat tibial plateau fracture model 
all differentially effect cartilage and bone tissues. 
However, major limitations of the imaging techniques described in this work are that there 
remains a high amount of manual contouring that is necessary to achieve these results and 
that it is an ex vivo technique, eliminating the possibility of longitudinal studies. While 
contrast-enhanced µCT imaging is less time-intensive then histopathological studies, 
automated contouring and segmentation of the CT images could drastically decrease the 
amount of time required to produce these results. Multiple research groups have started 
developing automated contouring methods for the quantification of cartilage and bone 
changes and have shown their utility in both rat [107] and mouse [150], [151] models of 
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OA. These methods have only quantified a limited number of the parameters described in 
this current work and there is still much work to be done in this area. 
In addition to the need to develop automated contouring algorithms, the further 
development of in vivo contrast enhanced µCT imaging would both dramatically reduce 
the number of animals needed in these studies [54] and potentially increase the statistical 
power to detect differences between groups and timepoints. Some work has been done in 
developing in vivo contrast enhanced µCT imaging for both pre-clinical[80], [150]–[152] 
and clinical[153] settings with promising results. In our own lab, preliminary pilot projects 
have shown that it is possible to track osteophyte growth in vivo using automated 
registration and rotation of the tibial plateaus of rats that underwent MMT surgery. The 
development of the automatic contouring methods mentioned in the previous paragraph 
would also be important for longitudinal tracking of disease changes because of the large 
datasets that would be produced from these studies. 
In addition to the pressing needs of developing automated contouring algorithms and in 
vivo imaging techniques, there is potential future work in the development of more 
sensitive measures of proteoglycan changes using EPIC-μCT. Voxel-based techniques 
from MRI have been shown to increase sensitivity to compositional changes [109] and 
could perhaps be adapted to increase sensitivity of attenuation changes in EPIC-μCT 
imaging. 
The surface shape changes described in chapter 3 may indicate local changes in cartilage 
thickness caused by altered joint kinematics in the MMT animals. In humans, it has been 
found that knee kinematics are correlated with ratios of medial to lateral cartilage thickness, 
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and these correlations change with age and presence of knee OA[25], [108]. Future work 
combining gait mechanics and EPIC-μCT imaging in the MMT model could lead to greater 
understanding of the relationship between knee kinematics and specific areas of tissue 
changes. 
One of the benefits of the techniques described in chapter 3 is that a large amount of 
information on various parameters describing multiple tissues can be extracted from one 
scan. Future work could use these techniques to explore the pathological development of 
other rat models of OA. This could lead to a greater understanding of how different disease 
initiations could lead to differential development but then result in similar end results in 
joint degeneration. 
6.2.2 In Vivo Therapeutic Mechanisms of µ-dHACM 
This work has explored one possible mode of tuning particulate amniotic membrane for 
the treatment of OA by investigating the effect of particle size. While this work did show 
that particle size did effect both factor elution and in vivo therapeutic efficacy of the 
particulate amniotic membrane, there was a large amount of overlap between the size 
profiles. More specific conclusions could be drawn if the particle sizes were more distinct 
as this would allow researchers to understand exactly which sizes are the most 
therapeutically beneficial. 
In addition, there are still numerous other tuneable aspects of particulate amniotic 
membrane such as using the particles as cell carriers[43], [154] or loading more proteins 
onto the particles. Amniotic membrane sheets are already known to facilitate chondrocyte 
culture in vitro[45], [126] and to contain large quantities of proteins[44], [145]. Enhancing 
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these natural traits of particulate amniotic membrane could lead to greater therapeutic 
effectiveness at treating OA. However, significant amounts of bioactive components can 
be eluted from the µ-dHACM in just 24 hours, as demonstrated by the extract studies in 
both Chapter 4 and Chapter 5; thus, care should be taken to not deplete beneficial protein 
content when adding cells or proteins to µ-dHACM. 
In the data presented in chapter 4, there was a therapeutic difference between µ-dHACM 
and RPS µ-dHACM and a difference in protein elution over 21 days but no difference 
between clearance of µ-dHACM and RPS µ-dHACM from the joint. The clearance results 
suggest that much of the tissue in both formulations is still retained in the joint out to six 
weeks but the therapeutic benefit has worn off (as demonstrated in the 6-week study 
contained in Appendix D). This, along with the differences seen in chapter 5 between direct 
and extract µ-dHACM and RPS µ-dHACM, suggests that the mechanism of µ-dHACM is 
more of a reservoir of growth factors rather than as cellular substrate for cartilage repair. 
This agrees with the lack of µ-dHACM and cartilage interactions in the previous study by 
Willett, et al[40]. Future work could further investigate this question of factor reservoir vs 
cellular substrate by investigating the effect of denatured amniotic membrane where the 
growth factors are no longer bioactive or by injection of other ECM particles such as 
collage or fibronectin of a similar particle size. Previous work in our lab has also 
investigated the use of heparin microparticles to sequester growth factors from 
mesenchymal stem cells to increase bone repair. These same microparticles could be used 
with µ-dHACM extract to investigate the effect of µ-dHACM growth factors without the 
bioactive ECM. 
6.2.3 In Vitro Therapeutic Mechanisms of µ-dHACM 
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The in vitro synoviocyte/µ-dHACM results described in chapter 5 demonstrate the effect 
of µ-dHACM on cytokine and MMP secretion from synoviocytes as well as shows the 
chondroprotective nature of µ-dHACM co-culture against IL-1β and TNF-α. However, 
there are many unanswered questions about the µ-dHACM that could be investigated with 
in vitro models. 
Fibroblast-like synoviocytes were utilized in this work but are only one of two cell types 
commonly described in the synovium, the other being macrophage-like synoviocytes[21], 
[22], [155]. Previous studies have looked at the effect of macrophage culture with 
synoviocytes and with chondrocytes[90], [138] and similar experiments could be 
performed to investigate how micronized amniotic membrane would interact with the 
different cell types. While more complex than the model used in this work, such models 
could provide a more complete understanding of micronized amniotic membranes 
interactions with the synovium. 
The increased MMP-3 content and MMP activity in the synovium/µ-dHACM cultures 
seem at odds with the GAG protection that the µ-dHACM provides both in the in vivo 
model in Chapter 4 and in the in vitro synovium/chondrocyte pellet co-cultures in Chapter 
5. Further work could investigate if other MMPs (such as MMP-1) or members of the 
ADAMTs family have lower concentrations in the synoviocyte/µ-dHACM cocultures. 
MMP zymography could also be used to identify which MMPs are most active in the 
synovium/µ-dHACM co-culture and in the pellet/synovium/µ-dHACM co-culture. 
The increase in IL-6, IL-8, fractalkine, and G-CSF seen in the synoviocyte-µdHACM co-
culture suggest that µ-dHACM may increase acute inflammatory mediators in vivo while 
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increasing neutrophil numbers. In addition, the decreased MCP-1 secretion may indicate a 
decrease in macrophage numbers. Immunohistochemistry and flow cytometry analysis of 
the synovial cells surrounding the µ-dHACM in vivo would provide further information on 
if this increase in neutrophils and decrease in macrophages is occurring in vivo. In addition, 
studies are needed that investigate systemic (serum) vs local (synovial fluid) levels of 
cytokines and how these levels change over time (acute vs chronic) in response to µ-
dHACM treatment. Finally, as there were differences in the RPS µ-dHACM vs µ-dHACM 
studies both in vivo and in vitro, studies that investigate the in vivo cytokines levels and 
their relationship with particle size could provide further information on how altering the 
particle size of the amnion influences its immunomodulatory function. 
Research utilizing µ-dHACM to treat more inflammatory models of arthritis, such as the 
antigen-induced arthritis model [156], [157] or the collagen-induced arthritis[158], which 
has been used to investigate the role of MCP-1 in arthritis development, would be useful 
to understand the effect of µ-dHACM in different arthritis etiologies. This, in turn, could 
help provide information concerning the role of µ-dHACM in modulating acute vs chronic 
inflammatory interactions. 
6.2.4 Large Animal Studies and Clinical Application 
While the small animal models and in vitro models described in this work show promise 
and add to the body of literature supporting the potential of particulate amniotic membrane 
as a disease modifying OA therapeutic, large animal studies and clinical trials would need 
to be performed to validate the efficacy of µ-dHACM to reduce OA progression. 
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Large animal studies provide greater understanding of the clinical potential of disease 
modifying OA drugs than small animal models because their size and mechanical 
environment more closely resembles the clinical environment. While amniotic membrane 
is indicated for and used extensively to treat multiple pathologies in large animals[159], 
there are few pre-clinical studies looking at the therapeutic effect of amniotic membrane in 
large animal orthopaedic models. One study did show that amniotic membrane has been 
shown to improve outcomes in sheep full thickness osteochondral defects[160]. Currently, 
our lab is collaborating with the San Antonio Military Medical Center to perform sheep 
studies investigating the effect of µ-dHACM in the sheep meniscectomy model and it is 
expected that this study will provide greater illumination of the clinical potential of µ-
dHACM to treat OA. 
Amniotic membrane has been used in humans for decades for successfully treating burns, 
skin wounds, and ocular defects, and several case studies have been performed to apply 
amniotic membrane to tendon, ligament, and spine applications[145]. As has been shown 
in these clinical applications, amniotic membrane can be transplanted into humans without 
rejection by the immune system. While amniotic membrane has shown promise in 
orthopaedic applications[161], [162], including OA[117], future work is needed to study 




APPENDIX A. CONTOURING GUIDELINES FOR EVALUATION 
OF THE RAT MMT MODEL USING EPIC-UCT 
A.1 Introduction and General Points 
These guidelines were developed for the analyses performed during the study described in 
Chapter 2. They are specifically for contouring medial plateaus of rat tibias at 1 and 3 
weeks following MMT surgery scanned using Scanco systems and evaluated using Scanco 
software. While the authors tried to rely on the use of common anatomical features that 
have been seen during these studies, factors like anatomical variability and rotational 
variability could cause images to appear different from the ones represented here. Other 
animal models and locations could also require different contouring guidelines. 
These guidelines only address contouring after the imaging has already been performed. 
For more details on EPIC-μCT imaging, please see references [3], [65], [66], [99]. 
A.2 Cartilage Attenuation, Volume, Thickness 
The entire medial plateau is contoured with set points at intervals of 5 to 10 slices and these 
set points are then morphed to create the rest of the contours. The boundaries are set as 
described below and the contours are drawn to include all cartilage and extend slightly into 
the air and subchondral bone. If there are any subchondral pores that would be thresholded 
as cartilage (this can be checked by using the preview button in the 3D-Evaluation window 
with the proper thresholds), avoid including them within the contours, even if that requires 
contouring directly on the cartilage/subchondral bone interface instead of slightly into the 
bone. After morphing from the set points, review all contours to make sure they do not 
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extend too far into the subchondral bone. Residual soft tissue on the cartilage surface can 
be recognized by the lack of continuity with the cartilage surface (see Figure A.6.5), and 
the obvious soft tissue should not be included within the contours. 
A.2.1. Sagittal Contouring (Figure A.6.1 and Figure A.6.2) 
 
Figure A.6.1: Sham Sagittal Contours. A) 5 slices lateral to the lateral contour end, 
B) lateral contour end, C-F) slices between contour ends, G) medial contour end, 
and H) 5 slices medial to the medial end. Notice ligament insertion point (*), non-
intact subchondral bone (#), subchondral bone edges (red arrows), missing soft 
tissue (white arrows), and proximal end divots ($) that influence the location of the 




Figure A.6.2: MMT Sagittal Contours. A) 5 slices lateral to the lateral contour end, 
B) lateral contour end, C-F) slices between contour ends, G) medial contour end, 
and H) 5 slices medial to the medial end. Notice ligament insertion point (*), non-
intact subchondral bone (#), proximal subchondral bone edges (red arrows), and 
proximal end divots ($) that influence the location of the anterior and posterior 
contour ends. 
A.2.1.1. Anterior Boundary 
The contour extends along the intact subchondral bone either to the ligament insertion point 
(this occurs on the very lateral side, toward the center of the full joint, between the plateaus) 
or to the inflection point of the subchondral bone curvature (during the middle portion of 
the plateau) or to where there is a sharp edge to the subchondral bone (on the medial side). 
A.2.1.2. Posterior Boundary 
On the posterior side, the contour extends along the intact subchondral bone and stops 
either at a) 0.5 mm before the posterior corner of subchondral bone, b) where a divot starts 
to slope into the subchondral bone (see Figure A.6.1.A-D), or c) any soft tissue covering 
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the cartilage that cannot be contoured around. The most anterior of these points is the one 
that should be used.  
A.2.1.3. Lateral Boundary 
The first contoured slice on the lateral side is where the subchondral bone is intact and 
measures greater than or equal to 1.25 mm between the anterior and posterior boundary. 
A.2.1.4. Medial Boundary 
The first contoured slice on the medial side is where the distance between the anterior and 
posterior boundary is greater than or equal to 1.25 mm or where the subchondral bone is 
no longer smooth or distinguishable from the cartilage over the majority of the surface, 
whichever occurs more laterally. 
A.2.2. Coronal Contouring (Figure A.6.3 and Figure A.6.4) 
 
Figure A.6.3: Sham Coronal Contours. A) 5 slices posterior to the posterior contour 
end, B) posterior contour end, C-G) slices between contour ends, and H) anterior 
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contour end. Notice ligament insertion points (*), subchondral bone edge (red 
arrow), and soft tissue (%) that influence the location of the contours. 
 
Figure A.6.4: MMT Coronal Contours. A) 5 slices posterior to the posterior contour 
end, B) posterior contour end, C-G) slices between contour ends, and H) anterior 
contour end. Notice ligament insertion points (*), subchondral bone edge (red 
arrows), missing tissue (white arrow), soft tissue (%), and divots ($) that influence 
the location of the contours. 
A.2.2.1. Posterior Boundary 
The first contoured slice on the medial side is where the distance between the lateral and 
medial edges of the contour is 1.25 mm or greater and surface of the subchondral bone is 
smooth and intact. 
A.2.2.2. Anterior Boundary 
The first contoured slice on the anterior side is just anterior to the disappearance of the 
most anterior ligament insertion point which appears as a big hole in the subchondral bone 
between the lateral and medial plateaus (see Figure A.6.3.D-F and Figure A.6.4.D-F).  
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A.2.2.3. Medial Boundaries 
On the medial side, the contours go to the edge of the subchondral bone. For curved edges, 
go to where the subchondral bone is at 45 degrees relative to the subchondral bone surface 
under the plateau. When there is a divot at the corner of the subchondral bone, stop the 
contour on the lateral side of that divot. Any contours posterior to that divot should not 
extend more medial than that edge even if the divot hasn’t developed yet; copying and 
pasting of previous contours can help to ensure this if necessary.  
A.2.2.4. Lateral Boundaries 
On the lateral side, the contours go either a) to 0.35 mm from the vertical edge of the 
subchondral bone, b) at the middle of the peak in the subchondral bone (if there are two, 
then use the more medial one), or c) to where soft tissue is present or dissection cuts in the 
cartilage are visible. The most medial of these points should be used. 
A.2.3. Analysis Thresholds 
The cartilage-air and bone-cartilage thresholds should be chosen for each new experiment 
and should include as much cartilage as possible while not extending into the bone or air. 
Be aware that diseased joints have higher average attenuation than controls so make sure 
to base thresholding decisions on sampling multiple slices from multiple specimens, 




After proper thresholds have been set, run the 3D evaluations for each sample and record 
the mean density / attenuation, mean thickness, and volume values. For the results shown 
in the main paper, the entire medial plateau was analyzed as well as the lateral, central, and 
medial thirds of the plateau. 
 
Figure A.6.5: Cartilage contour examples of subchondral bone pores and soft tissue. 
A) Example of contour extending into subchondral bone. Subchondral pores (red 
arrows) are avoided but normally the contours extend a few pixels into subchondral 
bone (white arrow). B) Entire medial tibial plateau with contour example from A. 
C) Example of contour avoiding obvious soft tissue (*). Notice that the contour stops 
where the soft tissue in no longer distinguishable from the cartilage surface. D) 




Figure A.6.6: Cartilage contouring examples of subchondral bone divots ($) in a) 
sagittal and b) coronal slices. These divots are the posterior and medial ending 
points of the sagittal and coronal contours, respectively. 
A.3  Subchondral Bone Mineral Density, Volume, Thickness, Porosity (Figure A.6.7) 
 
Figure A.6.7: Subchondral Bone Contours. A) Example of subchondral bone 
contour in sagittal plane, B) example of subchondral bone contour in coronal plane. 
Notice that subchondral pores (red arrows) are included in the contours but 
trabecular spaces (*) are not included. 
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A.3.1. Contouring for either the Sagittal or Coronal Plane 
The anterior, posterior, medial, and lateral boundaries are all the same as the cartilage 
analyses. The contours should include all the subchondral bone between the cartilage-bone 
interface and the endocortical boundary. Because subchondral bone porosity is one of the 
parameters measured and is calculated from the total and bone volumes, the contours 
should tightly follow the cartilage-bone interface and endocortical boundary. As such, it is 
recommended to have set points at intervals of a maximum of five slices. Using the preview 
button in the 3D-Evaluation window can also be helpful to check for areas of lower 
attenuation than the lower threshold. 
A.3.2. Analysis Thresholds 
The lower threshold for the subchondral bone analysis is the upper threshold used in the 
cartilage analysis. The upper threshold for the subchondral bone analysis is then set as the 
maximum value possible (1000 in the Scanco μCT40). 
A.3.3. Analysis 
After proper thresholds have been set, run the 3D evaluations for each sample and record 
the mean density, mean thickness, volume, and volume fraction (Bone Volume/Total 
Volume) values. Porosity can be calculated as 1 −
𝐵𝑜𝑛𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
𝑇𝑜𝑡𝑎𝑙 𝑉𝑜𝑙𝑢𝑚𝑒
. For the results shown in 
the main paper, the entire medial plateau was analyzed as well as the lateral, central, and 
medial thirds of the plateau. 




Figure A.6.8: Lesion Contours. A) Example of lesion contour in coronal plane, B) 
entire medial tibial plateau with lesion contour from A, C) example of lesion contour 
in sagittal plane, D) entire medial tibial plateau with lesion contour from C. Notice 
that the contour can extend into the subchondral bone but not into the air. 
A.4.1. Contouring 
The lesion volume analysis can be performed using either the sagittal or coronal plane 
sections. A lesion is defined as a loss of cartilage that extends through 50% or greater of 
the cartilage thickness. The contours are drawn to encompass the entire width of the lesion. 
The top of the contour should trace a visual continuation of the smooth surrounding 
cartilage, as if there was no lesion present, and extend into the subchondral bone but avoid 
any subchondral pores that have attenuation lower than cartilage. Surrounding erosions in 
the cartilage are only included in the lesion contour if they are obviously a continuous part 




After the contours have been drawn, the 3D evaluations are run with the lower threshold 
set as the lower threshold from the cartilage analyses and the upper threshold set as the 
maximum value possible (1000 in the Scanco μCT40). The lesion volume is then calculated 
by subtracted the bone volume (BV) value from the total volume (TV) value. 
A.5 Osteophyte Volume (Figure A.6.9) 
 
Figure A.6.9: Osteophyte Contours. A) Example of contour for mineralized tissue 
(green contour) and cartilage tissue (red contour) portions of the marginal tissue 
thickening in coronal plane in a sham sample. Notice the lack of soft tissue used to 
indicate the end of the cartilage contour (&). B) Example of contour for mineralized 
tissue (green contour) and cartilage tissue (red contour) portions of the marginal 
tissue thickening in coronal plane in a MMT sample.  Notice the soft tissue used to 
indicate where to end the cartilage contour. (#) 
For osteophyte analysis, two different contours are used, one for the mineralized tissue and 
one for the cartilaginous tissue. The mineralized tissue contours are bigger to include all 
the mineralized osteophyte, some of which may be adjacent to non-cartilaginous soft tissue, 
while the cartilaginous tissue contours are smaller to avoid inclusion of any residual soft 
tissue on the medial margins of the tibia. As the mineralized tissue contours are bigger, it 
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is suggested to start with those contours and then alter the contours for the cartilage 
analysis. 
It can be difficult to distinguish the soft tissue/bone interface because the mineralized 
osteophyte tissue looks like the subchondral bone and vice versa. Refer to sham and naïve 
samples to recognize natural joint structure; the newly mineralized tissue in osteophytes 
often has a disorganized appearance compared to healthy tibial plateaus. It is also suggested 
that one person perform these analyses for the whole experiment to increase consistency. 
A.5.1. Contouring – Mineralized Tissue 
Anterior and posterior starting slices are the same as the starting slices from the cartilage 
analysis described in Section A.2.2 above. On the plateau, the contours start just before the 
subchondral bone surface curves down towards the growth plate. The contour then extends 
along the bone surface down to the growth plate and includes all the soft and mineralized 
tissue medial to that bone surface, as shown in Figure A.6.9.  
A.5.2. Contouring – Cartilage 
Anterior and posterior starting slices are the same as the starting slices from the cartilage 
analysis described in Section A.2.2 above. On the plateau, the contours start just before the 
subchondral bone surface curves down towards the distal end. The contour then extends 
along the bone surface and includes all the soft and mineralized tissue medial to that bone 
surface. The contour stops where the residual soft tissue starts (indicated by fragments 
hanging from the surface and an increase in attenuation) or where the cartilage is no longer 
present. In practice, creating the cartilage contours can be as simple as taking the 
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mineralized tissue contours and transecting it with the contour correction tool, just above 
the soft tissue. Above the soft tissue, the contours should be the same. 
A.5.3. Analysis 
Run the 3D evaluations for all samples using the same thresholds as the cartilage and 




APPENDIX B. MATLAB PROGRAM FOR EVALUATING 
SURFACE ROUGHNESS 
B.1 Program Description 
The parameters that can be extracted from this surface roughness program include cartilage 
surface roughness and exposed bone. There is the possibility of developing other lesion 
volume measurements from this program as well. 
Cartilage surface roughness is calculated by 1) creating a 3D surface of the cartilage from 
the CT images, 2) fitting a user defined curve to that surface to account for the curvature 
of the surface, and 3) calculating the root mean square value of the pixel by pixel 
differences between the actual 3D surface and the fitted surface. 
Exposed bone is calculated by 1) creating 3D surfaces of both the cartilage and the 
subchondral bone from the CT images, and summing all the pixels where the two surfaces 
come within a defined distance of one another. Because of attenuation averaging that 
occurs when analog surfaces are discretized into pixels, the two surfaces are seldom 
defined by the same pixels, thus the defined distance (called the minimum thickness) is 
needed. 
All files listed here are available online at http://guldberglab.gatech.edu/downloads along 
with two sets of sample files (one damaged tibia and one control tibia) and their datasheet 




B.2 Program Instructions 
1. The files for analysis must be labeled in numerical, sequential order. 
2. The following M and FIG files should be in the one directory folder and that 













3. The images for analysis should be placed in the same folder as the M and FIG 
files. Example: In Figure 3.1, the folder ‘Sample Files’ is in ‘Current Folder’ 
along with the necessary .m and .fig files. The folder Sample Files contains a 
folder for each set of sample files (‘Control’ and ‘Damaged’). 
 
Figure B.7.1: Example of file locations for running surface roughness algorithm. 




4. A datasheet must also be included in either Current Folder or in the folder 
containing the samples (Example: The sample datasheet, ‘SampleDatasheet.xlsx’, 
is contained in the ‘Sample Files’ folder) and must contain the following 
information: 
a. Sample Name 
i. The name of the folder containing the image files: eg. ‘Sample 
Files/Damaged’ 
b. File Heading 
i. The part of image files’ names that does not change from image to 
image in one file. For the Scanco generated images in the sample 
folder this is the letters and numbers up to the first 0 following the 
underscore: eg. ‘R0014638_0’. 
c. File Ending 
i. The file type of the images: eg. ‘.TIF’. 
d. First File # 
i. The number for the first image slice of the analysis. This number 
makes up the part of the image files’ names that does change from 
image to image: eg. ‘407’. 
e. Last File # 
i. The number for the last image slice of the analysis. By changing 
the first and last file numbers, different areas of the cartilage can 
be analyzed (e.g. medial or lateral; anterior or posterior) 
5. Run the surface roughness program by typing “Surface_Roughness” in the 
command window. This brings up the Surface Roughness Program opening 
screen. 
6. Provide each requested value (See Figure B.7.2 for the proper inputs for the 
samples provided) 
a. Datasheet Name 
i. This is the name of the datasheet and needs to include the path (if 
there is one) to the datasheet from the ‘Current Folder’ 
b. Pixel size 
i. The size of the pixels in the analysis images as set by the scanner 
settings 
c. Fits 
i. The desired fit for the analysis used to account for the natural 
curvature of the surface. As explained Chapter 3, the surface 
roughness of the analyzed surface is calculated by taking the root 
mean square value of the difference between the actual cartilage 
surface and the fitted surface. Polynomial surfaces, discrete cosine 
transform functions, or LOWESS spline surfaces can all be used. 
1. Polynomial surfaces are written as ‘Poly24’ where the first 
digit (‘2’) is the polynomial order along the different 
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images files and the second digit (‘4’) is the polynomial 
order within one images file 
2. Discrete cosine transform functions are written as ‘dct80’ 
where the number following dct (‘80’) is the cutoff, in um, 
where cosine wavelengths below it are removed from the 
fitting surface and wavelengths above it are retained in the 
fitting surface. 
3. LOWESS spline surfaces are written simply as ‘lowess’. 
d. Input 
i. Choose what amount of inputs are desired for the analysis 
1. Rotation and Boundaries 
a. When the ‘Run’ button is pressed, the program will 
ask the user to provide the rotation angle and top, 
bottom, right, and left boundaries for the analysis 
(See Steps 8 and 9) 
2. Boundaries only 
a. When the ‘Run’ button is pressed, the program will 
ask the user to provide only the top, bottom, right, 
and left boundaries for the analysis (see step 9) 
3. No Input 
a. When the ‘Run’ button is pressed, the program will 
not request any additional input 
e. Cartilage Threshold 
i. Enter the threshold used for cartilage analysis. It may be necessary 
to try out a number of different values to find the appropriate 
threshold for the cartilage surface 
f. Bone and Lesion Measurements 
i. When checked, the program will not only calculate the cartilage 
surface roughness, but also map out the bone surface and calculate 
how much of the bone surface is exposed because of cartilage 
erosion. 
g. Bone Threshold (visible when Bone and Lesion Measurements is checked) 
i. Enter the threshold used for bone analysis. It may be necessary to 
try out a number of different values to find the appropriate 
threshold for the cartilage surface 
h. Min Thickness (visible when Bone and Lesion Measurements is checked) 
i. The minimum thickness that will be defined as cartilage and not 
exposed bone. This is the defined distance between the cartilage 
and bone surfaces described in the description of the exposed bone 




Figure B.7.2: Surface_Roughness GUI with example settings 
7. When all values have been defined in the opening screen, press the run button to 
run the surface roughness program. If any requested values have not been added 
properly, an error will show up on the GUI. 
8. If rotation and boundary inputs were chosen on the opening screen, the rotational 
input window (shown in Figure B.7.3) will appear displaying a CT image slice 
from the first sample on the datasheet. The image shown is the middle image slice 
between the first and last file # given in the datasheet. 
a. For the program to work properly, it is necessary to have the area of 
interest of the tibial plateau be vertical and the proximal end of the plateau 
be facing the right side of the screen. The white vertical lines in the 
window are to assist in ensuring it is vertical. Rotate the CT image using 
the ‘up’ or ‘down’ buttons in the rotational input window or by inputting 
an angle of rotation into the window. When the CT image is in the proper 




Figure B.7.3: angleGUI.m with example 2D image 
9. After the rotation has been set, or if only boundary inputs were chosen on the 
opening screen, the boundary input window (shown in Figure B.7.4) will appear 
displaying two CT image slices from the first sample on the datasheet. The left 
and right images are the first and last image slices, respectively, as defined by the 
first and last file # given in the datasheet. 
a. In this window, the user will define the area of interest that will be 
analyzed in the program. The user will choose, in this order, the top and 
bottom boundaries, followed by the right most boundary, followed by the 
left most boundary. 
b. The fitting function in MATLAB requires a rectangular surface, thus the 
same top and bottom boundaries are required for all CT image slices in a 
given sample. The boundaries are chosen to match, as closely as possible, 
the boundaries described in the contouring guidelines found in Chapter 3 
and they must pass through the cartilage surface on both images. 
c. The left and right most boundaries do not directly affect the cartilage 
surface roughness or subchondral bone analysis but rather are provided to 
reduce the amount of pixels scanned. Only the pixels between the four 
boundaries are scanned in the program thus the left and right boundaries 
can be used to remove any artifacts from the scanning procedure, such as 
the holding tube, that could be thresholded as cartilage or bone by the 
program. 
d. If any of the boundaries or the rotation need to be corrected after they have 
been set, the buttons at the bottom of the boundary input window can be 
  
 111 
used to remove the boundaries so new ones can be chosen or to return to 
the rotation input window. 
e. After the rotation and boundaries are correct, press the next button to 
move to the next sample in the datasheet. This will continue until all the 
samples in the datasheet have been set. 
f. After the rotation and boundaries for all samples have been set, clicking 
the next button in the boundary input window will start the analysis. 
 
Figure B.7.4: getInputsGUI.m with example 2D images for boundary input 
10. If no rotational or boundary inputs are chosen on the opening screen, or when the 
last sample’s rotation and boundaries are defined, the program will save all the 
rotation and boundaries inputs in an excel spreadsheet labeled the same as the 
datasheet but with ‘wParameters’ added to the end. These rotation and boundaries 
can be copied to the original datasheet and can be used for future analyses without 
needing to redo the rotation and boundary inputs. 
11. The program will then run though all the samples contained in the datasheet and 
calculate the requested parameters. These parameters will then be saved in the 





B.3.1. File Description 
angleGUI.m is a MATLAB® file that is called when the user needs to choose an angle for 
rotating the 2D images uploaded from the μCT machine in preparation for performing the 
surface roughness algorithm. This file is a GUI file and requires the MATLAB® figure 
angleGUI.fig to properly execute. See Figure B.7.5.  
 
Figure B.7.5: Image of angleGUI.m 
B.3.2.  File Text  
function varargout = angleGUI(varargin) 
% ANGLEGUI MATLAB code for angleGUI.fig 
%      ANGLEGUI, by itself, creates a new ANGLEGUI or raises the existing 
%      singleton*. 
% 
%      H = ANGLEGUI returns the handle to a new ANGLEGUI or the handle to 
%      the existing singleton*. 
% 
%      ANGLEGUI('CALLBACK',hObject,eventData,handles,...) calls the local 




%      ANGLEGUI('Property','Value',...) creates a new ANGLEGUI or raises the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before angleGUI_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property application 
%      stop.  All inputs are passed to angleGUI_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
 
% Edit the above text to modify the response to help angleGUI 
 
% Last Modified by GUIDE v2.5 02-Sep-2015 08:07:12 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @angleGUI_OpeningFcn, ... 
                   'gui_OutputFcn',  @angleGUI_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 




    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
 
 
% --- Executes just before angleGUI is made visible. 
function angleGUI_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to angleGUI (see VARARGIN) 
handles.fileName = varargin{2}; 
 
% Choose default command line output for angleGUI 
















% --- Outputs from this function are returned to the command line. 
function varargout = angleGUI_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Get default command line output from handles structure 
% close(handles.figure2) 





function rotAngle_Callback(hObject, eventdata, handles) 
% hObject    handle to rotAngle (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of rotAngle as text 
%        str2double(get(hObject,'String')) returns contents of rotAngle as a double 
if str2double(get(handles.imageNumber,'String')) < handles.Num(1) 
    set(handles.rotAngle,'String',num2str(handles.Num(1))); 
elseif str2double(get(handles.imageNumber,'String')) > handles.Num(2) 





% --- Executes during object creation, after setting all properties. 
function rotAngle_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to rotAngle (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
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% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 




% --- Executes on button press in downButton. 
function downButton_Callback(hObject, eventdata, handles) 
% hObject    handle to downButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
currentRotAngle = str2double(get(handles.rotAngle,'String')); 
if currentRotAngle <= -180 
    set(handles.rotAngle,'String',num2str(currentRotAngle)); 
else 





% --- Executes on button press in upButton. 
function upButton_Callback(hObject, eventdata, handles) 
% hObject    handle to upButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
currentRotAngle = str2double(get(handles.rotAngle,'String')); 
if currentRotAngle >= 180 
    set(handles.rotAngle,'String',num2str(currentRotAngle)); 
else 





% --- Executes on slider movement. 
function slider1_Callback(hObject, eventdata, handles) 
% hObject    handle to slider1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'Value') returns position of slider 






% --- Executes during object creation, after setting all properties. 
function slider1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to slider1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: slider controls usually have a light gray background. 
if isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 




% --- Executes on button press in finishedButton. 
function finishedButton_Callback(hObject, eventdata, handles) 
% hObject    handle to finishedButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 





imageRaw = imread(handles.fileName); 
myImage = imrotate(imageRaw,str2double(get(handles.rotAngle,'String'))); 
 
myImageSize = size(myImage); 
gridIndex = 1; 
while gridIndex < myImageSize 
    myImage(:,gridIndex) = 250; 








B.4.1. File Description 
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calculateSurfaceRoughness is the main file behind the surface roughness calculations. It 
receives all the inputs from the other functions, creates the 3D surfaces from the 2D images, 
calculates the desired parameters, and then writes the output Excel spreadsheet. All 
parameter calculations are in this file. 
B.4.2. File Text 
function [] = 
calculateSurfaceRoughness(dataSheetName,Num,Txt,Headers,Fits,pixelSize,cartThreshS
canco,boneThreshScanco,minThick,includeBone) 
% This function is called by Surface_Roughness.m after the input parameters 
% have been set. It calculates the surfaces for the roughness and lesion 
% volume calculations, runs the calculations and saves them as in the 
% output file 
 
%% Inputs from parent function 
% dataSheetName - the name of the input excel datasheet 
% Num - Double array of the starting and ending file numbers, rotation 
%       angles, and boundaries 
% Txt - Cell array with the file names from the input datasheet 
% Headers - Cell array with the header row from the input data sheet 
% Fits - Cell array with the list of fits that will be used in the analysis 
% pixelSize - Double with the size of the pixels in the original CT files 
% cartThreshScanco - Cartilage threshold that was submitted in the starting 
%                    screen. Should be the same value as the threshold used 
%                    in the Scanco analyses 
% boneThreshScanco - Bone threshold that was submitted in the starting 
%                    screen. Should be the same value as the threshold used 
%                    in the Scanco analyses 
% minThick - The minimum thickness in pixels that will be counted as 
%            cartilage and not exposed bone. Submitted in the starting 
%            screen 
% includeBone - Binary to indicate whether all the parameters that use the 
%               bone surface should be used to in this analysis. These 
%               parameters include exposed bone and lesion volume 
 
%% Set up and Input Save 
% This portion sets up the necessary variables. It also saves the rotation 
% angles and boundaries in the output excel file. 
[N,~] = size(Num); % Number of files that are being analyzed 
[NofFits,~] = size(Fits); % Number of fits that are to be utilized 
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cartThreshMatLab = cartThreshScanco/1000*32767/20000*256; %Converts the input 
Scanco threshold to greyscale threshold for use in matlab 
boneThreshMatLab = boneThreshScanco/1000*32767/20000*256; %Converts the input 
Scanco threshold to greyscale threshold for use in matlab 
 
% Create and save new datasheet with the input parameters 
newDataSheetName = strcat(dataSheetName,'wParameters.xlsx'); %Name of output 
excel file 
newDataSheet = cell(N + 1,10); %Creates cell array for later use in output excel file 
Txt = Txt(:,1:3); % Cut out extra cells in Txt array 
newDataSheet(1,:) = Headers; % Place Header into output cell array 
newDataSheet(2:(N + 1),1:3) = Txt; % Place Txt into output cell array 
newDataSheet(2:(N + 1),4:10) = num2cell(Num); % Convert Num to cell array and place 
into output cell array 
xlswrite(newDataSheetName,newDataSheet,1) % Save output cell to output excel file 
 
display('Setup Complete and Saved'); % Signals to user that this section of the function is 
completed 
 
%% Creates the surfaces and calculates the parameters for each the files 
for i = 1:N 
    %% This section creates the cartilage and bone surfaces for one file 
    nameStart = strcat(Txt{i,1}, '/', Txt{i,2}); % Create naming variable used when calling 
create3Dsurf 
    [fitCartSurf,plotCartSurf] = create3DSurf(nameStart, Txt{i,3}, Num(i,1), Num(i,2), 
Num(i,3), Num(i,4), Num(i,5), Num(i,6), Num(i,7), cartThreshMatLab); 
    % The previous function creates cartilage surface matrices from images: 
    % fitCartSurf - A 3 column matrix with the x,y,z values of the 
    %               cartilage surface for use in fitting the surface using 
    %               the 'fit' function. The x values are the tif image 
    %               number and the y values are the row numbers within the 
    %               tif images 
    % plotCartSurf - A mxn matrix the size of the analysis surface with the 
    %                z value for each point on that suface. m is the number 
    %                of tif images analyzed and n is the number of rows 
    %                analyzed in each tif. This matrix is used for plotting 
    %                the surfaces using the 'surf' function and for 
    %                calculating the lesion areas and volumes. 
     
    if includeBone 
        [fitBoneSurf,plotBoneSurf] = create3DSurf(nameStart, Txt{i,3}, Num(i,1), 
Num(i,2), Num(i,3), Num(i,4), Num(i,5), Num(i,6), Num(i,7), boneThreshMatLab); 
        % The previous function created bone surface matrices from the 
        % images: fitBoneSurf and plotBoneSurf are the same as for the 
        % cartilage surfaces, but with the bone threshold 
        display([Txt{i,1}, ' surfaces created']); 
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    else 
        display([Txt{i,1}, ' surface created']); 
    end 
    surfSize = size(plotCartSurf); 
     
    %% This section fits the surfaces with the requested fits and calculates the requested 
parameters using each requested fit. 
    for j = 1:NofFits 
        %% This section checks if the requested fit is dct and, if true, 
        % then fits the dct surface to the cartilage surface and creates 
        % the Z surface, which is the difference between the actual 
        % cartilage surface (plotCartSurf) and the fitted cartilage surface 
        % (fittedCartSurf) 
        tempStr = Fits{j}; % This string is necessary for checking if the requested fit is a 
discrete cosine transformation (dct) 
        if strcmp(tempStr(1:3),'dct') % Check if the requested fit is a dct 
            cutoff = str2double(tempStr(4:length(tempStr))); % Set the cutoff for the dct from 
the requested fit 
            fittedCartSurf = dctFitting(plotCartSurf,pixelSize,cutoff); % Fit the cartilage 
surface with the requested dct fit with the proper cutoff 
             
            if includeBone % Check if the bone surface and the resulting parameters are to be 
included in this analysis 
                fittedBoneSurf = dctFitting(plotBoneSurf,pixelSize,cutoff); % Fit the bone 
surface with the requested dct fit with the proper cutoff 
            end 
                         
        else 
            %% If the requested fit is not dct, this section fits the 
            % cartilage and bone surface with the requested fit (poly or 
            % lowess) and saves the fit to cartSurfFit and boneSurfFit, 
            % respectively. It then creates matrices of the fitted surfaces 
            % called fittedCartSurf and fittedBoneSurf that are the same 
            % sizes as their respective plotting surfaces. 
            cartSurfFit = fit([fitCartSurf(:,1),fitCartSurf(:,2)],fitCartSurf(:,3),Fits{j}); 
            fittedCartSurf = zeros(surfSize(1),surfSize(2)); 
            for k = 1:surfSize(1) 
                for l = 1:surfSize(2) 
                    fittedCartSurf(k,l) = cartSurfFit(k,l); 
                end 
            end 
             
            if includeBone 
                boneSurfFit = fit([fitBoneSurf(:,1),fitBoneSurf(:,2)],fitBoneSurf(:,3),Fits{j}); 
                fittedBoneSurf = zeros(surfSize(1),surfSize(2)); 
                for k = 1:surfSize(1) 
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                    for l = 1:surfSize(2) 
                        fittedBoneSurf(k,l) = boneSurfFit(k,l); 
                    end 
                end 
            end 
        end 
         
%         
plotGUI(Num(i,:),Txt(i,:),0,cartThreshScanco,boneThreshScanco,3,1,1,fittedCartSurf,fitt
edBoneSurf); 
%         pause 
         
        %% This section creates zSurf, the surface that is used to 
        % calculate the surface roughness value 
        zSurf = plotCartSurf - fittedCartSurf; 
         
        %% If lesion parameters are requested by the user, this section 
        % creates the surfaces used to calculate those parameters. 
        % Because the sham samples have thin cartilage at the edges, 
        % 5% of length or width along the respective edges is not 
        % included in the anlaysis. If 100% of the surface is desired, 
        % replace the 'for k' and 'for l' arguments with the comments 
        % at the end of their lines. 
        if includeBone 
            z50LesionSurf = zeros(surfSize(1),surfSize(2)); 
            zExBoneSurf = zeros(surfSize(1),surfSize(2)); 
            for k = round(surfSize(1)/20):(surfSize(1) - round(surfSize(1)/20)) % for k = 
1:surfSize(1) 
                for l = round(surfSize(2)/20):(surfSize(2) - round(surfSize(2)/20)) % for l = 
1:surfSize(2)  
                    if (plotCartSurf(k,l) - plotBoneSurf(k,l)) < minThick 
                        zExBoneSurf(k,l) = plotCartSurf(k,l) - fittedCartSurf(k,l); 
                    end 
                    if (plotCartSurf(k,l) - fittedCartSurf(k,l)) < 0.5*(fittedBoneSurf(k,l) - 
fittedCartSurf(k,l)) 
                        z50LesionSurf(k,l) = plotCartSurf(k,l) - fittedCartSurf(k,l); 
                    end 
                end 
            end 
        end 
         
        %% This section calculates the requested parameters and adds the 
        % names and values to the Header and Num arrays. 
        if ~includeBone 
            NofParameters = 1; 
        else 
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            NofParameters = 4; 
        end 
         
        Headers(11 + (j - 1)*NofParameters) = strcat(Fits(j),' Sq (um)'); % Add parameter 
name to the Header array 
        Num(i,8 + (j - 1)*NofParameters) = sqrt(mean2((abs(zSurf)).^2))*pixelSize; % Add 
parameter to the Num array 
         
        if includeBone 
            Headers(12 + (j - 1)*NofParameters) = strcat(Fits(j),' Lesion Area (50% 
Thickness) (um^2)'); % Add parameter name to the Header array 
            Num(i,9 + (j - 1)*NofParameters) = sum(sum(abs(z50LesionSurf < 
0)))*pixelSize^2/10^6; % Add parameter to the Num array 
             
            Headers(13 + (j - 1)*NofParameters) = strcat(Fits(j),' Lesion Volume (50% 
Thickness) (um^3)'); % Add parameter name to the Header array 
            Num(i,10 + (j - 1)*NofParameters) = sum(sum(abs(z50LesionSurf(z50LesionSurf 
< 0))))*pixelSize^3/10^9; % Add parameter to the Num array 
             
            Headers(14 + (j - 1)*NofParameters) = strcat(Fits(j),' Exposed Bone Area 
(um^2)'); % Add parameter name to the Header array 
            Num(i,11 + (j - 1)*NofParameters) = sum(sum(abs(zExBoneSurf < 
0)))*pixelSize^2/10^6; % Add parameter to the Num array 
        end 
         
        save([dataSheetName,'ErrorsFile.mat']); %This creates an error mat file with all of 
the variables used up to this point that can be loaded to recover lost data in the case of 
fatal program errors 
        display([Txt{i,1}, ' ', Fits{j}, ' completed']); 
    end 
end 
 
display('Calculations complete. Saving data...'); 
 
Num(N+2,1) = cartThreshScanco; 
Txt{N+2,1} = 'Scanco Cartilage Threshold:'; 
Num(N+3,1) = cartThreshMatLab; 
Txt{N+3,1} = 'MatLab Cartilage Threshold:'; 
 
if ~includeBone 
    newDataSheet = cell(N + 4,10 + NofFits*NofParameters); 
    TxtSize = size(Txt); 
    Txt(:,4:TxtSize(2)) = []; 
    newDataSheet(1,:) = Headers; 
    newDataSheet(2:(N + 4),1:3) = Txt; 
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    newDataSheet(2:(N + 4),4:(10 + NofFits*NofParameters)) = num2cell(Num(:,1:(7 + 
NofFits*NofParameters))); 
else 
    Num(N+4,1) = boneThreshScanco; 
    Txt{N+4,1} = 'Scanco Bone Threshold:'; 
    Num(N+5,1) = boneThreshMatLab; 
    Txt{N+5,1} = 'MatLab Bone Threshold:'; 
    newDataSheet = cell(N + 6,10 + NofFits*NofParameters); 
    TxtSize = size(Txt); 
    Txt(:,4:TxtSize(2)) = []; 
    newDataSheet(1,:) = Headers; 
    newDataSheet(2:(N + 6),1:3) = Txt; 











B.5.1. File Description 
create2DProf.m receives a filename for a specific image as well as a rotation angle, analysis 
boundaries, and threshold. It rotates the image per the rotation angle and scans the image 
between the provided top, bottom, left, and right boundaries to find the right most pixel of 
each row that has a grayscale value above the threshold. It then returns the row and column 
number of these pixels to the calling function. 
B.5.2. File Text 
% create2DProf.m 
% Author: David Reece 
% Created: 3/23/13 
% Last Modified: 07/29/16 
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% This file has inputs of the name of a specific tiff and the rotation angle and boundaries 
of the analysis. It uses these inputs to upload the tiff and create an array with the 
coordinates of the right most points of the tiff between the boundaries that have values 
above the given threshold. 
% Inputs: nameStart(string) - a string consisting of the first two columns for a 
particular row of the datasheet 
%   nameEnd(string) - a string consisting of the third column for a 
particular row of the datasheet 
%   fileNumber(double) - a double consisting of the fileNumber of the 
particular tiff within a set of tiffs defined by datasheet 
%   rotAngle(double) - a double with the angle (in degrees) to rotate 
the tiffs 
%   topRow(double) - a double with the row number for the top of the 
analysis 
%   bottomRow(double) - a double with the row number for the bottom 
of the analysis 
%   rightCol(double) - a double with the column number for the right 
of the analysis 
%   leftCol(double) - a double with the column number for the left of 
the analysis 
%   threshold(double) - a double of the greyscale threshold used to 
create the surfaces 
 
function [twoDProf] = create2DProf(nameStart, nameEnd, fileNumber, rotAngle, 
topRow, bottomRow, rightCol, leftCol, threshold) 
NofRows = bottomRow - topRow + 1; 
 
if fileNumber == 0 
    fileNumberStr = '000'; 
elseif fileNumber < 10 
    fileNumberStr = strcat('00',num2str(fileNumber)); 
elseif fileNumber < 100 
    fileNumberStr = strcat('0',num2str(fileNumber)); 
else 
    fileNumberStr = num2str(fileNumber); 
end 
 
twoDProf = zeros(NofRows,2); 
% Create file name and import and rotate images 
fileName = strcat(nameStart,fileNumberStr,nameEnd); 
% display('UploadingImage'); 
try 
    currentImageRaw = imread(fileName); 
catch imreadError 
    try currentImageRaw = imread(fileName); 
    catch imreadError 
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        display('Please enter: currentImageRaw = imread(fileName)'); 
        beep 
        keyboard 
    end 
end 
% display('Creating Prof'); 
 
currentImage = imrotate(currentImageRaw,rotAngle); 
 
% imageSize = size(currentImage); 
% currentImage(:,rightCol:imageSize(2)) = []; 
 
% Go through each row and find the last pixel to the right that has a value 
% greater or equal to threshold 
thresholdError = 0; 
for i = 1:NofRows 
    twoDProf(i,1) = i; 
    tempProf = leftCol - 1 + find(currentImage((i + topRow - 1),leftCol:rightCol) >= 
threshold,1,'last'); 
    try 
        twoDProf(i,2) = tempProf(1); 
    catch 
        if i <= 2 || i > (NofRows-2) 
            thresholdError = 1; 
        end 
        twoDProf(i,2) = leftCol; 
    end 
end 
if thresholdError 
    display(['File # ',fileNumberStr,' did not hit required threshold. Please reposition 
boundaries or change thresholds.']); 
end 
B.6 create3DSurf.m 
B.6.1. File Description 
create3DSurf receives the file names for the 2D images being used in the analysis along 
with analysis boundaries and threshold. It calls create2DProf.m to create the 2D surface 
profiles for each of the 2D images and compiles those profiles into a 3D surface which is 
then returned to the calling function. 
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B.6.2. File Text 
% create3DSurf.m 
% Author: David Reece 
% Created: 3/23/13 
% Last Modified: 11/13/13 
 
function [fittingSurf,plottingSurf] = create3DSurf(nameStart, nameEnd, firstFile, lastFile, 
rotAngle, topRow, bottomRow, rightCol, leftCol, threshold) 
 
NofFiles = lastFile - firstFile + 1; 
NofRows = bottomRow - topRow + 1; 
 
fittingSurf = zeros(NofFiles*NofRows,3); 
plottingSurf = zeros(NofFiles,NofRows,1); 
 
for i = 1:NofFiles 
    fileNumber = firstFile + i - 1; 
     
%     Map the cartilage surface and add to the end of fittingSurf 
    fittingSurf((i - 1)*NofRows + 1:i*NofRows, 1) = i; 
    fittingSurf((i - 1)*NofRows + 1:i*NofRows, 2:3) = create2DProf(nameStart, nameEnd, 
fileNumber, rotAngle, topRow, bottomRow, rightCol, leftCol, threshold); 
     
%     Take the most recent values from create2DProf and put into plottingSurf 





B.7.1. File Description 
dctFitting.m receives a 3D surface along with a cutoff period. It then uses a discrete cosine 
transform to convert the surface to cosine functions, removes all functions with periods 
longer than the cutoff period, converts the remain cosine functions back to a 3D surface, 
and returns the new surface to the calling function. 




% Author: David Reece 
% Created: 5/7/13 
% Last Modified: 5/7/13 
 
function fittedSurf = dctFitting(originalSurf,T,Tc) 
 
surfSize = size(originalSurf); 
L1 = surfSize(1); 
L2 = surfSize(2); 
Fs = 1/T; 
Fc = 1/Tc; 
 
f1 = Fs/2*linspace(0,1,L1); 
f2 = Fs/2*linspace(0,1,L2); 
 
index1 = find(f1 > Fc,1,'first'); 
index2 = find(f2 > Fc,1,'first'); 
 
filter = zeros(L1,L2); 
filter(1:index1 - 1,1:index2 - 1) = ones(index1 - 1,index2 - 1); 
 
dctSurf = dct2(originalSurf).*filter; 
 
fittedSurf = idct2(dctSurf); 
B.8 getInputsGUI.m 
B.8.1. File Description 
getInputsGUI.m is a GUI that is called when the user needs to input the analysis 
boundaries. It displays both the first and last files from the range given in the data sheet 




Figure B.7.6 Image of getInputsGUI.m 
B.8.2. File Text 
function varargout = getInputsGUI(varargin) 
% GETINPUTSGUI MATLAB code for getInputsGUI.fig 
%      GETINPUTSGUI, by itself, creates a new GETINPUTSGUI or raises the existing 
%      singleton*. 
% 
%      H = GETINPUTSGUI returns the handle to a new GETINPUTSGUI or the handle 
to 
%      the existing singleton*. 
% 
%      GETINPUTSGUI('CALLBACK',hObject,eventData,handles,...) calls the local 
%      function named CALLBACK in GETINPUTSGUI.M with the given input 
arguments. 
% 
%      GETINPUTSGUI('Property','Value',...) creates a new GETINPUTSGUI or raises 
the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before getInputsGUI_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property application 
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%      stop.  All inputs are passed to getInputsGUI_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
 
% Edit the above text to modify the response to help getInputsGUI 
 
% Last Modified by GUIDE v2.5 24-Sep-2015 14:47:42 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @getInputsGUI_OpeningFcn, ... 
                   'gui_OutputFcn',  @getInputsGUI_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 




    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
% --- Executes just before getInputsGUI is made visible. 
function getInputsGUI_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to getInputsGUI (see VARARGIN) 
handles.Num = varargin{1,1}; 
handles.Txt = varargin{1,2}; 
handles.askforRotAngles = varargin{1,3}; 
handles.askforRotAnglesActual = varargin{1,3}; 
handles.dataSheetName = varargin{1,4}; 
handles.cartThresh = varargin{1,5}/1000*32767/20000*256; %This converts the input 
threshold from CT attenuation values to the equivalent TIF greyscale value. 
handles.boneThresh = varargin{1,6}/1000*32767/20000*256; 




% Choose default command line output for getInputsGUI 
handles.output = hObject; 
 




% UIWAIT makes getInputsGUI wait for user response (see UIRESUME) 
uiwait(handles.figure1); 
 
% --- Outputs from this function are returned to the command line. 
function varargout = getInputsGUI_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Get default command line output from handles structure 
close(handles.figure1) 
varargout{1} = handles.Num; 
 
% --- Executes on button press in nextButton. 
function nextButton_Callback(hObject, eventdata, handles) 
% hObject    handle to nextButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
cla 
handles.figNum = handles.figNum + 1; 
 
NumSize = size(handles.Num); 
if handles.figNum > NumSize(1) 
    uiresume(handles.figure1); 
else 
    axes(handles.axes1); 
    hold off; 
    axes(handles.axes2); 
    hold off; 
    guidata(handles.figure1, handles); 
    setBoundaries(handles); 
end 
 
% --- Executes on button press in upperBoundButton. 
function upperBoundButton_Callback(hObject, eventdata, handles) 
% hObject    handle to upperBoundButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 




askforBoundary = true; 
while askforBoundary 
    [~, yBoundaries] = ginput(1); 
    yBoundaries = int16(yBoundaries); 
    askforBoundary = checkBoundaries(handles, yBoundaries); 
end 
 
if int16(yBoundaries) > handles.Num(handles.figNum,5) 
    delete(handles.yBoundPlot(2,:)); 
    axes(handles.axes1); 
    handles.yBoundPlot(1,1) = plot([0 
2000],[handles.Num(handles.figNum,5),handles.Num(handles.figNum,5)],'w-'); 
    handles.yBoundPlot(2,1) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    axes(handles.axes2); 
    handles.yBoundPlot(1,2) = plot([0 
2000],[handles.Num(handles.figNum,5),handles.Num(handles.figNum,5)],'w-'); 
    handles.yBoundPlot(2,2) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    handles.Num(handles.figNum,4) = handles.Num(handles.figNum,5); 
    handles.Num(handles.figNum,5) = int16(yBoundaries); 
else 
    axes(handles.axes1); 
    handles.yBoundPlot(1,1) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    axes(handles.axes2); 
    handles.yBoundPlot(1,2) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 




% --- Executes on button press in lowerBoundButton. 
function lowerBoundButton_Callback(hObject, eventdata, handles) 
% hObject    handle to lowerBoundButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
delete(handles.yBoundPlot(2,:)); 
askforBoundary = true; 
while askforBoundary 
    [~, yBoundaries] = ginput(1); 
    yBoundaries = int16(yBoundaries); 
    askforBoundary = checkBoundaries(handles, yBoundaries); 
end 
 
if int16(yBoundaries) < handles.Num(handles.figNum,4) 
    delete(handles.yBoundPlot(1,:)); 
    axes(handles.axes1); 
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    handles.yBoundPlot(2,1) = plot([0 
2000],[handles.Num(handles.figNum,4),handles.Num(handles.figNum,4)],'w-'); 
    handles.yBoundPlot(1,1) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    axes(handles.axes2); 
    handles.yBoundPlot(2,2) = plot([0 
2000],[handles.Num(handles.figNum,4),handles.Num(handles.figNum,4)],'w-'); 
    handles.yBoundPlot(1,2) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    handles.Num(handles.figNum,5) = handles.Num(handles.figNum,4); 
    handles.Num(handles.figNum,4) = int16(yBoundaries); 
else 
    axes(handles.axes1); 
    handles.yBoundPlot(2,1) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 
    axes(handles.axes2); 
    handles.yBoundPlot(2,2) = plot([0 2000],[yBoundaries,yBoundaries],'w-'); 




% --- Executes on button press in rotButton. 
function rotButton_Callback(hObject, eventdata, handles) 
% hObject    handle to rotButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
handles.askforRotAnglesActual = handles.askforRotAngles; 





% --- Executes to set boundaries for each new set of images 
function setBoundaries(handles) 
cla 
i = handles.figNum; 
firstFile = handles.Num(i,1); 
lastFile = handles.Num(i,2); 
middleFile = ceil((firstFile + lastFile)/2); 
 
%% Changes the file numbers to strings 
if firstFile == 0 
    firstFileStr = '000'; 
elseif firstFile < 10 
    firstFileStr = strcat('00',num2str(firstFile)); 
elseif firstFile < 100 
    firstFileStr = strcat('0',num2str(firstFile)); 
else 






if middleFile == 0 
    middleFileStr = '000'; 
elseif middleFile < 10 
    middleFileStr = strcat('00',num2str(middleFile)); 
elseif middleFile < 100 
    middleFileStr = strcat('0',num2str(middleFile)); 
else 





if lastFile == 0 
    lastFileStr = '000'; 
elseif lastFile < 10 
    lastFileStr = strcat('00',num2str(lastFile)); 
elseif lastFile < 100 
    lastFileStr = strcat('0',num2str(lastFile)); 
else 





%% Import middle image and prompt user for rotation angle 
if handles.askforRotAngles 
    try 
        imread(middleFileName,1); 
    catch readError 
        display(readError.message); 
        newDataSheetName = strcat(handles.dataSheetName,'wFileError.xlsx'); 
        xlswrite(newDataSheetName,handles.Txt,1,'A2'); 
        xlswrite(newDataSheetName,handles.Num,1,'D2'); 
    end 
    handles.Num(i,3) = angleGUI('JaneReeceisCute',middleFileName); 
end 
 
%% Checks the files to make sure they exist and if not, program spits out spreadsheet 
with parameters up to this file 
try 
    imread(firstFileName,1); 
catch readError 
    display(readError.message); 
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    newDataSheetName = strcat(handles.dataSheetName,'wFileError.xlsx'); 
    xlswrite(newDataSheetName,handles.Txt,1,'A2'); 




    imread(lastFileName,1); 
catch readError 
    display(readError.message); 
    newDataSheetName = strcat(handles.dataSheetName,'wFileError.xlsx'); 
    xlswrite(newDataSheetName,handles.Txt,1,'A2'); 




%% Rotate and display images in GUI 
firstImageRaw = imread(firstFileName,1); 
firstImage = imrotate(firstImageRaw,handles.Num(i,3)); 
axes(handles.axes1); 
imshow(firstImage); 
lastImageRaw = imread(lastFileName,1); 





handles.firstImage = firstImage; 




%% Ask for Boundaries, check that they cross cartilage and bone, and display 
askforFirstBoundary = true; 
while askforFirstBoundary 
    [~, yBoundaries(1)] = ginput(1); 




handles.yBoundPlot(1,1) = plot([0 2000],[yBoundaries(1),yBoundaries(1)],'w-'); 
axes(handles.axes2); 
hold on; 
handles.yBoundPlot(1,2) = plot([0 2000],[yBoundaries(1),yBoundaries(1)],'w-'); 
 




    [~, yBoundaries(2)] = ginput(1); 
    askforSecondBoundary = checkBoundaries(handles, int16(yBoundaries(2))); 
end 
axes(handles.axes1); 
handles.yBoundPlot(2,1) = plot([0 2000],[yBoundaries(2),yBoundaries(2)],'w-'); 
axes(handles.axes2); 
handles.yBoundPlot(2,2) = plot([0 2000],[yBoundaries(2),yBoundaries(2)],'w-'); 
 
[rightXBoundary, ~] = ginput(1); 
axes(handles.axes1); 
handles.xBoundPlot(1,1) = plot([rightXBoundary,rightXBoundary],[0 2000],'r-'); 
axes(handles.axes2); 
handles.xBoundPlot(1,2) = plot([rightXBoundary,rightXBoundary],[0 2000],'r-'); 
 
[leftXBoundary, ~] = ginput(1); 
axes(handles.axes1); 
handles.xBoundPlot(2,1) = plot([leftXBoundary,leftXBoundary],[0 2000],'r-'); 
axes(handles.axes2); 
handles.xBoundPlot(2,2) = plot([leftXBoundary,leftXBoundary],[0 2000],'r-'); 
 
handles.Num(i,4) = int16(min(yBoundaries)); 
handles.Num(i,5) = int16(max(yBoundaries)); 
handles.Num(i,6) = int16(rightXBoundary); 
handles.Num(i,7) = int16(leftXBoundary); 
 
if ~handles.askforRotAnglesActual 





% --- Executes to check if boundaries cross bone and cartilage 
function boundaryIsBad = checkBoundaries(handles, boundary) 
set(handles.errorPanel,'Visible','off'); 
boundaryIsBad = false; 
if isempty(find(handles.firstImage(boundary,:) >= handles.cartThresh,1)); 
    boundaryIsBad = true; 
    set(handles.errorPanel,'String','Boundary doesn''t cross cartilage surface of first image. 
Please select different boundary.'); 
    set(handles.errorPanel,'Visible','on'); 
elseif isempty(find(handles.firstImage(boundary,:) >= handles.boneThresh,1)); 
    boundaryIsBad = true; 
    set(handles.errorPanel,'String','Boundary doesn''t cross bone surface on first image. 
Please select different boundary.'); 
    set(handles.errorPanel,'Visible','on'); 
elseif isempty(find(handles.lastImage(boundary,:) >= handles.cartThresh,1)); 
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    boundaryIsBad = true; 
    set(handles.errorPanel,'String','Boundary doesn''t cross cartilage surface on last image. 
Please select different boundary.'); 
    set(handles.errorPanel,'Visible','on'); 
elseif isempty(find(handles.lastImage(boundary,:) >= handles.boneThresh,1)); 
    boundaryIsBad = true; 
    set(handles.errorPanel,'String','Boundary doesn''t cross bone surface on last image. 
Please select different boundary.'); 




% --- Executes on button press in rightXBoundButton. Added 2/20/14 
function rightXBoundButton_Callback(hObject, eventdata, handles) 
% hObject    handle to rightXBoundButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
delete(handles.xBoundPlot(1,:)); 
[rightXBoundary, ~] = ginput(1); 
axes(handles.axes1); 
handles.xBoundPlot(1,1) = plot([rightXBoundary,rightXBoundary],[0 2000],'r-'); 
axes(handles.axes2); 
handles.xBoundPlot(1,2) = plot([rightXBoundary,rightXBoundary],[0 2000],'r-'); 




% --- Executes on button press in leftXBoundButton. 
function leftXBoundButton_Callback(hObject, eventdata, handles) 
% hObject    handle to leftXBoundButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
delete(handles.xBoundPlot(2,:)); 
[leftXBoundary, ~] = ginput(1); 
axes(handles.axes1); 
handles.xBoundPlot(2,1) = plot([leftXBoundary,leftXBoundary],[0 2000],'r-'); 
axes(handles.axes2); 
handles.xBoundPlot(2,2) = plot([leftXBoundary,leftXBoundary],[0 2000],'r-'); 
handles.Num(handles.figNum,7) = int16(leftXBoundary); 
guidata(handles.figure1, handles); 
B.9 plotGUI.m 
B.9.1. File Description 
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plotGUI.m is a GUI that is opened when the user chooses to ‘Run Plots’ on the main 
Surface_Roughness GUI. It allows the user to choose a 2D image with the file chosen on 
the Surface_Roughness GUI and then displays that image along with the cartilage and/or 
bone surfaces created in create3DSurf.m for the chosen image. It is a resource to help the 
user understand the algorithm and to troubleshoot any issues. It can also be used to create 
images of the 2D images with their cartilage and/or bone surfaces. See Figure B.7.7 
 
Figure B.7.7: Image of plotGUI.m 
B.9.2. File Text 
function varargout = plotGUI(varargin) 
% PLOTGUI MATLAB code for plotGUI.fig 
%      PLOTGUI, by itself, creates a new PLOTGUI or raises the existing 
%      singleton*. 
% 
%      H = PLOTGUI returns the handle to a new PLOTGUI or the handle to 
%      the existing singleton*. 
% 
%      PLOTGUI('CALLBACK',hObject,eventData,handles,...) calls the local 
%      function named CALLBACK in PLOTGUI.M with the given input arguments. 
% 
%      PLOTGUI('Property','Value',...) creates a new PLOTGUI or raises the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before plotGUI_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property application 




%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
 
% Edit the above text to modify the response to help plotGUI 
 
% Last Modified by GUIDE v2.5 14-Apr-2014 13:18:55 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @plotGUI_OpeningFcn, ... 
                   'gui_OutputFcn',  @plotGUI_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 




    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
 
% --- Executes just before plotGUI is made visible. 
function plotGUI_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to plotGUI (see VARARGIN) 
handles.Num = varargin{1,1}; 
handles.Txt = varargin{1,2}; 
handles.askforRotAngles = varargin{1,3}; 
handles.cartThresh = varargin{1,4}/1000*32767/20000*256; 
handles.boneThresh = varargin{1,5}/1000*32767/20000*256; 
handles.minThick = varargin{1,6}; 
handles.calExBone = varargin{1,7}; 
handles.plotLesion = varargin{1,8}; 
if handles.plotLesion 
    handles.cartFitSurf = varargin{1,9}; 
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% Choose default command line output for plotGUI 
handles.output = hObject; 
 








% UIWAIT makes plotGUI wait for user response (see UIRESUME) 
% uiwait(handles.figure1); 
 
% --- Outputs from this function are returned to the command line. 
function varargout = plotGUI_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Get default command line output from handles structure 
varargout{1} = handles.output; 
 
function imageNumber_Callback(hObject, eventdata, handles) 
% hObject    handle to imageNumber (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% Hints: get(hObject,'String') returns contents of imageNumber as text 
%        str2double(get(hObject,'String')) returns contents of imageNumber as a double 
if str2double(get(handles.imageNumber,'String')) < handles.Num(1) 
    set(handles.imageNumber,'String',num2str(handles.Num(1))); 
elseif str2double(get(handles.imageNumber,'String')) > handles.Num(2) 





% --- Executes during object creation, after setting all properties. 
function imageNumber_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to imageNumber (see GCBO) 
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% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
% --- Executes on button press in preButton. 
function preButton_Callback(hObject, eventdata, handles) 
% hObject    handle to preButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
currentImageNumber = str2double(get(handles.imageNumber,'String')); 
if currentImageNumber <= handles.Num(1) 
    set(handles.imageNumber,'String',num2str(currentImageNumber)); 
else 





% --- Executes on button press in nextButton. 
function nextButton_Callback(hObject, eventdata, handles) 
% hObject    handle to nextButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
currentImageNumber = str2double(get(handles.imageNumber,'String')); 
if currentImageNumber >= handles.Num(2) 
    set(handles.imageNumber,'String',num2str(currentImageNumber)); 
else 






nameStart = strcat(char(handles.Txt(1)),'/',char(handles.Txt(2))); 
nameEnd = handles.Txt{3}; 
 
imageNumber = str2double(get(handles.imageNumber,'String')); 
 
%Map the cartilage and bone surfaces and give back the coordinates 
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[cartProf] = create2DProf(nameStart, nameEnd, imageNumber, handles.Num(3), 




    [boneProf] = create2DProf(nameStart, nameEnd, imageNumber, handles.Num(3), 




if imageNumber == 0 
    imageNumberStr = '000'; 
elseif imageNumber < 10 
    imageNumberStr = strcat('0',num2str(imageNumber)); 
% elseif imageNumber < 100 
%     imageNumberStr = strcat('0',num2str(imageNumber)); 
else 
    imageNumberStr = num2str(imageNumber); 
end 
 
fileName = strcat(nameStart,imageNumberStr,nameEnd); 
imageRaw = imread(fileName); 
myImage = imrotate(imageRaw,handles.Num(3)); 
offsetVal = 25; 
 
imageSize = size(myImage); 
if imageSize(2) - handles.Num(6) < offsetVal 
    offsetVal = imageSize(2) - handles.Num(6); 
end 
if handles.Num(7) < offsetVal 
    offsetVal = handles.Num(7); 
end 
 
myImage(handles.Num(5)+offsetVal:end,:) = []; 
myImage(1:handles.Num(4)-offsetVal,:) = []; 
myImage(:,handles.Num(6)+offsetVal:end) = []; 






plot(cartProf(:,2) - handles.Num(7) + offsetVal,cartProf(:,1) + offsetVal - 1,'wo'); 
 
if handles.calExBone && handles.plotLesion 
    indexValue = imageNumber - handles.Num(1) + 1; 
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    plot(boneProf(:,2) - handles.Num(7) + offsetVal,boneProf(:,1) + offsetVal,'ro'); 
    for i = 1:length(cartProf) 
        if (cartProf(i,2) - handles.cartFitSurf(indexValue,i)) < 
0.25*(handles.boneFitSurf(indexValue,i) - handles.cartFitSurf(indexValue,i)) 
            plot([cartProf(i,2) - handles.Num(7) + offsetVal,boneProf(i,2) - handles.Num(7) + 
offsetVal],[cartProf(i,1) + offsetVal,boneProf(i,1) + offsetVal],'g-','LineWidth',6); 
        end 
    end 
    plot(handles.cartFitSurf(indexValue,:) - handles.Num(7) + offsetVal,cartProf(:,1) + 
offsetVal,'w-'); 
    plot(handles.boneFitSurf(indexValue,:) - handles.Num(7) + offsetVal,boneProf(:,1) + 
offsetVal,'r-'); 
end     
 
if handles.calExBone && ~handles.plotLesion 
    plot(boneProf(:,2) - handles.Num(7) + offsetVal,boneProf(:,1) + offsetVal,'ro'); 
 
%     (6/10/16 DSR) I changed how the exposed bone was calculated in 
%     calculateSurfaceRoughness.m by having it calculate exposed bone from 
%     the fitted bone surface instead of the actual bone point. This should 
%     help reduce the errors that would be caused by high attenuation 
%     cartilage. However, that means in order for the plots from plotGUI to 
%     match the actual values, we need to get fitted surfaces into here. 
%     Once Kaley does that, I will add this feature of plotting the exposed 
%     bone back. 
 
%     for i = 1:length(cartProf) 
%         if cartProf(i,2) - boneProf(i,2) < handles.minThick 
%             plot([cartProf(i,2) - handles.Num(7) + offsetVal,boneProf(i,2) - 
handles.Num(7) + offsetVal],[cartProf(i,1) + offsetVal,boneProf(i,1) + offsetVal],'g-
','LineWidth',6); 
%         end 




% --- Executes on slider movement. 
function slider_Callback(hObject, eventdata, handles) 
% hObject    handle to slider (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'Value') returns position of slider 






% --- Executes during object creation, after setting all properties. 
function slider_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to slider (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: slider controls usually have a light gray background. 
if isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor',[.9 .9 .9]); 
end 
B.10 Surface_Roughness.m 
B.10.1. File Description 
Surface_Roughness.m is the parent program for all the files listed here. This program is 
the run the user should run to start the analysis. When this program is run, it will open a 
GUI that allows the user to input the datasheet name, pixel size, and desired fits and what 
inputs should be requested and if the bone analyses should be performed. It also has options 
to allow the user to display the 2D profiles and 3D surfaces that the program uses in the 




Figure B.7.8: Image of Surface_Roughness GUI 
B.10.2. File Text 
function varargout = Surface_Roughness(varargin) 
% SURFACE_ROUGHNESS MATLAB code for Surface_Roughness.fig 
%      SURFACE_ROUGHNESS, by itself, creates a new SURFACE_ROUGHNESS or 
raises the existing 
%      singleton*. 
% 
%      H = SURFACE_ROUGHNESS returns the handle to a new 
SURFACE_ROUGHNESS or the handle to 
%      the existing singleton*. 
% 
%      SURFACE_ROUGHNESS('CALLBACK',hObject,eventData,handles,...) calls the 
local 





%      SURFACE_ROUGHNESS('Property','Value',...) creates a new 
SURFACE_ROUGHNESS or raises the 
%      existing singleton*.  Starting from the left, property value pairs are 
%      applied to the GUI before Surface_Roughness_OpeningFcn gets called.  An 
%      unrecognized property name or invalid value makes property application 
%      stop.  All inputs are passed to Surface_Roughness_OpeningFcn via varargin. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
 
% Edit the above text to modify the response to help Surface_Roughness 
 
% Last Modified by GUIDE v2.5 02-Feb-2016 11:39:25 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @Surface_Roughness_OpeningFcn, ... 
                   'gui_OutputFcn',  @Surface_Roughness_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 




    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
 
% --- Executes just before Surface_Roughness is made visible. 
function Surface_Roughness_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to Surface_Roughness (see VARARGIN) 
 
% Set inital error, figure, and input handles to match GUI starting values 
handles.noNameError = false; 
handles.noFitsError = false; 
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handles.noPixelError = false; 
handles.noFileNumError = false; 
handles.noMinThickError = true; 
handles.noCartThreshError = true; 
handles.noBoneThreshError = true; 
handles.askforRotAngles = true; 
set(handles.surfFiguresPanel,'Visible','off'); 
 
% Choose default command line output for Surface_Roughness 
handles.output = hObject; 
 
% Update handles structure 
guidata(hObject, handles); 
 
% UIWAIT makes Surface_Roughness wait for user response (see UIRESUME) 
% uiwait(handles.figure1); 
 
% --- Outputs from this function are returned to the command line. 
function varargout = Surface_Roughness_OutputFcn(hObject, eventdata, handles)  
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% There are no outputs for this GUI 
 
% --- Executes when bone threshold has been altered and makes sure it is a number. 
function boneThresh_Callback(hObject, eventdata, handles) 
% hObject    handle to boneThresh (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of boneThresh as text 
%        str2double(get(hObject,'String')) returns contents of boneThresh as a double 
 
if isnan(str2double(get(hObject,'String'))) % Check if bone threshold is not a number 
    set(handles.errorPanel,'String','Please enter only a numerical value for the bone 
threshold.'); % Display error on error panel 
    handles.noBoneThreshError = false; 
else 
    set(handles.errorPanel,'String',''); % Clear error panel 
    handles.noBoneThreshError = true; 
end 
guidata(handles.figure1, handles); % Update handles structure; 
 
% --- Executes on button press in calBone and updates GUI accordingly. 
function calBone_Callback(hObject, eventdata, handles) 
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% hObject    handle to calBone (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hint: get(hObject,'Value') returns toggle state of calBone 
 
if get(hObject,'Value') % If calBone is checked, show bone threshold and minimum 
thickness items in GUI 
    set(handles.boneThresh,'Visible','on'); 
    set(handles.boneThresh,'String','280'); 
    set(handles.boneThreshText,'Visible','on'); 
    set(handles.minThick,'Visible','on'); 
    set(handles.minThickText,'Visible','on'); 
else % If calBone is not checked, hide bone threshold and minimum thickness items in 
GUI 
    set(handles.boneThresh,'Visible','off'); 
    set(handles.boneThresh,'String','0'); 
    set(handles.boneThreshText,'Visible','off'); 
    set(handles.minThick,'Visible','off'); 
    set(handles.minThickText,'Visible','off'); 
end 
 
% --- Executes when cartilage threshold has been altered and makes sure it is a number. 
function cartThresh_Callback(hObject, eventdata, handles) 
% hObject    handle to cartThresh (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of cartThresh as text 
%        str2double(get(hObject,'String')) returns contents of cartThresh as a double 
if isnan(str2double(get(hObject,'String'))) % Check if cartilage threshold is not a number 
    set(handles.errorPanel,'String','Please enter only a numerical value for the cartilage 
threshold.'); % Display error on error panel 
    handles.noCartThreshError = false; 
else 
    set(handles.errorPanel,'String',''); %Clear error panel 
    handles.noCartThreshError = true; 
end 
guidata(handles.figure1, handles); % Update handles structure; 
 
% --- Executes when datasheet name has been altered and makes sure it can be read into 
matlab. 
function dataSheetName_Callback(hObject, eventdata, handles) 
% hObject    handle to dataSheetName (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 




% Hints: get(hObject,'String') returns contents of dataSheetName as text 
%        str2double(get(hObject,'String')) returns contents of dataSheetName as a double 
try % See if datasheet can be read into matlab 
    [~,~] = xlsread(get(hObject,'String')); 
    handles.noNameError = true; 
    set(handles.errorPanel,'String',''); %Clear error panel 
catch fileError % If datasheet cannot be read, save error message as fileError 
    set(handles.errorPanel,'String',fileError.message); % Display fileError on error panel 
    handles.noNameError = false; 
end 
guidata(handles.figure1, handles); % Update handles structure 
 
% --- Executes when file number has been altered and verifies it is in the datasheet. 
function fileNum_Callback(hObject, eventdata, handles) 
% hObject    handle to fileNum (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of fileNum as text 
%        str2double(get(hObject,'String')) returns contents of fileNum as a double 
if handles.noNameError % Only executes if the datasheet name has already been 
validated. 
    [~,Txt] = xlsread(get(handles.dataSheetName,'String')); % Reads datasheet and saves 
the text from the datasheet as a matrix of strings called Txt 
    Txt(1,:) = []; % Trims off the column headings from Txt 
    txtSize = size(Txt); 
    i = str2double(get(handles.fileNum,'String')) - 1; 
%     [i,~] = find(strcmp(get(handles.fileNum,'String'),Txt) == true); % Searches Txt for 
the file number matching the file number drawn fileNum 
    if i > 0 && i <= txtSize(1) %isempty(i) 
        handles.noFileNumError = true; 
        set(handles.errorPanel,'String',''); %Clear error panel 
    else 
        set(handles.errorPanel,'String','Row Number not found in datasheet. Please try 
again.'); 
        handles.noFileNumError = false; 
    end 
end 
 
guidata(handles.figure1, handles); % Update handles structure 
         
% --- Executes when the table is edited. 
function fitsTable_Callback(hObject, eventdata, handles) 
% hObject    handle to fitsTable (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
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% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of fitsTable as text 
%        str2double(get(hObject,'String')) returns contents of fitsTable as a double 
handles.Fits = cellstr(get(hObject,'String')); 
handles.Fits = handles.Fits(~cellfun('isempty',handles.Fits)); 
handles.Fits = strtrim(handles.Fits); 
set(hObject,'String',handles.Fits); 
handles.noFitsError = true; 
NofFits = length(handles.Fits); 
errorStr = strcat('Please correct the following fit entries:',{' '}); 
for i = 1:NofFits 
    tempStr = handles.Fits{i}; 
    if length(tempStr) < 4 
        errorStr = strcat(errorStr,tempStr,{' '}); 
        set(handles.errorPanel,'String',errorStr); 
        handles.noFitsError = false; 
    elseif strcmp(tempStr(1:4),'lowe') 
        if ~strcmp(tempStr(1:length(tempStr)),'lowess') 
            errorStr = strcat(errorStr,tempStr,{' '}); 
            set(handles.errorPanel,'String',errorStr); 
            handles.noFitsError = false; 
        end 
    elseif strcmp(tempStr(1:3),'dct') || strcmp(tempStr(1:3),'DCT') || 
strcmp(tempStr(1:3),'Dct') 
        if isnan(str2double(tempStr(4:length(tempStr)))) 
            errorStr = strcat(errorStr,tempStr,{' '}); 
            set(handles.errorPanel,'String',errorStr); 
            handles.noFitsError = false; 
        end 
    else 
        try 
            fitoptions(handles.Fits{i}); 
        catch dummyVariable 
            errorStr = strcat(errorStr,tempStr,{' '}); 
            set(handles.errorPanel,'String',errorStr); 
            handles.noFitsError = false; 
        end 
    end     
end 
if handles.noFitsError 
    set(handles.errorPanel,'String',''); 
end 
guidata(handles.figure1, handles); % Update handles structure 
 
% --- Executes on button press in goBackButton. 
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function goBackButton_Callback(hObject, eventdata, handles) 
% hObject    handle to goBackButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 












% --- Executes when selected object is changed in inputPanel. 
function inputPanel_SelectionChangeFcn(hObject, eventdata, handles) 
% hObject    handle to the selected object in inputPanel  
% eventdata  structure with the following fields (see UIBUTTONGROUP) 
% EventName: string 'SelectionChanged' (read only) 
% OldValue: handle of the previously selected object or empty if none was selected 
% NewValue: handle of the currently selected object 
% handles    structure with handles and user data (see GUIDATA) 
if get(handles.rotateButton,'Value') 
    handles.askforRotAngles = true; 
elseif get(handles.boundariesButton,'Value') 
    handles.askforRotAngles = false; 
    handles.askforBoundaries = true; 
elseif get(handles.noInputButton,'Value') 
    handles.askforRotAngles = false; 
    handles.askforBoundaries = false; 
end 
guidata(handles.figure1, handles); % Update handles structure 
 
% --- Executes when object has been altered. 
function minThick_Callback(hObject, eventdata, handles) 
% hObject    handle to minThick (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of minThick as text 
%        str2double(get(hObject,'String')) returns contents of minThick as a double 
if isnan(str2double(get(hObject,'String'))) 
    set(handles.errorPanel,'String','Please enter only a numerical value for the minimum 
thickness'); 




    set(handles.errorPanel,'String',''); %Clear error panel 
    handles.noMinThickError = true; 
end 
guidata(handles.figure1, handles); % Update handles structure 
 
% --- Executes when object has been altered. 
function pixelSize_Callback(hObject, eventdata, handles) 
% hObject    handle to pixelSize (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
% Hints: get(hObject,'String') returns contents of pixelSize as text 
%        str2double(get(hObject,'String')) returns contents of pixelSize as a double 
if isnan(str2double(get(hObject,'String'))) 
    set(handles.errorPanel,'String','Please enter only a numerical value for the pixel size'); 
    handles.noPixelError = false; 
else 
    set(handles.errorPanel,'String',''); %Clear error panel 
    handles.noPixelError = true; 
end 
guidata(handles.figure1, handles); % Update handles structure 
     
% --- Executes on button press in plotRunButton. 
function plotRunButton_Callback(hObject, eventdata, handles) 
% hObject    handle to plotRunButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
clc %Clear command window 
set(handles.errorPanel,'String',''); %Clear error panel 
if ~handles.noNameError 
    set(handles.errorPanel,'String','Please correct datasheet name.'); 
elseif ~handles.noFileNumError 
    fileNum_Callback([],[],handles); 
elseif ~handles.noBoneThreshError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the bone 
threshold.'); 
elseif ~handles.noCartThreshError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the cartilage 
threshold.'); 
elseif ~handles.noMinThickError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the minimum 
thickness.'); 
else 
    [Num,Txt] = xlsread(get(handles.dataSheetName,'String')); 
    Txt(1,:) = []; 
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    Txt(:,4:5) = []; 
    i = str2double(get(handles.fileNum,'String')) - 1; 
%     [i,~] = find(strcmp(get(handles.fileNum,'String'),Txt) == true); 
    if handles.askforRotAngles || handles.askforBoundaries 




    else 
        updatedNum = Num(i,:); 
    end 






% --- Executes on button press in plotsButton. 
function plotsButton_Callback(hObject, eventdata, handles) 
% hObject    handle to plotsButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 












% --- Executes on button press in runButton. 
function runButton_Callback(hObject, eventdata, handles) 
% hObject    handle to runButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
clc; %Clear command window 
set(handles.errorPanel,'String',''); %Clear error panel 
if ~handles.noNameError 
    set(handles.errorPanel,'String','Please correct datasheet name.'); 
elseif ~handles.noPixelError 
    set(handles.errorPanel,'String','Please enter a numerical value for the pixel size.'); 
elseif ~handles.noFitsError 




    set(handles.errorPanel,'String','Please enter only a numerical value for the bone 
threshold.'); 
elseif ~handles.noCartThreshError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the cartilage 
threshold.'); 
elseif ~handles.noMinThickError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the minimum 
thickness.'); 
else 
    [Num,Txt] = xlsread(get(handles.dataSheetName,'String')); 
    Headers = [Txt(1,1) Txt(1,2) Txt(1,3) Txt(1,4) Txt(1,5) 'Rot Angle' 'Top Row' 'Bottom 
Row' 'Right Column' 'Left Column']; 
    Txt(1,:) = []; 
    Txt(:,4:5) = [];     
    if handles.askforRotAngles || handles.askforBoundaries 
        updatedNum = 
getInputsGUI(Num,Txt,handles.askforRotAngles,get(handles.dataSheetName,'String'),str
2double(get(handles.cartThresh,'String')),str2double(get(handles.boneThresh,'String'))); 
    else 
        updatedNum = Num; 
    end 







% --- Executes on button press in surfRunButton. 
function surfRunButton_Callback(hObject, eventdata, handles) 
% hObject    handle to surfRunButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 




    set(handles.errorPanel,'String','Please correct datasheet name.'); 
elseif ~handles.noFileNumError 
    fileNum_Callback([],[],handles); 
elseif ~handles.noBoneThreshError 
    set(handles.errorPanel,'String','Please enter only a numerical value for the bone 
threshold.'); 
elseif ~handles.noCartThreshError 





    set(handles.errorPanel,'String','Please enter only a numerical value for the minimum 
thickness.'); 
else 
    [Num,Txt] = xlsread(get(handles.dataSheetName,'String')); 
    Txt(1,:) = []; 
    Txt(:,4:5) = []; 
    i = str2double(get(handles.fileNum,'String')) - 1; 
%     [i,~] = find(strcmp(get(handles.fileNum,'String'),Txt) == true); 
    nameStart = strcat(Txt{i,1}, '/', Txt{i,2}); 
    if handles.askforRotAngles || handles.askforBoundaries 




    else 
        updatedNum = Num(i,:); 
    end 




     
    if get(handles.cartSurfButton,'Value') 
        figure 
        h = surf(plotCartSurf); 
        axis equal; 
        axis off 
        colormap 'Jet' 
%         set(h,'edgecolor','none') 
        if get(handles.calBone,'Value') 




            hold on; 
            surf(plotBoneSurf); 
            surfSize = size(plotCartSurf); 
            for j = 1:surfSize(1) 
                for k = 1:surfSize(2); 
                    if plotCartSurf(j,k) - plotBoneSurf(j,k) < 
str2double(get(handles.minThick,'String')) 
                        plot3(k,j,plotCartSurf(j,k),'wo'); 
                    end 
                end 
            end 
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            hold off; 
        end 
    elseif ~handles.noFitsError 
        set(handles.errorPanel,'String','Please enter desired fit.'); 
    elseif any(strncmp('dct',handles.Fits,3)) && ~handles.noPixelError 
        set(handles.errorPanel,'String','Please enter a numerical value for the pixel size.'); 
    else 
        for j = 1:size(handles.Fits) 
            tempStr = handles.Fits{j}; 
            if strcmp(tempStr(1:3),'dct') 
                cutoff = str2double(tempStr(4:length(tempStr))); 
                fittedCartSurf = 
dctFitting(plotCartSurf,str2double(get(handles.pixelSize,'String')),cutoff); 
            else 
                cartSurfFit = 
fit([fitCartSurf(:,1),fitCartSurf(:,2)],fitCartSurf(:,3),handles.Fits{j}); 
                surfSize = size(plotCartSurf); 
                fittedCartSurf = zeros(surfSize(1),surfSize(2)); 
                for k = 1:surfSize(1) 
                    for l = 1:surfSize(2) 
                        fittedCartSurf(k,l) = cartSurfFit(k,l); 
                    end 
                end 
            end 
             
            if get(handles.fittedSurfButton,'Value') 
                figure 
                h = surf(fittedCartSurf) 
                axis equal 
                axis off 
                colormap 'Jet' 
                set(h,'edgecolor','none') 
                 
            elseif get(handles.bothSurfButton,'Value') 
                figure 
                hold on 
                surf(plotCartSurf) 
                surf(fittedCartSurf) 
                view(-38,30) 
                axis equal 
                hold off 
                 
            elseif get(handles.diffSurfButton,'Value') 
                zSurf = plotCartSurf - fittedCartSurf; 
                figure 
                h = surf(zSurf); 
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                axis equal % Makes the aspect ratio such that the axis appear equally spaced 
%                 axis([1 229 1 47 -7.5098 5.9275]) % Can be used to set the axis for all 
figures to the same values so they appear as the same size 
                axis off % Turns off axis 
                colormap 'Jet' 
                set(h,'edgecolor','none') % Turns off edge of surface 
                caxis([-7,5.5]) % Sets the colormap to between two set values 
%                 saveas(h,[get(handles.fileNum,'String'),'MedialFigure.tif']) 
            end 
        end 
    end 
end 
 
% --- Executes on button press in surfsButton. 
function surfsButton_Callback(hObject, eventdata, handles) 
% hObject    handle to surfsButton (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 












% --- Executes when selected object is changed in surfFiguresPanel. 
function surfFiguresPanel_SelectionChangedFcn(hObject, eventdata, handles) 
% hObject    handle to the selected object in surfFiguresPanel  
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
 
%% 
% These functions below all execute during object creation, after setting all 
% properties. They are required for the GUI to function and are created 
% automatically. No alterations have been made to them. DSR 11.3.14 
function dataSheetName_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to dataSheetName (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
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if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function pixelSize_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to pixelSize (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function cartThresh_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to cartThresh (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function boneThresh_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to boneThresh (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function minThick_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to minThick (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 




% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function fileNum_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to fileNum (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function fitsTable_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to fitsTable (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 





APPENDIX C. CORONAL EPIC-UCT CARTILAGE, 
SUBCHONDRAL BONE, AND LESION VOLUME DATA FROM 
CHAPTER 3 
 
Figure C.8.1: EPIC-μCT cartilage parameters in the coronal slice method of analysis 
– attenuation (A), volume (B), and thickness (C) in the coronal slice method of 
analysis. Data are grouped by location (entire medial tibial plateau and lateral, 
central, and medial thirds thereof), time point (one- or three-weeks post-surgery), and 
surgery group (sham or medial meniscus transection {MMT}). Data shown as mean 
± 95% confidence interval and significance was determined using two-way ANOVAs 




Figure C.8.2: EPIC-μCT subchondral plate parameters in the coronal slice method 
of analysis – mineral density (A), volume (B), porosity (C), and thickness (D) in the 
coronal slice method of analysis. Data are grouped by location (entire medial tibial 
plateau and lateral, central, and medial thirds thereof), time point (one- or three-
weeks post-surgery), and surgery group (sham or medial meniscus transection 
{MMT}). Data shown as mean ± 95% confidence interval and significance was 




Figure C.8.3: EPIC-μCT lesion volume in the coronal slice method of analysis. Data 
shown as mean ± 95% confidence interval. n = 7-8. Significance was determined using 
from Wilcoxon signed rank test comparing if lesion volumes are significantly 




APPENDIX D. INTRA-ARTICULAR DELIVERY OF MICRONIZED 
DEHYDRATED HUMAN AMNION/CHORION MEMBRANE 
REDUCES DEGENERATIVE CHANGES IN OSTEOARTHRITIC 
JOINTS 
The following paper contains data from a study that was designed and started by Tanu 
Thote, PhD. Her graduation necessitated that I complete the study and manuscript. The 
preliminary data was already included in her dissertation so it is contained here in the 
appendices rather than in the main body of my dissertation. 
9.1 Introduction 
Osteoarthritis (OA) is a leading cause of chronic disability in the US[163] and is estimated 
to affect over 13% of adults in the US[164]. OA is a complex disease characterized by 
various morphological and compositional changes in the joint including cartilage surface 
erosion, loss of proteoglycans, lesion and osteophyte formation, and synovial 
inflammation[165]. The current standard of therapy is targeted towards symptomatic relief 
in the form of non-steroidal anti-inflammatory drugs, steroid injections, 
viscosupplementation, and eventual total knee replacement[166]. A variety of disease 
modifying OA drugs (DMOADs) have been tested in clinical trials though none have 
shown a clear therapeutic benefit to date[167]–[169]. Despite this extensive research on 




Extracellular matrix (ECM) therapies are under development for various regenerative 
medicine applications including wound healing, muscle loss, and periodontal 
applications[170]–[172]. One such therapy is amnion membrane derived from donated 
placentae. Amnion has been shown to possess anti-inflammatory properties, display low 
immunogenicity, and promote wound healing while inhibiting scar formation[112]–[114]. 
This tissue has been previously used in the clinic for applications such as repairing tendons 
and corneal defects[173]–[178]. 
A dehydrated preparation of human amnion/chorion membrane (dHACM) has been 
developed using the PURION® process, which maintains bioactive components following 
devitalization and dehydration of the tissue (US Patent 8,357,403-Placenta Tissue Grafts. 
US Patent 8,372,437-Placenta Tissue Grafts. US Patent 8,409,626-Placenta Tissue Grafts). 
dHACM has been previously shown to retain numerous growth factors such as basal 
fibroblast growth factor (bFGF), transforming growth factor β(TGFβ) and platelet derived 
growth factor (PDGF), as well as cytokines and tissue inhibitors of metalloproteinases 
(TIMPs)[44], [111], [123].  
In a previous study, we demonstrated the therapeutic potential of a micronized, injectable 
version of dHACM (μ-dHACM; EpiFix® Injectable, MiMedx Group, Inc. Marietta, GA) 
to slow post-traumatic joint degeneration, by testing its efficacy in a pre-clinical rat OA 
model. Articular cartilage changes were analyzed via equilibrium partitioning of an ionic 
contrast agent micro-computed tomography (EPIC-µCT). A single intra-articular injection 
of µ-dHACM administered 24 hours after surgical injury inhibited lesion formation and 
reduced cartilage proteoglycan loss in the widely used rat medial meniscal transection 
(MMT) model[40]. While this previous study demonstrated ameliorated OA development 
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at three weeks following surgery with acute delivery of a micronized amnion ECM 
treatment, critical issues such as the duration of therapeutic effect and the potential to treat 
joints with established OA have yet to be evaluated. 
In the present study, we examined both the longer-term effects (six-weeks post-surgery) of 
immediate delivery of µ-dHACM in the MMT model and the effects of a delayed injection, 
where µ-dHACM was injected three-weeks post-MMT surgery. As has been shown in 
previous work[3], [40], [99], features consistent with OA progression are consistently 
developed by three-weeks post-surgery in the MMT model, hence treating at this time point 
rather than acutely is more relevant to clinical OA, i.e. a patient typically presents with 
symptoms and is treated after joint damage and disease progression have begun. 
The objective of the present study was to characterize the longer-term effects of immediate 
delivery (24-hours post-surgery) of a micronized amnion ECM treatment and to determine 
whether this treatment could reduce the progression of established OA as evaluated by 
EPIC-µCT and histology. It was hypothesized that the duration of therapeutic effect of 
acute µ-dHACM treatment would extend to the six-week endpoint and that delayed 
injection, administered three weeks after induction of OA, would attenuate further joint 
degeneration in the rat MMT model. 
9.2 Materials and Methods  
9.2.1 Preparation of µ-dHACM 
µ-dHACM was manufactured using the proprietary PURION® process and is compliant 
with the American Association of Tissue Banks’ regulations for donor tissues (MiMedx 
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Group, Inc. Marietta, GA). This process produces a dehydrated, devitalized amnion and 
chorion tissue graft which is then sterilized and micronized. 
9.2.2 Surgical Methods 
The Georgia Institute of Technology IACUC approved experimental procedures for these 
in vivo studies. Weight matched adult male Lewis rats (Charles River, Wilmington, MA) 
weighing 300-325g were acclimated for 1 week after receipt. The animals were 
anesthetized with isoflurane and given sustained-released buprenorphine injections. The 
skin over the medial aspect of the left femoro-tibial joint was shaved and aseptically 
prepared. For the MMT surgery, the medial collateral ligament was exposed by blunt 
dissection and transected to reflect the meniscus toward the femur. The joint space was 
visualized, and a full thickness cut was made through the meniscus at its narrowest 
point[48]. For sham surgeries (n=7), the medial collateral ligament was exposed and 
transected but the meniscus was not transected. The muscle was closed with 4.0 Vicryl 
sutures and the skin stapled using wound clips. 
The MMT animals received an intra-articular injection at 24-hours (acute treatment; n=7) 
or three-weeks (delayed treatment; n=5) post-surgery of 50 µL of µ-dHACM (EpiFix® 
Injectable, MiMedx Group Inc. Marietta GA). µ-dHACM was resuspended in saline at 
80mg/mL and injected into the articular joint space using a 25-gauge needle (BD, Franklin 
Lakes, NJ). As a control, separate MMT animals received an intra-articular injection of 50 
µL saline at three-weeks post-surgery (n=6). All animals were euthanized at six-weeks 
post-surgery via CO2 inhalation. 
9.2.3 EPIC-µCT Analysis of Articular Cartilage and Subchondral Bone 
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EPIC-µCT was used to quantitatively evaluate articular cartilage structure, composition 
and subchondral bone as described previously[3], [69]. Dissected tibiae were immersion 
fixed in 10% neutral buffered formalin for 48 hours then stored in 70% ethanol (v/v) until 
ready for scanning. Immediately prior to scanning, tibiae were patted dry and then 
immersed in 2 ml of 30% Hexabrix™ 320 contrast agent (Covidien, Hazelwood, MO) and 
70% PBS at 37°C for 30 minutes[63], [65]. Samples were placed in covered sample 
chambers and scanned in air using a µCT 40 (Scanco Medical, Brüttisellen, Switzerland) 
at 45 kVp, 177 µA, 200 ms integration time, a voxel size of 16 µm, and with a scan time 
of ~26 min[65]. Raw data were automatically reconstructed to 2D grayscale tomograms. 
These were orthogonally transposed to yield sagittal sections for cartilage and subchondral 
bone analysis and coronal sections for osteophyte analysis. Segmentation for all EPIC-μCT 
analyses was performed using a semi-automatic contouring method that uses global 
thresholds (based on visual inspection and attenuation histograms) and Gaussian filtering 
(sigma = 1.00, support = 1). Direct distance transformation algorithms were used to 
quantify 3D thickness[65], [179], [180].  
For cartilage analysis, sagittal sections were evaluated in the medial third of the medial 
tibial plateau (Figure D.9.1.A) and the air-cartilage and cartilage-bone thresholds for the 
analysis were 179 and 740 mg hydroxyapatite per cubic centimeter (mg HA/cm3), 
respectively. Outcome measures included average articular cartilage attenuation and 
thickness. Cartilage attenuation is a quantitative parameter that has been demonstrated to 
be inversely proportional to sulfated glycosaminoglycan (sGAG) content[63], [66]. 
Degraded cartilage has a lower sGAG content and therefore, after incubation in Hexabrix, 
a higher contrast agent content and higher attenuation values[65]. Subchondral bone was 
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also analyzed in the medial third region of the medial tibial plateau with thresholds of 740-
3047 mg HA/cm3 and mineral density and thickness were calculated. 
 
Figure D.9.1: Representative figures illustrating evaluation areas. A. Medial third of 
medial tibial plateau indicated by black rectangle. B. Representative image of an 
osteophyte observed on the tibia in the rat medial meniscal tear model with volumes 
of interest for cartilage volume (red) and mineralized volume (green) 
Coronal sections were used to analyze osteophytes, defined as a thickening on the medial 
tibial margin[99] (Figure D.9.1.B). The osteophyte cartilage volume was measured in 
volumes of interest that excluded peripheral soft tissue because the soft tissue has similar 
x-ray attenuation as cartilage. Threshold values of 179-670 mg HA/cm3 were used to 
segment the cartilage from air and bone. The osteophyte mineralized volume 
measurements were made in volumes of interest that did include the peripheral soft tissue, 
and the mineralized tissue was segmented from air, cartilage, and the soft tissue using 
threshold values of 670-3047 mg HA/cm3. A lower cartilage-bone threshold was used in 
the osteophyte analysis compared to the previous cartilage and subchondral bone analyses 
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because the newly mineralized tissue in the osteophytes has lower mineral density than 
subchondral cortical bone. 
9.2.4 Articular Cartilage Surface Roughness and Lesion Area  
For surface roughness measurements, sequential 2D grayscale images of sagittal slices of 
the medial third of the tibial plateau were imported into MATLAB® (MathWorks, Natick, 
MA). A custom built algorithm, using the same global thresholds as the previous cartilage 
analysis to separate the bone and cartilage surfaces from each other and the surrounding 
air, scanned each image sequentially to create a 3D digital representation of the cartilage 
and bone surfaces[181]. The cartilage surface was fit with a 3D polynomial surface that 
was fourth order along the ventral/dorsal axis and second order along the medial/lateral 
axis. The surface roughness was then calculated as the root mean square of the differences 
between the cartilage and polynomial surfaces. Exposed subchondral bone was calculated 
as a measure of cartilage lesion area by summing the total area where the bone and cartilage 
surfaces were separated by less than 2 pixels (32 µm). This 2-pixel cutoff was chosen based 
off the 2D images of the lesions and accounts for the partial volume effects that occur at 
the interface of high and low density materials in μCT imaging.  
9.2.5 Histology 
Following EPIC-µCT scanning of the tibiae, tibiae and femora were decalcified in Cal-Ex 
II (Thermo Fisher Scientific, Waltham, MA) on a shaker plate for 7-8 days. Dehydrated 
samples were routinely processed into paraffin embedded blocks. Sections were cut at 5µm 
thickness and sections were stained with hematoxylin and eosin (H&E). 
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9.2.6 Statistical analysis 
All quantitative data were expressed as mean ± 95% confidence interval of the mean. All 
joint parameters between groups were evaluated using one factor (treatment) ANOVA with 
Tukey’s test for post-hoc analysis except for the exposed bone parameter. Exposed bone 
was analyzed using the nonparametric Kruskal-Wallace one-way analysis of variance with 
Dunn’s post-hoc analysis because this parameter was not normally distributed for all 
groups. Statistical significance was set at p < 0.05. All data were 
analyzed using GraphPad Prism software version 7.0 (GraphPad Software, Inc., La Jolla, 
CA). 
9.3 Results 
EPIC-µCT analyses at six-weeks post-surgery revealed significant differences in articular 
cartilage and subchondral bone structure and composition among the experimental groups. 
Representative sagittal cuts from 3D contrast-enhanced cartilage x-ray attenuation maps 
show higher attenuation (i.e. lower sGAG content) of cartilage for the MMT + saline 
treatment (saline) and MMT + 24-hour μ-dHACM treatment (acute treatment) groups 
compared to sham and MMT + 3-week μ-dHACM treatment (delayed treatment) groups 
(Figure D.9.2, red = high attenuation/low sGAG content, green = low attenuation/high 
sGAG content). Quantitative analysis of 3D EPIC-µCT images within the medial third of 
the medial tibial plateau revealed significantly lower cartilage attenuation in sham and 
delayed treatment groups compared to saline and acute treatment groups, indicating higher 
sGAG content in sham and delayed treatment groups (Figure D.9.3.A). Cartilage thickness 
was significantly lower in sham and delayed treatment groups compared to saline and acute 
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treatment groups (Figure D.9.3.B). In contrast, no significant difference in cartilage 
attenuation or thickness was observed between the sham and delayed treatment groups. 
Subchondral bone mineral density was significantly higher in saline, acute treatment, and 
delayed treatment groups compared to sham while the delayed treatment group had 
significantly lower mineral density compared to the acute treatment group (Figure 
D.9.3.C). Only the acute treatment group had significantly thicker subchondral bone than 
sham group (Figure D.9.3.D). 
Figure D.9.2: Representative medial tibial cartilage attenuation maps. The maps 
show lower attenuation in sham and delayed treatment samples. Pseudocolor 
attenuation bar at bottom indicates red as high attenuation and green as low 
attenuation. A. Sham sample displays smooth cartilage surface with green color 
indicating healthy sulfated glycosaminoglycan (sGAG) content. B. Saline treatment 
sample displays high attenuation indicating lower sGAG content. C. Sample receiving 
acute treatment (24-hours post-surgery) with micronized dehydrated human 
amnion/chorion membrane (μ-dHACM) displays high attenuation and the beginning 
of lesion development D. Sample with delayed treatment (three-weeks post-surgery) 
with μ-dHACM displays green central portion indicating healthy sGAG content. 




Figure D.9.3: EPIC-µCT cartilage and subchondral bone parameters. Delayed 
treatment (three-weeks post-surgery) of micronized dehydrated human 
amnion/chorion membrane (μ-dHACM) results in lower cartilage attenuation and 
thickness and subchondral bone mineral density in the medial third of the medial 
tibial plateau compared to saline and acute μ-dHACM treatment (24-hours post-
surgery) groups. A,B. Cartilage attenuation and thickness were significantly higher 
than sham in the saline and acute μ-dHACM treatment groups, while both 
parameters in the delayed treatment group were significantly lower than saline and 
acute treatment groups. C. Subchondral bone mineral density was significantly 
higher than sham in all other groups while mineral density in the delayed treatment 
group was significantly lower than acute treatment groups. Data shown as mean ± 
95% confidence interval. n = 5-7. 
Surface roughness and exposed bone area were calculated using a custom program. 
Analysis of the medial third of the medial tibial plateau showed an increase in surface 
roughness in saline and acute treatment groups compared to sham and delayed treatment 
(Figure D.9.4.A). Exposed bone area was calculated as a measure of cartilage lesion size 
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and was significantly higher in the saline and acute treatment groups compared to sham 
while the delayed treatment group had significantly lower exposed bone area compared to 
the acute delivery group (Figure D.9.4.B). 
 
Figure D.9.4: Evaluation of surface roughness and exposed bone using custom 
program. A. Cartilage surface roughness was significantly higher than sham in the 
saline and acute (24-hours post-surgery) micronized dehydrated human 
amnion/chorion membrane (μ-dHACM) treatment groups, while surface roughness 
in the delayed μ-dHACM treatment (three-weeks post-surgery) group was 
significantly lower than saline and acute treatment groups. B. Exposed bone was 
significantly greater in saline and acute treatment groups compared to the sham, and 
significantly less in delayed treatment compared to acute treatment. Data shown as 
mean ± 95% confidence interval. n = 5-7. 
Osteophytes are a thickening and partial mineralization of cartilage tissue at the marginal 
edge of the medial tibial plateau. The cartilage and mineralized tissue volume along the 
medial edge of the tibial plateau were quantified in 3D using coronal EPIC-μCT images to 
quantify thickening from osteophyte formation. Osteophyte cartilage volume was 
significantly higher in the saline and acute treatment groups compared to sham (Figure 
D.9.5.A). Osteophyte cartilage volume was not significantly increased in the delayed 
treatment group relative to sham controls. Similar results were observed for osteophyte 
mineralized volume with a significant increase in the saline and acute treatment groups 
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compared to sham (Figure D.9.5.B). Osteophyte cartilage and mineralized volumes were 
not significantly increased in the delayed treatment group compared to the sham controls 
and osteophyte cartilage volume was significantly less in the delayed treatment group 
compared to the acute treatment group. 
 
Figure D.9.5: EPIC-µCT osteophyte parameters. Saline and acute (24-hour post-
surgery) micronized dehydrated human amnion/chorion membrane (μ-dHACM) 
treatment groups display osteophyte progression compared to sham. A. Osteophyte 
cartilage volume was significantly greater in saline and acute treatment groups 
compared to the sham group and significantly less in the delayed μ-dHACM 
treatment (three-weeks post-surgery) group compared to the acute treatment group. 
B. Marginal mineralized volume was significantly greater in saline and acute 
treatment groups compared to the sham group. Data shown as mean ± 95% 
confidence interval. n = 5-7. 
Histology was performed on tibiae and femora at the six-week time point. µ-dHACM was 
not visible in the synovium surrounding the femur (data not shown). Representative images 
of coronal tibial sections showed degradation of cartilage surface and development of 
osteophytes in the saline (Figure D.9.6.C&D) and acute treatment groups (Figure 
D.9.6.E&F). The sham group demonstrated smooth cartilage surfaces with no osteophyte 
development (Figure D.9.6.A&B). The delayed treatment group demonstrated smooth 




Figure D.9.6: Representative H&E histology images for the tibiae. A–B. Sham sample 
showed no cartilage damage. C-D. Saline sample exhibited cartilage surface damage 
on the medial plateau indicated by fibrillations and lesions and osteophyte 
development indicated by cartilage thickening on the medial edge of the plateau. E-
F. Acute micronized dehydrated human amnion/chorion membrane (μ-dHACM) 
treatment (24-hour post-surgery) did not protect against cartilage damage or 
osteophyte development as surface fibrillations and cartilage thickening are still 
observed. G-H. Delayed μ-dHACM treatment protected cartilage against damage as 
cartilage lesions are not observed. Delayed treatment also reduced osteophyte 
development as indicated by the reduced cartilage thickening. Scale bar in 4x mosaics 




ECM based therapeutics have shown promise for multiple therapeutic applications and are 
currently being investigated as clinical treatment options for OA[142]. In a previous study, 
we demonstrated the therapeutic benefit of a single intra-articular injection of µ-dHACM 
(24 hours post-surgery) in the rat MMT model after three weeks[40]. The purpose of the 
present study was to evaluate whether the same single acute treatment with µ-dHACM 
would provide a protective effect at six-weeks post-surgery and whether the delivery of a 
single treatment would have a beneficial effect once disease had been established.  
It was hypothesized that an acute treatment of µ-dHACM at 24-hours post-surgery would 
show sustained therapeutic benefit at six-weeks post-surgery but this was not the case as 
illustrated by the EPIC-µCT results. The lack of a chondro-protective effect of the single 
24 hour µ-dHACM injection could be attributed to the unrepaired destabilization of the 
joint that resulted in continued disease development throughout the six-week study period. 
The standard end point for therapeutic evaluation in the MMT model is three-weeks post-
surgery and few studies of potential therapeutics have been extended to six weeks[182]–
[184]. 
In previous MMT studies, OA-like symptoms such as lower proteoglycan content and 
lesion formation were already present in the medial tibial plateau at three weeks[3], [40], 
[48]; therefore, the delayed treatment at three weeks was intended to be more representative 
of the clinical scenario, where the patient is seeking treatment after disease symptoms have 
already developed.  The delayed intra-articular injection of µ-dHACM delivered at three-
weeks post-MMT surgery, when the rat tibial plateau has already demonstrated significant 
disease progression[3], [48], resulted in reduced disease progression in the MMT model at 
the six week time point. Lower cartilage attenuation and surface roughness were observed 
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in the delayed treatment group compared to saline controls. Delayed treatment also reduced 
subchondral bone sclerosis and osteophyte formation compared to the acute treatment. A 
recent study by Raines et al., where MMT animals were treated two weeks after surgery 
with a particulate amniotic membrane and umbilical cord matrix, also showed reduced 
disease progression at six weeks post-surgery compared to controls[116]. Taken together, 
the Raines study and this present study suggest that amniotic membrane based treatments 
could provide a therapeutic benefit even when injected into joints with established 
osteoarthritis-like pathology. 
In the previous study with a three week end point, articular surface fibrillation, lesion 
number and lesion volume were used as indicators of reduced cartilage damage in animals 
receiving an intra-articular injection at 24 hours post-surgery compared to the saline control 
group[40]. In this six-week study, more widespread cartilage lesions necessitated the use 
of exposed bone area as an alternative indicator of lesion size as this metric is less prone to 
user bias for samples with larger lesions compared with calculating lesion volume. 
We were not able to identify μ-dHACM in the synovium at six weeks by histology. In a 
previous study, µ-dHACM particles were still present in the synovium three weeks after 
injection but appeared reduced in size[40].  Taken together, this study and our previous 
work indicate that the µ-dHACM particles are rapidly sequestered within a few days into 
the synovial membrane where they appear to be fully remodeled between 3 and 6 weeks. 
While the mechanism by which micronized amnion ECM produces a therapeutic effect are 
not clearly understood, the growth factor composition of µ-dHACM, including bFGF, 
TGF-beta, and TIMPs, could be a contributory factor[44], [123]. Osteophyte formation 
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results from endochondral ossification brought about by alterations in bone turnover[185], 
[186] and can be attenuated by bFGF[187]. In addition, FGF protein signaling, among 
others, determines the rate of chondrocyte proliferation[121]. TGF-beta has previously 
been implicated in proliferation of perichondrium derived chondro-progenitor cells[188]. 
Moreover, matrix metalloproteinase inhibitors such as TIMPs have been implicated in 
reducing subchondral bone sclerosis and cartilage damage in osteoarthritis models[189]. 
Other potential mechanisms of micronized amnion ECM action could involve its potential 
as a cell recruiter and substrate. Amnion ECM has been shown to induce migration of 
mesenchymal stem cells and recruit mesenchymal progenitor cells to implantation 
sites[44]. Amniotic membrane has been shown to be a suitable substrate to culture cells 
and also to amplify chondrocytes in vitro[126]. These properties, in addition to the 
micronized particle dimensions which may help prevent rapid clearance from the joint, 
could be contributing towards the observed therapeutic effect. Further research is needed 
to understand how amnion ECM influences the joint, including the development of suitable 
in vivo and in vitro evaluation methods to examine cellular and genetic responses. 
Micronized amnion ECM has previously been demonstrated to slow the development of 
post-traumatic OA following meniscal injury in the rat MMT model.  This study extended 
the previous work to determine that the duration of acute treatment benefit is transitory in 
the face of continued joint instability.  However, contrast-enhanced μCT analysis further 
revealed that a single intra-articular injection of micronized amnion ECM at three-weeks 
post MMT surgery, after OA features have developed, significantly slowed and partially 
reversed OA progression. This study therefore supports continued investigation of 
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